<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Medical interventions for traumatic hyphema - Woreta, FA - 2023 | Cochrane Library</title> <meta content="Medical interventions for traumatic hyphema - Woreta, FA - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005431.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Medical interventions for traumatic hyphema - Woreta, FA - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005431.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005431.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Medical interventions for traumatic hyphema" name="citation_title"/> <meta content="Fasika A Woreta" name="citation_author"/> <meta content="Johns Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="Kristina B Lindsley" name="citation_author"/> <meta content="University Medical Center Utrecht" name="citation_author_institution"/> <meta content="Almutez Gharaibeh" name="citation_author"/> <meta content="Faculty of Medicine, The University of Jordan" name="citation_author_institution"/> <meta content="Sueko M Ng" name="citation_author"/> <meta content="University of Colorado Denver - Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Roberta W Scherer" name="citation_author"/> <meta content="Johns Hopkins Bloomberg School of Public Health" name="citation_author_institution"/> <meta content="roberta.w.scherer@gmail.com" name="citation_author_email"/> <meta content="Morton F Goldberg" name="citation_author"/> <meta content="Johns Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD005431.pub5" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/03/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005431.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005431.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005431.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [therapeutic use]; Aminocaproic Acid [therapeutic use]; *Antifibrinolytic Agents [therapeutic use]; Aspirin [therapeutic use]; *Glaucoma [drug therapy]; Hyphema [drug therapy, therapy]; Mydriatics [therapeutic use]; *Tranexamic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005431.pub5&amp;doi=10.1002/14651858.CD005431.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005431\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005431\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","pt","ms","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005431.pub5",title:"Medical interventions for traumatic hyphema",firstPublishedDate:"Mar 13, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005431.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005431.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005431.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005431.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005431.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005431.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005431.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005431.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005431.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005431.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1565 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005431.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-sec-0276"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-sec-0266"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/appendices#CD005431-sec-0281"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/supinfo/CD005431StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/supinfo/CD005431StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Medical interventions for traumatic hyphema</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#CD005431-cr-0004">Fasika A Woreta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#CD005431-cr-0005">Kristina B Lindsley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#CD005431-cr-0006">Almutez Gharaibeh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#CD005431-cr-0007">Sueko M Ng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#CD005431-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Roberta W Scherer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information#CD005431-cr-0009">Morton F Goldberg</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information/en#CD005431-sec-0292">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 March 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005431.pub5">https://doi.org/10.1002/14651858.CD005431.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005431-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005431-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005431-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005431-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005431-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005431-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD005431-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005431-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005431-abs-0001" lang="en"> <section id="CD005431-sec-0001"> <h3 class="title" id="CD005431-sec-0001">Background</h3> <p>Traumatic hyphema is the entry of blood into the anterior chamber, the space between the cornea and iris, following significant injury to the eye. Hyphema may be associated with significant complications that uncommonly cause permanent vision loss. Complications include elevated intraocular pressure, corneal blood staining, anterior and posterior synechiae, and optic nerve atrophy. People with sickle cell trait or disease may be particularly susceptible to increases in intraocular pressure and optic atrophy. Rebleeding is associated with an increase in the rate and severity of complications. </p> </section> <section id="CD005431-sec-0002"> <h3 class="title" id="CD005431-sec-0002">Objectives</h3> <p>To assess the effectiveness of various medical interventions in the management of traumatic hyphema. </p> </section> <section id="CD005431-sec-0003"> <h3 class="title" id="CD005431-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2022, Issue 3); MEDLINE Ovid; Embase.com; PubMed (1948 to March 2022); the ISRCTN registry; ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). The last date of the search was 22 March 2022. </p> </section> <section id="CD005431-sec-0004"> <h3 class="title" id="CD005431-sec-0004">Selection criteria</h3> <p>Two review authors independently assessed the titles and abstracts of all reports identified by the electronic and manual searches. We included randomized and quasi‐randomized trials that compared various medical (non‐surgical) interventions versus other medical interventions or control groups for the treatment of traumatic hyphema following closed‐globe trauma. We applied no restrictions on age, gender, severity of the closed‐globe trauma, or level of visual acuity at time of enrollment. </p> </section> <section id="CD005431-sec-0005"> <h3 class="title" id="CD005431-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane and assessed the certainty of evidence using GRADE. </p> </section> <section id="CD005431-sec-0006"> <h3 class="title" id="CD005431-sec-0006">Main results</h3> <p>We included 23 randomized and seven quasi‐randomized studies with a total of 2969 participants. Interventions included antifibrinolytic agents (systemic and topical aminocaproic acid, tranexamic acid, and aminomethylbenzoic acid), corticosteroids (systemic and topical), cycloplegics, miotics, aspirin, conjugated estrogens, traditional Chinese medicine, monocular versus bilateral patching, elevation of the head, and bed rest. </p> <p>We found no evidence of an effect on visual acuity for any intervention, whether measured within two weeks (short term) or for longer periods. In a meta‐analysis of two trials, we found no evidence of an effect of aminocaproic acid on long‐term visual acuity (RR 1.03, 95% confidence interval (CI) 0.82 to 1.29) or final visual acuity measured up to three years after the hyphema (RR 1.05, 95% CI 0.93 to 1.18). Oral tranexamic acid appeared to provide little to no benefit on visual acuity in four trials (RR 1.12, 95% CI 1.00 to 1.25). The remaining trials evaluated the effects of various interventions on short‐term visual acuity; none of these interventions was measured in more than one trial. No intervention showed a statistically significant effect (RRs ranged from 0.75 to 1.10). Similarly, visual acuity measured for longer periods in four trials evaluating different interventions was also not statistically significant (RRs ranged from 0.82 to 1.02). The evidence supporting these findings was of low or very low certainty. </p> <p>Systemic aminocaproic acid reduced the rate of recurrent hemorrhage (RR 0.28, 95% CI 0.13 to 0.60), as assessed in six trials with 330 participants. A sensitivity analysis omitting two studies not using an intention‐to‐treat analysis reduced the strength of the evidence (RR 0.43, 95% CI 0.17 to 1.08). We obtained similar results for topical aminocaproic acid (RR 0.48, 95% CI 0.20 to 1.10) in two trials with 131 participants. We assessed the certainty of the evidence as low. Systemic tranexamic acid had a significant effect in reducing the rate of secondary hemorrhage (RR 0.33, 95% CI 0.21 to 0.53) in seven trials with 754 participants, as did aminomethylbenzoic acid (RR 0.10, 95% CI 0.02 to 0.41), as reported in one study. Evidence to support an associated reduction in risk of complications from secondary hemorrhage (i.e. corneal blood staining, peripheral anterior synechiae, elevated intraocular pressure, and development of optic atrophy) by antifibrinolytics was limited by the small number of these events. Use of aminocaproic acid was associated with increased nausea, vomiting, and other adverse events compared with placebo. We found no evidence of an effect on the number of adverse events with the use of systemic versus topical aminocaproic acid or with standard versus lower drug dose.  </p> <p>The number of days for the primary hyphema to resolve appeared to be longer with the use of systemic aminocaproic acid compared with no use, but this outcome was not altered by any other intervention. </p> <p>The available evidence on usage of systemic or topical corticosteroids, cycloplegics, or aspirin in traumatic hyphema was limited due to the small numbers of participants and events in the trials. </p> <p>We found no evidence of an effect between a single versus binocular patch on the risk of secondary hemorrhage or time to rebleed. We also found no evidence of an effect on the risk of secondary hemorrhage between ambulation and complete bed rest. </p> </section> <section id="CD005431-sec-0007"> <h3 class="title" id="CD005431-sec-0007">Authors' conclusions</h3> <p>We found no evidence of an effect on visual acuity of any of the interventions evaluated in this review. Although the evidence was limited, people with traumatic hyphema who receive aminocaproic acid or tranexamic acid are less likely to experience secondary hemorrhage. However, hyphema took longer to clear in people treated with systemic aminocaproic acid. </p> <p>There is no good evidence to support the use of antifibrinolytic agents in the management of traumatic hyphema, other than possibly to reduce the rate of secondary hemorrhage. The potentially long‐term deleterious effects of secondary hemorrhage are unknown. Similarly, there is no evidence to support the use of corticosteroids, cycloplegics, or non‐drug interventions (such as patching, bed rest, or head elevation) in the management of traumatic hyphema. As these multiple interventions are rarely used in isolation, further research to assess the additive effect of these interventions might be of value. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005431-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005431-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005431-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005431-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005431-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005431-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005431-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD005431-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD005431-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005431-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005431-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005431-abs-0002" lang="en"> <h3>Medical treatment for traumatic hyphema</h3> <p><b>Key messages</b> </p> <p>We found no evidence that any medical treatment affected visual acuity (sharpness of vision), whether measured within a few weeks or longer. We also found that no medical treatment resulted in fewer complications from the hyphema itself, although this evidence is weak because few events occurred. We found limited evidence that antifibrinolytics (drugs that affect blood clotting) reduced the risk of new bleeding in the eye. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out which medical treatments are effective for the management of traumatic hyphema, a condition in which blood collects in the anterior segment (front of the eye) following significant trauma (physical injury to the eye). It was important to evaluate possible treatments for traumatic hyphema, because complications from the condition can affect final vision.  </p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at a medical (non‐surgical) treatment compared with another medical treatment or comparison group in people with traumatic hyphema. We compared and summarized the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 30 studies with a total of 2969 participants addressing our review question. Studies were conducted in the USA, Canada, Sweden, Denmark, China, South Africa, Malaysia, Iran, and Israel. The studies included more males than females, and participants tended to be children or young adults. Treatments included antifibrinolytic agents taken orally or applied directly to the eye (aminocaproic acid, tranexamic acid, and aminomethylbenzoic acid), oral or topical corticosteroids, other kinds of eye drops, aspirin, estrogens, traditional Chinese medicine, patching, elevation of the head, and bed rest. Most studies looked at how often fresh bleeding occurred, because this secondary bleeding is often associated with more complications. Other outcomes examined included visual acuity and the length of time it took for the blood in the eye to be absorbed. </p> <p><b>Main results</b> </p> <p>We found no evidence that any medical treatment affected final vision, but we graded the evidence as generally of low certainty. Antifibrinolytic agents did appear to reduce the risk of new bleeding in the eye, but participants taking oral aminocaproic acid (an antifibrinolytic agent) appeared to have more nausea and vomiting compared with those in the comparison group. It was unclear whether antifibrinolytics reduced complications of secondary bleeding, as these events occurred infrequently in the studies. We found no evidence for the effectiveness of any other medical treatment in reducing the rate of fresh bleeding or the number of complications. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The evidence for a beneficial effect of any of the evaluated treatments was uncertain because the numbers of participants and events were small.  </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We reviewed studies published up to 22 March 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005431-sec-0276" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005431-sec-0276"></div> <h3 class="title" id="CD005431-sec-0277">Implications for practice</h3> <section id="CD005431-sec-0277"> <p>Limited evidence suggests that people with traumatic hyphema who receive aminocaproic acid are less likely to experience secondary hemorrhage than those who do not. Complications resulting from secondary hemorrhage, such as glaucoma, corneal blood staining, or optic atrophy, can lead to permanent impairment of vision. We did not identify a significant effect on final visual acuity (VA) following hyphema. Moreover, oral aminocaproic acid was shown to produce significant side effects including gastrointestinal upset and systemic hypotension, and participants without secondary hyphemas who were treated with aminocaproic acid showed slower clearing of hyphema than control groups. </p> <p>Tranexamic acid seems to be as effective as aminocaproic acid in terms of effect on secondary hemorrhage but with fewer gastric side effects. Given the risk of systemic side effects of antifibrinolytic agents, these are not widely used in clinical practice. Data from the few studies that evaluated the effect of corticosteroids on final VA and risk of secondary hemorrhage do not support the presumed benefits, though corticosteroid usage may aid in relieving the associated inflammation in such cases. Intraocular pressure control is an important aspect of hyphema management, in particular in individuals with sickle cell trait or disease. </p> <p>Controlled clinical trials comparing non‐drug treatment modalities versus placebo did not show a protective effect. We found no convincing evidence of benefit of binocular patching over monocular patching, bed rest over moderate activity, or elevation of the head in a semi‐reclined position in the treatment of traumatic hyphema. Given that most of these interventions were used collectively in many of the studies presented, it was not possible to assess the extent to which any of these interventions may have contributed to any reported positive results. </p> </section> <h3 class="title" id="CD005431-sec-0278">Implications for research</h3> <section id="CD005431-sec-0278"> <p>There is insufficient high‐quality evidence from large randomized controlled trials to support the use of corticosteroids or cycloplegics and limited evidence for the use of antifibrinolytics in the treatment of traumatic hyphema. It is possible that topical aminocaproic acid or a lower dose of systemic aminocaproic acid (50 mg/kg instead of 100 mg/kg) may be efficacious in reducing the occurrence of secondary hemorrhages, with a potential reduction in the risk of systemic side effects. Future research of such agents aimed at assessing the impact on final VA after the resolution of hyphema, time to achieve final VA, occurrence of rebleeding, cost, and quality of life (side effects and time lost from school and employment) would be most helpful to guide treatment recommendations. Ongoing or future studies on the medical treatment of hyphema should study individuals with sickle cell disease/trait in particular. To date there are no studies with direct comparisons of aminocaproic acid versus tranexamic acid, and only one study compared aminocaproic acid versus prednisolone. Further research to study the additive effect of non‐medical interventions in hyphema management might be of value, as they are not usually used independently of one another. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005431-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005431-sec-0008"></div> <div class="table" id="CD005431-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Systemic aminocaproic acid compared with placebo for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic aminocaproic acid compared with placebo for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> 100 mg aminocaproic acid every 4 hours </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic aminocaproic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> 20/40 or better ≤ 2 weeks after treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>769 per</b> </p> <p><b>1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>699 per 1000</b> </p> <p>(438 to 1015)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.57 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 5 other studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medium‐term visual acuity</b> 20/40 or better &gt; 2 weeks and ≤ 2 months after treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term visual acuity</b> 20/40 or better &gt; 2 months after treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>731 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>752 per 1000</b><br/>(599 to 942) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> (0.82 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 4 other studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> 20/40 or better at resolution of hyphema </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>866 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>908 per 1000</b><br/>(805 to 1021) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> (0.93 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 4 other studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average time to resolution of the hemorrhage ranged from 4.1 to 6.7 days in participants receiving oral aminocaproic acid and from 2.4 to 6.3 days in participants receiving placebo (data not meta‐analyzable). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary hemorrhage</b> at any time point </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/>(19 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> (0.13 to 0.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> nausea or vomiting </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/>(36 to 612) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.60</b> (2.09 to 35.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 3 other studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1).<br/><sup>3</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005431-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical aminocaproic acid compared with placebo for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical aminocaproic acid compared with placebo for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> 25% to 30% aminocaproic acid in gel every 6 hours </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Topical aminocaproic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> 20/40 or better ≤ 2 weeks after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>481 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b><br/>(226 to 770) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.47 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 1 other study.</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medium‐term visual acuity</b> 20/40 or better &gt; 2 weeks and ≤ 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported no difference between groups after 2 weeks of follow‐up.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term visual acuity</b> 20/40 or better &gt; 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> 20/40 or better at resolution of hyphema </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 study, average time to resolution of the hemorrhage was 11.1 days in participants receiving topical aminocaproic acid compared with 9.3 days in those receiving placebo with gel, and 9.5 days in those receiving placebo without gel; in the second study, the authors reported "no difference" in time to resolution between study groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary hemorrhage</b> at any time point </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b><br/>(45 to 250) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> (0.20 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> systemic hypotension </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported that 13% of participants in the topical aminocaproic acid group versus 11% of participants in the placebo group had systemic hypotension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−2).<br/><sup>2</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1).<br/><sup>3</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1).<br/><sup>4</sup>Downgraded for imprecision (−1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005431-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Systemic tranexamic acid compared with control for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic tranexamic acid compared with control for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> 25 to 75 mg/kg tranexamic acid per day </p> <p><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Tranexamic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> 20/40 or better ≤ 2 weeks after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>646 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>724 per 1000</b> (646 to 807) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> (1.00 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 2 other studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medium‐term visual acuity</b> 20/40 or better &gt; 2 weeks and ≤ 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term visual acuity</b> 20/40 or better &gt; 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> 20/40 or better at resolution of hyphema </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 study, average time to resolution of the hemorrhage was 4.0 days in 72 participants receiving tranexamic acid and 3.7 days in 59 participants receiving placebo. In another study, average time to resolution was 4.6 days in 17 participants receiving tranexamic acid and 3.9 days in 18 participants not receiving the drug. A third study reported that resolution was delayed in the tranexamic acid group, and a fourth study reported faster resolution in the tranexamic acid group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary hemorrhage</b> at any time point </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(36 to 91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.21 to 0.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>754 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> nausea </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported that 1 of 19 participants receiving tranexamic acid complained of nausea; another study reported that no adverse events were observed in either the drug‐treated or the control group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (−1).<br/><br/><sup>2</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1).<br/><sup>3</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005431-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Systemic or topical corticosteroids compared with placebo or control treatment for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic or topical corticosteroids compared with placebo or control treatment for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> oral or topical corticosteroids </p> <p><b>Comparison:</b> placebo or a control treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Placebo or control treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corticosteroids</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>493 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b><br/>(478 to 735) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.97 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> between 20/20 and 20/40 at end of treatment; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>900 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>909 per 1000</b> </p> <p>(756 to 1107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> (0.84 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/40 ≤ 2 weeks after treatment; topical corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b><br/>(235 to 910) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b> (0.38 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> between 20/20 and 20/25 at end of treatment; topical corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>943 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>962 per 1000</b> </p> <p>(887 to 1047)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.94 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b>; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The first study reported that average resolution of primary hemorrhage was 3.5 days in the oral corticosteroid group and 3.7 days in the control group. The second study reported that average resolution of primary hemorrhage was 4.45 days in the oral corticosteroid group and 4.48 days in the control group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b>; </p> <p>topical corticosteroids</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A single study reported that hyphema cleared in 10/13 participants in the corticosteroid group and 16/21 participants in the control group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>259 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b><br/>(103 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b> (0.40 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; topical corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(4 to 115) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.29</b> (0.05 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1).<br/><sup>3</sup>Downgraded for risk of bias (−1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005431-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Other pharmaceutical agents compared with placebo or other control interventions for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Other pharmaceutical agents compared with placebo or other control interventions for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> other pharmaceutical agent </p> <p><b>Comparison:</b> placebo or other control interventions </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Placebo or <b>other control interventions</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pharmaceutical agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/60 at end of treatment; cycloplegics vs miotics </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>434 per 1000</b><br/>(211 to 768) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.46 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% homatropine versus 4% pilocarpine</p> <p> </p> <p>Visual acuity measured at end of treatment, typically within 2 weeks of occurrence of hyphema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; conjugated estrogen </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b><br/>(120 to 552) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> (0.55 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjugated estrogen, 5 to 10 mg intramuscularly for children under 10 years of age and 20 mg intravenously for children 10 years of age or older and adults, vs placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; cycloplegics </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(3 to 149) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> (0.15 to 6.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% homatropine versus 4% pilocarpine in first study; 1% atropine versus 2% pilocarpine in second study </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; aspirin </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(24 to 716) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.83</b> (0.33 to 10.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg aspirin 3 times/day for 5 days vs observation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for risk of bias (−1).<br/><sup>3</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005431-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Non‐pharmaceutical interventions compared with control for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐pharmaceutical interventions compared with control for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> non‐pharmaceutical interventions </p> <p><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Non‐pharmacuetical agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/60 at end of treatment; monocular vs binocular eye patching </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>808 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>662 per 1000</b><br/>(541 to 808) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.67 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity measured at end of treatment, typically within 2 weeks of occurrence of hyphema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> between 20/20 and 20/50; monocular vs binocular eye patching </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>846 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>803 per 1000</b><br/>(652 to 998) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.77 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time frame when visual acuity measured not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/50 at end of treatment; </p> <p>ambulatory vs bed rest</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>846 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>931 per 1000</b><br/>(710 to 1218) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> (0.84 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (1)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity measured at end of treatment, typically within 2 weeks of occurrence of hyphema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b>; ambulatory vs bed rest </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A single study reported that mean resolution of primary hemorrhage was 5.8 days in the ambulatory group and 5.6 days in the bed rest group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; monocular vs binocular eye patching </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b><br/>(51 to 254) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> (0.35 to 1.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (2)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; ambulatory treatment vs bed rest </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b><br/>(108 to 445) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.28</b> (0.68 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for risk of bias (−1).<br/><sup>3</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005431-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005431-sec-0009"></div> <p>The original version of this review was first published in 2011 (<a href="./references#CD005431-bbs2-0113" title="GharaibehA , SavageHI , SchererRW , GoldbergMF , LindsleyK . Medical interventions for traumatic hyphema. Cochrane Database of Systematic Reviews2011, Issue 1. Art. No: CD005431. [DOI: 10.1002/14651858.CD005431.pub2]">Gharaibeh 2011</a>). This is the third update of the review. </p> <section id="CD005431-sec-0010"> <h3 class="title" id="CD005431-sec-0010">Description of the condition</h3> <section id="CD005431-sec-0011"> <h4 class="title">Introduction</h4> <p>Traumatic hyphema is the entry of blood into the anterior chamber (the space between the cornea and iris) subsequent to a blow or a projectile striking the eye. Apart from the direct consequences of the initial trauma, traumatic hyphema is usually a self‐limiting condition that rarely causes permanent loss of vision in the absence of associated damage to the cornea, lens, or optic nerve. Traumatic hyphema is an important clinical entity because of the risks associated with significant initial reduction in vision and because of associated injuries to the tissues of the eye. In young children, it can lead to the development of irreversible amblyopia. Complications resulting from secondary hemorrhage, such as glaucoma, corneal blood staining, or optic atrophy, can lead to permanent impairment of vision, especially if the hyphema is prolonged in association with elevated intraocular pressure (IOP). </p> </section> <section id="CD005431-sec-0012"> <h4 class="title">Epidemiology</h4> <p>Traumatic hyphema is usually seen in children or young adults, with an incidence of approximately 2 per 10,000 children per year (<a href="./references#CD005431-bbs2-0112" title="WrightKW . Pediatric ocular trauma: pediatric hyphema. In: WrightKW , SpiegelPH , editors(s). Pediatric Ophthalmology and Strabismus. Vol. 6. Springer, 2003:79-82.">Wright 2003</a>). Males predominate, with a male‐to‐female ratio of 3:1 (<a href="./references#CD005431-bbs2-0097" title="Crouch ER Jr, WilliamsPB . Trauma: ruptures and bleeding. In: TasmanW , JaegerEM , editors(s). Duane's Clinical Ophthalmology. Vol. 4. Philadelphia: JB Lippincott, 1993:1-18.">Crouch 1993</a>). Sports injuries account for 60% of traumatic hyphemas (<a href="./references#CD005431-bbs2-0098" title="Crouch ER Jr, CrouchER . Management of traumatic hyphema: therapeutic options. Journal of Pediatric Ophthalmology and Strabismus1999;36(5):238.">Crouch 1999</a>). </p> </section> <section id="CD005431-sec-0013"> <h4 class="title">Presentation and diagnosis</h4> <p>Patients usually present with a sudden decrease or loss of vision following an injury to the eye. The loss of vision depends on the level of hyphema: a person with a microhyphema occasionally may present with normal vision or with minimally blurred vision, whereas a person with a full hyphema may present with almost complete loss of vision. With time, blood in the anterior chamber is forced by gravity to the bottom of the anterior chamber. Subsequently, vision clears gradually unless associated injuries, traumatic uveitis, glaucoma, optic atrophy, or corneal blood staining contributes to further and sometimes longstanding losses of vision. </p> <p>The severity of traumatic hyphema varies from microhyphema, where red blood cells are suspended in the anterior chamber and seen only with a biomicroscope (slit‐lamp), to a layered hyphema, where fresh or clotted blood may be observed grossly in the lower anterior chamber. In a full or total hyphema, the entire anterior chamber is filled with blood, and the iris and other intraocular structures cannot be seen by the examiner. </p> <p>Recurrent hemorrhage, occurring at a rate of 2% to 38% (<a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a>), increases the time to visual recovery and is associated with poorer visual outcomes. Secondary hemorrhage typically occurs three to five days after the incident hyphema and may occur due to clot lysis and retraction within the traumatized vessels. </p> <p>Hyphema in the setting of sickle cell trait/disease appears to be particularly dangerous, because the naturally hypoxic and relatively acidotic anterior chamber induces sickling of red blood cells. Sickling in turn prevents normal egress of those blood cells through the trabecular meshwork. Hyphema patients with sickle cell trait/disease may be at a higher risk for elevated IOP (<a href="./references#CD005431-bbs2-0104" title="LaiJC , FekratS , BarrronY , GoldbergMF . Traumatic hyphema in children: risk factors for complications. Archives of Ophthalmology2001;119(1):64-70.">Lai 2001</a>). </p> <p>The most important sign for diagnosing hyphema is the presence of blood in the anterior chamber assessed by a slit‐lamp exam. Various grading schemes for hyphema have been proposed. Objective quantification of the level of hyphema is critical, because a sudden increase in the height of a layered hyphema is indicative of 'rebleed.' Immediate measurement of IOP and a dilated ophthalmoscopic exam (to rule out traumatic retinal tears, dialyses, and detachment) are also indicated at a relatively early time after clearance of hyphema. </p> </section> </section> <section id="CD005431-sec-0014"> <h3 class="title" id="CD005431-sec-0014">Description of the intervention</h3> <p>Management of traumatic hyphema focuses on preventing repeated eye trauma and rebleed; promoting the settling of blood away from the visual axis; controlling traumatic anterior uveitis; and monitoring in order to initiate early prophylaxis or treatment for both secondary glaucoma and corneal blood staining. Methods employed to prevent recurrent or iatrogenic trauma include shielding the eye, bed rest, and avoidance of diagnostic interventions such as scleral depression or gonioscopy that could deform the globe. Elevation of the head while sleeping, topical corticosteroids, and cycloplegic medications are frequently used in the management of traumatic hyphema. Hospitalization, once considered essential in order to enforce bed rest, has been questioned and is currently advocated only for patients perceived to be at high risk of rebleed, at risk of non‐compliance with bed rest at home, or possibly with sickle cell trait/disease so that IOP can be frequently measured. </p> <p>The use of antifibrinolytic agents such as epsilon‐aminocaproic acid and tranexamic acid in traumatic hyphema is controversial. These agents are reported to potentially reduce the rate of recurrent hemorrhage, but are known to have several possible side effects, such as nausea, vomiting, muscle cramps, conjunctival suffusion, headache, rash, pruritis, dyspnea, toxic confusional states, arrhythmias, and systemic hypotension. Epsilon‐aminocaproic acid is contraindicated in women who are pregnant and in people with coagulopathies or renal diseases, and should be used cautiously in people with hepatic, cardiovascular, or cerebrovascular diseases. A topical gel form of epsilon‐aminocaproic acid has not yet received US Food and Drug Administration (FDA) approval; it appears to have comparable effectiveness, with fewer side effects, as compared with the oral form, and thus might be used on an outpatient basis. Tranexamic acid (Cyklokapron) is reported to be more potent than epsilon‐aminocaproic acid and has similar side effects, but with fewer gastric side effects (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>). </p> <p>Corticosteroids have also been used to treat hyphema and are reported to be effective (<a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a>). Investigators have studied both topical and systemic corticosteroids, applying these agents for varying lengths of time with or without other interventions, such as bed rest or cycloplegics. Topical administration of corticosteroids avoids the side effects of systemic corticosteroid use, but it is not known whether topically applied corticosteroids are as effective as systemic corticosteroids in reducing the rate of rebleed. The mechanism of action of corticosteroids is thought to be due to stabilization of the blood‐ocular barrier, direct inhibition of fibrinolysis, or reduced inflammation (<a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a>). </p> <p>Surgical evacuation of hyphema is generally not needed. In the past, surgical evacuation was often contraindicated due to the possibility of sudden decreases in IOP and increased risk of recurrent hemorrhage (due to decompression of the blood vessels in the damaged iris and ciliary body). However, surgical 'washout' is advocated in people with non‐clearing hyphema, in whom secondary glaucoma threatens to cause permanent visual loss due to glaucomatous optic neuropathy or to corneal blood staining. Surgical washout is often performed (via simple paracentesis) in people with sickle cell trait because of the increased risk from elevated IOP. </p> </section> <section id="CD005431-sec-0015"> <h3 class="title" id="CD005431-sec-0015">How the intervention might work</h3> <p>The mode of action of medications used to treat traumatic hyphema, especially the antifibrinolytics, is through slowing or inhibiting the resorption of the blood clot within traumatized blood vessels. Aminocaproic acid slows the dissolution of the fibrin blood clot by competing at sites that bind lysine, including lysine sites on tissue plasminogen activator, and inhibiting the conversion of plasminogen to plasmin, the enzyme involved in the breakdown of the fibrin clot (<a href="./references#CD005431-bbs2-0109" title="SheppardJD , CrouchER , WilliamsPB , Crouch ER Jr, RastogiS , Garcia-ValenzuelaE . Hyphema. Updated: 22 December 2009. emedicine.medscape.com/1190165.overview (accessed 8 January 2010).">Sheppard 2009</a>; <a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a>). Aminocaproic acid also competitively inhibits the binding of plasmin to the fibrin clot itself. Both of these mechanisms result in a slowing of the breakdown of the fibrin clot, thus stabilizing it and potentially reducing the risk of secondary hemorrhage. Tranexamic acid also binds to fibrin and is believed to act through a similar mechanism. The action of aminobenzoic acid involves inhibition of fibrinolysis, and estrogens decrease antithrombin activity, both of which result in delays of clot resorption (<a href="./references#CD005431-bbs2-0111" title="WestlundLE , LundénR , WallénP . Effect of EACA, PAMBA, AMCA and AMBOCA on fibrinolysis induced by streptokinase, urokinase and tissue activator. Haemostasis1982;11(4):235-41.">Westlund 1982</a>). In addition to inhibition of fibrinolysis, corticosteroids are also believed to stabilize the blood‐ocular barrier and reduce inflammation.   </p> <p>The goal of most of the other interventions used in the management of traumatic hyphema is to prevent complications from the trauma or from a rebleed, including further trauma, anterior uveitis, secondary glaucoma, optic atrophy, or corneal blood staining. These interventions have included bed rest and eye patching to prevent further trauma; use of mydriatic or miotic agents to prevent motion of the iris, increased IOP, or uveitis; corticosteroids to prevent inflammation; and elevation of the head to facilitate settling of the blood in the anterior chamber. Hospitalization facilitates close monitoring of more severe cases of trauma or rebleeding (or both), allowing more timely medical or surgical intervention, if warranted. </p> </section> <section id="CD005431-sec-0016"> <h3 class="title" id="CD005431-sec-0016">Why it is important to do this review</h3> <p>Despite the existence of guidelines for the management of traumatic hyphema (<a href="./references#CD005431-bbs2-0098" title="Crouch ER Jr, CrouchER . Management of traumatic hyphema: therapeutic options. Journal of Pediatric Ophthalmology and Strabismus1999;36(5):238.">Crouch 1999</a>; <a href="./references#CD005431-bbs2-0107" title="RheeD , PyferM . The Wills Eye Manual. Lippincott Williams and Wilkins, 1999.">Rhee 1999</a>; <a href="./references#CD005431-bbs2-0109" title="SheppardJD , CrouchER , WilliamsPB , Crouch ER Jr, RastogiS , Garcia-ValenzuelaE . Hyphema. Updated: 22 December 2009. emedicine.medscape.com/1190165.overview (accessed 8 January 2010).">Sheppard 2009</a>), the safety and effectiveness of various therapeutic modalities such as the use of antifibrinolytic agents, their routes of administration, use of corticosteroids, and hospitalization are controversial. Evidence for the impact of rebleed on visual outcomes, glaucoma, optic atrophy, and blood staining is limited. Furthermore, rebleed, which is a surrogate outcome (rather than visual outcome), dominates the published literature on management of traumatic hyphema. It is important to examine the impact of the various antifibrinolytic medications, routes of administration, and dosages used across various populations. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005431-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005431-sec-0017"></div> <p>To assess the effectiveness of various medical interventions in the management of traumatic hyphema. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005431-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005431-sec-0018"></div> <section id="CD005431-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005431-sec-0020"> <h4 class="title">Types of studies</h4> <p>We included randomized and quasi‐randomized trials.</p> </section> <section id="CD005431-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included trials in which the study population consisted of people with traumatic hyphema following closed‐globe trauma. We applied no restrictions on age, gender, or severity of the closed‐globe trauma or level of visual acuity (VA) at the time of enrollment. </p> </section> <section id="CD005431-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We considered trials in which:</p> <p> <ol id="CD005431-list-0001"> <li> <p>antifibrinolytic agents (e.g. epsilon‐aminocaproic acid, tranexamic acid) or corticosteroids in any form or dosage, with the intention of treating or reducing the signs or symptoms of traumatic hyphema, were compared with other treatments, placebo, or no treatment. There was no time limit on the duration of treatment; </p> </li> <li> <p>bed rest was compared with ambulatory management;</p> </li> <li> <p>bilateral patching was compared with unilateral or no patching;</p> </li> <li> <p>outpatient management was compared with inpatient management; or</p> </li> <li> <p>any other medical (non‐surgical) intervention was compared with another medical intervention or no intervention. </p> </li> </ol> </p> </section> <section id="CD005431-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD005431-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005431-list-0002"> <li> <p>Proportion of participants with best‐corrected visual acuity (BCVA) of 20/40 or better assessed at short‐, medium‐, and long‐term follow‐up, defined respectively as two weeks or less; more than two weeks but within two months; and more than two months from the traumatic event. We also assessed VA at resolution of hyphema. </p> </li> <li> <p>Time to resolution of primary hemorrhage (hyphema) defined as the length of time from onset to disappearance of hyphema. </p> </li> </ol> </p> </section> <section id="CD005431-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes for this review were sequelae of traumatic hyphema assessed at the time of last study follow‐up. </p> <p> <ol id="CD005431-list-0003"> <li> <p>Proportion of participants with rebleed (i.e. secondary hemorrhage), defined as (a) an increase in height of layered hyphema using a biomicroscopic caliper or by any other method; or (b) the occurrence of fresh (red) blood in the eye with the existing clot. We also reported the average time to rebleed among participants with rebleed when this information was available. </p> </li> <li> <p>Proportion of participants with corneal blood staining.</p> </li> <li> <p>Proportion of participants with peripheral anterior synechiae (PAS) formation.</p> </li> <li> <p>Proportion of participants with elevated IOP or glaucoma development, as defined by trial investigators. </p> </li> <li> <p>Proportion of participants with optic atrophy development.</p> </li> </ol> </p> <section id="CD005431-sec-0026"> <h6 class="title">Adverse effects</h6> <p>We summarized the reported topical and systemic adverse effects related to treatment.</p> </section> <section id="CD005431-sec-0027"> <h6 class="title">Quality of life outcomes</h6> <p>We described available data on indicators of quality of life.</p> </section> <section id="CD005431-sec-0028"> <h6 class="title">Economic outcomes</h6> <p>We assessed the need for bed rest or hospitalization versus outpatient care. We also compared length of hospital stay as described in the primary reports. No other economic outcomes were reported. </p> </section> <section id="CD005431-sec-0029"> <h6 class="title">Follow‐up</h6> <p>There were no restrictions based on length of follow‐up.</p> </section> </section> </section> </section> <section id="CD005431-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005431-sec-0031"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following electronic databases for randomized controlled trials (RCTs) and controlled clinical trials. There were no language or publication year restrictions. The date of the search was 22 March 2022. </p> <p> <ul id="CD005431-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 3) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 22 March 2022) (<a href="./appendices#CD005431-sec-0282">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 22 March 2022) (<a href="./appendices#CD005431-sec-0283">Appendix 2</a>). </p> </li> <li> <p>Embase.com (1980 to 22 March 2022) (<a href="./appendices#CD005431-sec-0284">Appendix 3</a>). </p> </li> <li> <p>PubMed (1948 to 22 March 2022) (<a href="./appendices#CD005431-sec-0285">Appendix 4</a>). </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 22 March 2022) (<a href="./appendices#CD005431-sec-0286">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 22 March 2022) (<a href="./appendices#CD005431-sec-0287">Appendix 6</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 22 March 2022) (<a href="./appendices#CD005431-sec-0288">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD005431-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included trial reports to find additional trials. We also searched the ISI Web of Science Social Sciences Citation Index (SSCI) to find studies that cited the included trials. We planned to contact the primary investigators of the included trials for details of additional trials, but were unable to do so, because most trials were published more than 10 years ago. We did not conduct manual searches of conference proceedings or abstracts specifically for this review. </p> </section> </section> <section id="CD005431-sec-0033"> <h3 class="title" id="CD005431-sec-0033">Data collection and analysis</h3> <section id="CD005431-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed the titles and abstracts of all reports identified by the electronic and manual searches as per the <a href="#CD005431-sec-0019">Criteria for considering studies for this review</a>. We classified the abstracts as (a) definitely include, (b) unsure, or (c) definitely exclude. We obtained full copies of those abstracts classified as (a) or (b) and reassessed them as per the <a href="#CD005431-sec-0019">Criteria for considering studies for this review</a>. We assessed the studies as (1) include, (2) awaiting assessment, or (3) exclude. We documented the concordance between review authors and resolved any disagreements by consensus or by consulting a third review author. We planned to contact authors of studies classified as (2) for clarification of unclear inclusion and exclusion criteria, but were unable to do so. We excluded from the review studies identified by both review authors as (3), documenting our reasons for exclusion in the <a href="./references#CD005431-sec-0299" title="">Characteristics of excluded studies</a> table. We included studies identified as (1) in the review and described them in the <a href="./references#CD005431-sec-0298" title="">Characteristics of included studies</a> table. The review authors were unmasked to the reports' authors, institutions, and trial results during this assessment. </p> </section> <section id="CD005431-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted the data for the primary and secondary outcomes onto data collection forms developed by Cochrane Eyes and Vision. Any discrepancies were resolved by discussion. We attempted to contact primary investigators for missing data, but were unable to do so. One review author entered all data into Review Manager 5, <a href="./references#CD005431-bbs2-0105" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>, or RevMan Web, <a href="./references#CD005431-bbs2-0106" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>, and a second review author verified all values. </p> </section> <section id="CD005431-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors assessed the sources of systematic bias in trials according to the methods described in Chapter 8 of the <i>Cochrane Handbookfor Systematic Reviews of Interventions</i> (<a href="./references#CD005431-bbs2-0103" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We considered the following parameters: adequate sequence generation and allocation concealment (selection bias), masking of participants and researchers (performance bias), masking of outcome assessors (detection bias), adequate handling of incomplete data by reporting rates of follow‐up and using intention‐to‐treat analysis (attrition bias), and complete reporting of outcomes (reporting bias). We assessed each of the parameters as low, high, or unclear risk of bias. We documented agreement between authors, resolving any disagreements by consensus or by involving a third review author. We used masking of participants and care providers as a quality criterion only in interventions where masking was feasible. We contacted the authors of trials categorized as at unclear risk of bias for additional information when contact information for the trial authors was available. In cases where we were unable to contact the study authors or the study authors did not respond to our request, we assigned a grade based on the available information. </p> </section> <section id="CD005431-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <section id="CD005431-sec-0038"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous outcomes, we calculated summary risk ratios (RR) with 95% confidence intervals (CIs). We analyzed VA outcomes as dichotomous variables. For each follow‐up period with sufficient data, we compared the proportion of participants with VA 20/40 or better between the treatment and control groups. We analyzed data on the proportion of participants with secondary hemorrhage, corneal blood stain, PAS formation, glaucoma development, and optic atrophy development as dichotomous data. </p> </section> <section id="CD005431-sec-0039"> <h5 class="title">Continuous data</h5> <p>We calculated mean differences (MD) for continuous outcomes. We analyzed the time to resolution of primary hemorrhage (hyphema), defined as the length of time from onset to disappearance, as a continuous variable. We also analyzed the length of time to rebleed, duration of hospitalization, and other quality of life and economic outcomes as continuous data. </p> </section> <section id="CD005431-sec-0040"> <h5 class="title">Ordinal data</h5> <p>We summarized ordinal data qualitatively.</p> </section> <section id="CD005431-sec-0041"> <h5 class="title">Counts and rate data</h5> <p>We summarized counts and rate data in rate ratios when the event was rare, and as continuous outcome data when the event was more common. We analyzed adverse events data as counts and rates. </p> </section> </section> <section id="CD005431-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the affected eye or eyes of the individual participant.</p> </section> <section id="CD005431-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of the included studies to obtain additional data when contact information for the trial authors was available. When we were unable to retrieve additional data because we were unable to contact the authors or received no response, we imputed data with the available information from the study report. We reported loss to follow‐up for each study when this information was available. We also noted when intention‐to‐treat analyses were performed. </p> </section> <section id="CD005431-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to assess for statistical heterogeneity and examined clinical heterogeneity using forest plots. We considered I<sup>2</sup> values greater than 50% to represent statistical heterogeneity between studies. </p> </section> <section id="CD005431-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not use funnel plots to assess the possibility of small‐study effects or reporting biases, because no more than 10 studies were included in a meta‐analysis. </p> </section> <section id="CD005431-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We analyzed data according to the guidelines in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005431-bbs2-0099" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). We tested for statistical heterogeneity. Where we detected no statistical heterogeneity and there was no clinical heterogeneity among the trials, we combined the results in a meta‐analysis using a fixed‐effect model. In cases of statistical or clinical heterogeneity, we did not combine study results but instead presented a tabulated summary. </p> </section> <section id="CD005431-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses according to age, race, presence of sickle cell trait/disease, presenting IOP, and severity of hyphema, but these analyses were precluded due to insufficient numbers of trials. We planned to present results by subgroup as an Additional table. </p> </section> <section id="CD005431-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to determine the impact of excluding studies of lower methodologic quality. We planned to conduct sensitivity analyses to determine the impact of excluding unpublished studies or industry‐funded studies, but there were no included studies with these characteristics. </p> </section> <section id="CD005431-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed each outcome using the GRADE approach, which judges the certainty of the evidence based on risk of bias, inconsistency, indirectness, imprecision, and publication bias, as described in Chapter 11 of the <i>Cochrane Handbookfor Systematic Reviews of Interventions</i> (<a href="./references#CD005431-bbs2-0108" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , AklE , Guyatt GH on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>). We prepared a summary of findings table for each main comparison and included the following outcomes. </p> <p> <ol id="CD005431-list-0005"> <li> <p>Proportion of participants with BCVA of 20/40 or better assessed at short‐term follow‐up, defined as two weeks or less from the traumatic event. </p> </li> <li> <p>Proportion of participants with BCVA of 20/40 or better assessed at medium‐term follow‐up, defined as more than two weeks but within two months of the traumatic event. </p> </li> <li> <p>Proportion of participants with BCVA of 20/40 or better assessed at long‐term follow‐up, defined as more than two months from the traumatic event. </p> </li> <li> <p>Proportion of participants with BCVA of 20/40 or better assessed at resolution of hyphema. </p> </li> <li> <p>Time to resolution of primary hemorrhage (hyphema), defined as the length of time from onset to disappearance of hyphema. </p> </li> <li> <p>Proportion of participants with rebleed (i.e. secondary hemorrhage).</p> </li> <li> <p>Proportion of participants with adverse effects.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005431-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005431-sec-0050"></div> <section id="CD005431-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD005431-sec-0052"> <h4 class="title">Results of the search</h4> <p>The original electronic literature searches conducted in June 2010 identified 836 potentially relevant references. In the 2011 publication of this review (<a href="./references#CD005431-bbs2-0113" title="GharaibehA , SavageHI , SchererRW , GoldbergMF , LindsleyK . Medical interventions for traumatic hyphema. Cochrane Database of Systematic Reviews2011, Issue 1. Art. No: CD005431. [DOI: 10.1002/14651858.CD005431.pub2]">Gharaibeh 2011</a>), we included 26 studies as reported in 33 publications and excluded 41 studies in 42 publications. </p> <p>After revising and updating the electronic searches as of August 2013, we identified 460 additional references. In the 2013 publication of this review (<a href="./references#CD005431-bbs2-0114" title="GharaibehA , SavageHI , SchererRW , GoldbergMF , LindsleyK . Medical interventions for traumatic hyphema. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD005431. [DOI: 10.1002/14651858.CD005431.pub3]">Gharaibeh 2013</a>), we included 27 studies reported in 38 publications and excluded 62 studies reported in 63 publications. </p> <p>We updated the searches for this review in June 2018. Of 479 records identified by the searches, we examined the full‐text reports of two studies and excluded both (<a href="./references#CD005431-bbs2-0092" title="ZhangH , SunHQ , ChenR . Clinical analysis on the chymotrypsin treatment of 42 patients with contusive hyphema at grade III. International Eye Science2013;13(12):2517-8. ">Zhang 2013</a>; <a href="./references#CD005431-bbs2-0093" title="ZhangHF , KangJ , MaQM , ZhaoZH , JiaZY . Effect of Hexue mingmu tablets in the treatment of hyphema. International Eye Science2014;14(9):1710-2. ">Zhang 2014</a>). We identified no new eligible trials since the 2013 version of this review. </p> <p>We performed updated database searches in March 2022, which yielded 1081 unique records. After screening of titles and abstracts, we retrieved five full‐text reports for further review. We additionally found two relevant publications through searching the reference lists of included studies. We included three new studies (five reports) and excluded two studies (two reports) in this update. </p> <p>We included a total of 30 studies in 43 publications and excluded a total of 66 studies in 67 publications in this review. A study flow diagram is shown in <a href="#CD005431-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD005431-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005431-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005431-sec-0053"> <h4 class="title">Included studies</h4> <p>For details of included studies, see <a href="./references#CD005431-sec-0298" title="">Characteristics of included studies</a>. </p> <p>Twenty‐three studies were RCTs, and seven studies used a quasi‐randomized method to assign participants to treatment groups. The review outcomes reported by the included studies are listed in <a href="#CD005431-tbl-0007">Table 1</a>. </p> <div class="table" id="CD005431-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of outcomes* reported by intervention</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcomes</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Adverse effects</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Duration of hospitalization or quality of life outcomes</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Visual acuity</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Time to resolution of primary hemorrhage</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary hemorrhage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of corneal blood staining</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of PAS formation</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of pathologic increase in IOP or glaucoma</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of optic atrophy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of rebleed</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to rebleed</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Aminocaproic acid vs placebo</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Oral aminocaproic acid</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Topical aminocaproic acid</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Low‐dose</b> <b>vs standard‐dose aminocaproic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Oral vs topical aminocaproic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Oral tranexamic acid vs control</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No rebleeds occurred</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization and days off work reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Aminomethylbenzoic acid vs placebo</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Corticosteroids vs control</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Oral corticosteroids</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of PAS formation reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Topical corticosteroids</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Oral aminocaproic acid vs oral prednisone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Oral tranexamic acid vs oral prednisone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Topical tranexamic acid vs oral prednisone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Conjugated estrogen vs placebo</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Cycloplegics vs miotics</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Aspirin vs observation</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Traditional Chinese medicine vs control treatment</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Monocular vs binocular patching</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of secondary glaucoma reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life outcomes reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Ambulatory vs conservative treatment</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Elevation of the head vs control</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of secondary glaucoma reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*See <a href="#CD005431-sec-0023">Types of outcome measures</a> for detailed descriptions of outcomes.<br/>**Noted as 'partially reported' if some information was reported but it was insufficient for quantitative data analyses. </p> <p>Abbreviations: IOP: intraocular pressure; NS: not significant; PAS: peripheral anterior synechiae; VA: visual acuity. </p> </div> </div> <p>All but two of the included studies restricted entry to people with primary traumatic hyphema: <a href="./references#CD005431-bbs2-0085" title="WelshN . The management of traumatic glaucoma. South African Medical Journal1971;45(44):1250-2. ">Welsh 1971</a> also included people with perforated globes that had been sutured and were treated as closed‐globe injuries, and <a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> also included people with secondary hemorrhage. Most studies included all age groups, although some studies excluded very young children (e.g. less than four or seven years) (<a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a>; <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>; <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a>; <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>; <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a>), and one study included children only (<a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>). Of studies reporting demographic data, the mean age of participants ranged from 10 to 32 years, and the proportion of male participants ranged from 67% to 100%. Studies took place in a number of different countries: three in China; five in Iran; two each in Sweden and South Africa; one each in Denmark, Israel, and Malaysia; and the remainder in Canada and the USA. The race of participants varied by country, with nine studies reporting 50% or more black participants. </p> <p>The included studies investigated three types of antifibrinolytic agents: epsilon‐aminocaproic acid (aminocaproic acid), tranexamic acid, and aminomethylbenzoic acid. Other types of pharmaceuticals investigated were corticosteroids, including prednisone, prednisolone, hydrocortisone, and cortisone; conjugated estrogen; aspirin; and topical mydriatics and miotics. One study compared traditional Chinese medicine (Yunnan Baiyao) versus antihemorrhagic agents. Non‐pharmaceutical interventions included the use of monocular or binocular patching, eye shields, bed rest, and elevation of the head. The primary outcome for all but three studies was the risk of a secondary hemorrhage. </p> <section id="CD005431-sec-0054"> <h5 class="title">Aminocaproic acid</h5> <p>Eight studies investigated the use of aminocaproic acid compared with placebo in treating traumatic hyphema: six studies prescribed oral aminocaproic acid (<a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a>; <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>; <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>; <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>; <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>), and two studies prescribed topical aminocaproic acid (<a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a>; <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a>). The dosage of oral aminocaproic acid used in five studies was 100 mg/kg of body weight every four hours for five days (<a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>; <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>; <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>; <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>); the remaining study used a loading dose of 75 mg/kg of body weight, then doses of 60 mg/kg of body weight every four hours, although the length of treatment was not reported (<a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a>). The six studies included a total of 331 participants (34 to 94 participants per study); 175 participants were randomized to receive oral aminocaproic acid, and 156 participants were randomized to receive placebo pills. The follow‐up periods ranged from the length of hospitalization (typically about one to two weeks) to 3.4 years after discharge. </p> <p>Two studies (206 participants) evaluated topical aminocaproic acid. <a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> had three treatment groups: 45 participants were randomized to receive aminocaproic acid (two drops of 25% aminocaproic acid in 2% carboxymethylene gel applied to the inferior fornix of the affected eye every six hours for five days) plus homatropine eye drops three times per day; 44 participants were randomized to receive placebo gel plus homatropine eye drops; and 66 participants were randomized to receive homatropine eye drops only. Homatropine is a cycloplegic agent used to temporarily prevent the eye muscles from moving and to enlarge the pupil. The follow‐up period for this study was 14 days. In <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a>, 24 participants were randomized to receive aminocaproic acid (30% aminocaproic acid in 2% gel instilled in the inferior fornix following one drop of 0.05% proparacaine hydrochloride every six hours for five days), and 27 participants were randomized to receive placebo gel applied in the same manner as in the intervention group. Participants in this study were managed on an outpatient or inpatient basis and followed for seven days. </p> <p>One study compared oral aminocaproic acid versus topical aminocaproic acid for the treatment of traumatic hyphema (<a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a>). Of the 118 participants eligible for inclusion in the study, 64 participants agreed to be randomized to receive either topical aminocaproic acid (0.2 mL of 30% aminocaproic acid in 2% carboxymethylene gel applied to the inferior fornix every six hours plus oral placebo solution every four hours for five days) or oral aminocaproic acid (50 mg/kg of body weight of oral aminocaproic acid, up to 30 g per day, plus placebo gel every four hours for five days). The 54 participants who declined study entry were followed as an untreated control group. The participants in this study were hospitalized and followed for five days. </p> <p>The last study investigating the use of aminocaproic acid compared low‐dose oral aminocaproic acid (50 mg/kg, up to 5 g per dose or 30 g per day every four hours for five days) versus standard‐dose oral aminocaproic acid (100 mg/kg, up to 5 g per dose or 30 g per day every four hours for five days) for the treatment of traumatic hyphema (<a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a>). The participants in this study, 26 in the low‐dose group and 33 in the standard‐dose group, were followed for the duration of hospitalization. </p> </section> <section id="CD005431-sec-0055"> <h5 class="title">Tranexamic acid</h5> <p>Seven studies investigated the use of oral tranexamic acid compared with a control in treating traumatic hyphema (<a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a>; <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>; <a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a>; <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>; <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a>; <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a>). Two of these studies also included a third arm assigned to oral prednisone (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>). The studies included a total of 863 participants: 367 assigned to tranexamic acid, 390 to a control intervention, and 141 to prednisone. The doses of tranexamic acid administered in these studies varied from 75 mg/kg per day for five days to 1.5 g per day for seven days. Participants were followed for five to 12 days. The study by <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> assigned 42 mg/kg oral tranexamic acid daily for five days to 82 participants; 0.75 mg/kg oral prednisone daily for five days to 81 participants; and daily placebo for five days to 81 participants. <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a> similarly assigned 75 mg/kg daily of oral tranexamic acid to 60 participants; 0.8 mg daily of oral prednisone to 60 participants; and daily placebo to 62 participants. All participants were followed for five days in both studies (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>). In three studies, participants were assigned to oral tranexamic acid 25 mg/kg per day for seven days (<a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a>; <a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a>; <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>). In <a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a>, both the group receiving tranexamic acid (n = 17) and the control group (n = 18) received bilateral patching, bed rest, sedation, analgesics, and topical corticosteroid drops from day 3 through day 7. Both groups were followed for one week. Participants in both the tranexamic acid and the control group in the study by <a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a> also received betamethasone, hematropine, timolol, acetazolamide, and chloramphenicol for five days in addition to the tranexamic acid (<a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a>). In <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>, 59 participants were randomized to receive oral tranexamic acid and 53 participants were randomized to receive complete bed rest for six days; participants were followed for seven days. <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> compared the same dose of tranexamic acid, 25 mg/kg daily for seven days, along with hospitalization and bed rest (n = 102) versus hospitalization and bed rest alone in the control group (n = 130). Participants were followed for 12 days. In <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a>, 19 participants were randomized to receive the largest dose of tranexamic acid, three 500 mg tablets of oral tranexamic acid three times a day for seven days (for an overall total dose of 31.5 g tranexamic acid), and 20 participants were randomized to receive three tablets of placebo three times a day for seven days. </p> <p>One study investigated the use tranexamic acid eye drops (<a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a>). In this study, 45 participants were assigned to 5% tranexamic acid eye drops administered every 6 hours along with 2% homotropine for 5 days or until clot resolution, and 45 participants were assigned to 1 mg/kg oral prednisone administered as a single daily dose for 5 days or until clot resolution. </p> </section> <section id="CD005431-sec-0056"> <h5 class="title">Aminomethylbenzoic acid</h5> <p>One study compared oral aminomethylbenzoic acid versus placebo for the treatment of traumatic hyphema (<a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a>). The study, published in Chinese, randomized 60 participants to the intervention group and 32 participants to the placebo group. Participants in the intervention group received oral aminomethylbenzoic acid 0.5 g plus oral vitamin B<sub>1</sub> 20 mg three times a day for six days. The dosage of aminomethylbenzoic acid was modified for children to "follow age‐recommended dose"; the vitamin B<sub>1</sub> dosage remained the same. Participants in the control group received oral vitamin B<sub>1</sub> (20 mg) three times a day for six days. The follow‐up period for the study was one week following blood resolution. </p> </section> <section id="CD005431-sec-0057"> <h5 class="title">Corticosteroids</h5> <p>Five studies examined the use of corticosteroids, three using an oral preparation (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>; <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>), and two using a topical preparation (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>; <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a>). <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> compared oral prednisone versus placebo for the treatment of traumatic hyphema. Twenty‐three participants were randomized to the treatment group: oral prednisone, 40 mg/day for adults and children over 10 years old; 15 mg/day for children between four and 10 years; and 10 mg/day for children between 18 months and four years, for seven days; and 20 participants were randomized to the control group: lactose placebo capsules administered daily for seven days. All participants were followed for seven days, and some for up to six months. Two studies consisted of three intervention arms. In the study by <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>, one arm included 82 participants who received oral tranexamic acid 75 mg/kg per day, divided into three doses per day, for five days. The second arm included 81 participants who received oral prednisolone 0.75 mg/kg per day, divided into two doses per day, for five days. The third arm included 81 participants who received placebo administered three times per day. The follow‐up period for this study was five days or until discharge. Similarly, in the study by <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>, 60 participants received 75 mg/kg oral tranexamic acid; 60 participants received 0.8 mg oral prednisone; and 62 participants received a placebo; all were divided into three doses per day. The remaining two studies administered topical corticosteroids. In <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a>, atropine plus corticosteroid eye drops (Decadron) was administered five times daily in 58 participants, while the control group of 59 participants simply received bed rest. The fifth study, <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>, compared the use of 0.5% hydrocortisone acetate in 13 participants versus topical 0.5% chloramphenicol in 21 participants. </p> </section> <section id="CD005431-sec-0058"> <h5 class="title">Antifibrinolytic agents versus corticosteroids</h5> <p>Three studies compared the use of antifibrinolytic agents versus corticosteroids for the treatment of traumatic hyphema. The first study included 122 participants, 64 of whom were allocated to receive oral aminocaproic acid and 58 to receive oral prednisone. All participants were followed through the treatment period (<a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a>). Participants in the aminocaproic acid group received 50 mg/kg oral aminocaproic acid (up to 30 g per day) every four hours plus two doses of placebo for five days. Participants in the prednisone group received 40 mg/day of oral prednisone in two doses plus six doses of placebo; children and adults weighing less than 60 kg were given 0.6 mg/kg/day of prednisone for five days. The other two studies, described above, divided participants into three groups: oral prednisolone, oral tranexamic acid, and placebo (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>). </p> </section> <section id="CD005431-sec-0059"> <h5 class="title">Conjugated estrogen</h5> <p>One study compared the use of conjugated estrogen versus placebo to treat traumatic hyphema (<a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a>). Participants randomized to receive conjugated estrogen were given 5 mg intramuscularly (children less than five years of age); 10 mg intramuscularly (children five years of age or older but less than 10 years of age); and 20 mg intravenously (children 10 years of age or older and adults), for five days. The 85 participants in the study were followed for five days or until discharge. </p> </section> <section id="CD005431-sec-0060"> <h5 class="title">Cycloplegics versus miotics</h5> <p>Two studies compared the use of cycloplegics (agents that paralyze the ciliary muscle and dilate the pupil) versus miotics (agents that constrict the pupil). <a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> evaluated 1% atropine ointment in 28 participants versus 2% pilocarpine (or eserine) ointment in 30 participants; participants were followed until the hyphema cleared (one to seven days). <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> examined the effects of 1% homatropine eye drops in 17 participants; 4% pilocarpine in 17 participants; homatropine plus pilocarpine in 17 participants; and neither agent in 19 participants over a period of one to two weeks. </p> </section> <section id="CD005431-sec-0061"> <h5 class="title">Aspirin</h5> <p>One study compared aspirin (500 mg three times a day for five days) versus observation for the treatment of traumatic hyphema (<a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>). Of the 51 included participants, 23 were randomized to the aspirin group and 28 to the observation group. All participants were followed for seven days. </p> </section> <section id="CD005431-sec-0062"> <h5 class="title">Traditional Chinese medicine</h5> <p>One study compared Yunnan Baiyao, a traditional Chinese medicine formula, versus control treatment for traumatic hyphema (<a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>). Yunnan Baiyao is an herbal supplement with alleged hemostatic and anti‐inflammatory properties. The 45 participants in the Yunnan Baiyao group received 0.5 g of the medicine four times a day orally in addition to oral antibiotics and topical 0.5% vinegar eye drops; the 38 participants in the control group received antihemorrhagic agents such as carbazochrome and etamsylate. Participants were treated for up to five days (until complete resolution of the hyphema) and followed up for one week. </p> </section> <section id="CD005431-sec-0063"> <h5 class="title">Monocular versus binocular patching</h5> <p>Two studies compared monocular versus binocular patching. <a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> compared monocular patching in 35 participants versus binocular patching in 29 participants. Follow‐up was one to seven days. In one of the comparisons conducted by <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>, 27 participants wore binocular patches; 26 participants wore monocular patches; and 10 participants wore no patch. Participants were followed up for one to two weeks. </p> </section> <section id="CD005431-sec-0064"> <h5 class="title">Ambulatory versus conservative treatment</h5> <p>In two studies, the test and control interventions consisted of multiple components but could be assessed as treatments allowing moderate activity compared with bed rest. <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> evaluated an intervention that included bed rest with elevation of the head, bilateral patches, an eye shield over the injured eye, and sedation in 66 participants compared with an intervention comprised of moderate ambulatory activity, patching, shielding of the injured eye, and no sedation in 71 participants. The second study, <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>, compared bed rest versus ambulation in 26 participants each. </p> </section> <section id="CD005431-sec-0065"> <h5 class="title">Combination and other interventions</h5> <p>In one study (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>), various components of a multiple‐component intervention were tested sequentially and separately. Four of these comparisons are described above (i.e. 0.5% hydrocortisone eye drops versus 0.5% chloramphenicol eye drops, monocular versus binocular patching, cycloplegics versus miotics, and ambulation versus bed rest). In addition, <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> also presented results on the following comparisons: 1) oral trypsin in 15 participants compared with oral papase in 18 participants or no treatment in 10 participants; and 2) oral acetazolamide 250 mg in 18 participants compared with oral glycerol 1 mL/kg in 18 participants and no treatment in 10 participants. </p> <p>The remaining study compared the time to resolution for participants lying flat either on the right or left side versus remaining in a semi‐reclined position (i.e. with the head elevated) (<a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a>). </p> </section> </section> <section id="CD005431-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 66 studies. The reasons for exclusion are provided in the <a href="./references#CD005431-sec-0299" title="">Characteristics of excluded studies</a> table. We excluded 47 studies because the study design was not a randomized or controlled clinical trial; nine studies because they included non‐traumatic hyphema cases and did not report outcomes for traumatic hyphema cases separately; seven studies because no original data were presented; and three studies because they investigated interventions outside the scope this review (e.g. surgical interventions and patient education interventions). </p> </section> </section> <section id="CD005431-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD005431-sec-0068"> <h4 class="title">Allocation</h4> <p>Twenty‐three of the 30 included studies were RCTs. Eight studies specified using computerized randomization to generate the allocation sequence, and one study used a randomization list; we judged these studies as having a low risk of sequence generation bias (<a href="#CD005431-fig-0002">Figure 2</a>). Fourteen of the 23 RCTs did not report methods of allocation and were therefore assessed as having an unclear risk of sequence generation bias. Of the 23 included RCTs, nine reported having implemented allocation concealment: two studies used sealed, numbered envelopes; two studies used coded bottles; and five studies maintained the randomization code at a pharmacy or other central study center. The remaining 14 RCTs did not report methods of allocation concealment. The seven studies that were not RCTs were controlled clinical trials but did not use randomization to assign participants to treatment. Participants were allocated by alternation in four studies, and by date of admission in one study. The remaining two controlled clinical trials did not report method of allocation. </p> <div class="figure" id="CD005431-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodologic quality summary: review authors' judgements about each methodologic quality item for each included study. Green: low risk of bias; red: high risk of bias; yellow: unclear risk of bias." data-id="CD005431-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodologic quality summary: review authors' judgements about each methodologic quality item for each included study. Green: low risk of bias; red: high risk of bias; yellow: unclear risk of bias. </p> </div> </div> </div> </section> <section id="CD005431-sec-0069"> <h4 class="title">Blinding</h4> <p>Thirteen of the 23 included RCTs were double‐masked (participants and investigators), placebo‐controlled trials. One study investigating two doses of oral aminocaproic acid was also double‐masked (<a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a>). Participants and treating physicians were partially masked in two studies in which there was only one placebo‐controlled group for two intervention groups with different treatment regimens (<a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a>; <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>). In both of these studies, it was noted that the ophthalmologists and outcome assessors were not involved in participant treatment and were masked to the treatment groups. The interventions of interest in three studies precluded masking: the first study compared aspirin three times daily versus observation only (<a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>); the second study compared bed confinement versus walking and oral tranexamic acid three times daily (<a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>); and the third study compared oral tranexamic acid with oral prednisone (<a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a>). Two studies did not mention whether or not masking had occurred (<a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a>; <a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>), and the authors of two studies reported that no masking was done (<a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a>; <a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a>). </p> <p>Masking of participants was not possible because of the type of interventions in four of the seven quasi‐randomized studies included in this review (<a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>; <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>; <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>; <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a>), and was not reported in one (<a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a>). Masking of participants with the use of placebo pills could have been implemented but was not achieved in the remaining two quasi‐randomized studies (<a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a>; <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a>). Masking of outcome assessors was not reported or unclear in all seven quasi‐randomized studies. </p> </section> <section id="CD005431-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition rates for the included studies were minimal due to the nature of the condition and treatment regimens. Typically, treatment duration for traumatic hyphema at the time the studies were completed was one week or less, and hospitalization was frequently implemented. Nineteen of the 30 included studies reported no exclusions or losses to follow‐up, thus using intention‐to‐treat analyses. Of the 10 studies that excluded participants from the analysis, four studies excluded only one or two participants due to an adverse effect of treatment (<a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a>; <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a>), treatment failure (<a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a>), or loss of a participant's medical record (<a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>). It was unclear how many participants had originally been randomized in one study, so attrition was unknown (<a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>). The reason for loss was also unclear in the study by <a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a>. The remaining five studies did not conduct intention‐to‐treat analyses, although all reported the number of exclusions and losses to follow‐up. </p> </section> <section id="CD005431-sec-0071"> <h4 class="title">Selective reporting</h4> <p>All but five of the included studies reported risk of a secondary hemorrhage as a primary outcome: in two studies, time to resolution of the hyphema was reported as the primary outcome (<a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a>; <a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a>); in another two studies, secondary hemorrhage was reported as a secondary outcome with no primary outcome identified (<a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>; <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>); and in the fifth study, absence of secondary hemorrhage was part of the composite outcome of being "cured" (<a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>). All investigators except Zi and colleagues and Wang and colleagues reported results for secondary hemorrhage. In four included studies the risk of reporting bias was unclear (<a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a>; <a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a>; <a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>; <a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>): reporting was unclear due to the lack of study details available in the abstract and no full version being published (<a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a>); study outcomes were not clearly stated (<a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a>; <a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>); and only results for secondary hemorrhage were reported, although VA and IOP were measured throughout the duration of the study (<a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>). </p> </section> <section id="CD005431-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>We detected no other potential sources of bias in 20 of the included studies. We classified four studies as having an unclear risk of other bias because the publications had poor descriptions of study methods and results (<a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a>; <a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a>; <a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>; <a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>). In two studies, some participants were selected to receive surgery either at recruitment (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>), or after having been assigned to a treatment group (<a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>). We classified three studies as having an unclear risk of other bias, because they were funded by pharmaceutical companies that either manufactured the drug being investigated in the study or that supplied the study drug (<a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a>; <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a>; <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a>). We classified one study as having a high risk of other bias because the data reported in the trial registry differed substantially from the data reported in the publication with respect to number of study participants and method used to generate the random sequence (<a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a>). </p> </section> </section> <section id="CD005431-sec-0073"> <h3 class="title" id="CD005431-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD005431-tbl-0001"><b>Summary of findings 1</b> Systemic aminocaproic acid compared with placebo for traumatic hyphema</a>; <a href="./full#CD005431-tbl-0002"><b>Summary of findings 2</b> Topical aminocaproic acid compared with placebo for traumatic hyphema</a>; <a href="./full#CD005431-tbl-0003"><b>Summary of findings 3</b> Systemic tranexamic acid compared with control for traumatic hyphema</a>; <a href="./full#CD005431-tbl-0004"><b>Summary of findings 4</b> Systemic or topical corticosteroids compared with placebo or control treatment for traumatic hyphema</a>; <a href="./full#CD005431-tbl-0005"><b>Summary of findings 5</b> Other pharmaceutical agents compared with placebo or other control interventions for traumatic hyphema</a>; <a href="./full#CD005431-tbl-0006"><b>Summary of findings 6</b> Non‐pharmaceutical interventions compared with control for traumatic hyphema</a> </p> <section id="CD005431-sec-0074"> <h4 class="title">Systemic aminocaproic acid versus control</h4> <p>Six studies evaluated oral aminocaproic acid versus placebo (<a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a>; <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>; <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>; <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>; <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>). We assessed all six studies as at overall low risk of bias. </p> <section id="CD005431-sec-0075"> <h5 class="title">Visual acuity</h5> <p>No study observed a difference in VA measured at two weeks or less after the hospital admission. At the time of discharge, <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> observed VA of 20/40 or better in 14 of 21 (67%) participants in the systemic aminocaproic acid group and in 10 of 13 (77%) participants in the placebo group (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.57 to 1.32; <a href="./references#CD005431-fig-0003" title="">Analysis 1.1</a>). We graded the certainty of evidence for short‐term VA outcomes as low, downgrading for imprecision (wide CI) and indirectness (lack of standard follow‐up time point) (<a href="./full#CD005431-tbl-0001">summary of findings Table 1</a>). </p> <p>No study of systemic aminocaproic acid reported VA outcomes at medium‐term follow‐up (more than two weeks but within two months). </p> <p>Two studies evaluating systemic aminocaproic acid measured long‐term VA at nine months or from six months to 2.5 years after discharge (<a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>; <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>). Neither study found a difference in the proportion of participants who achieved useful final VA, defined as VA between 20/20 and 20/40 (<a href="./references#CD005431-fig-0004" title="">Analysis 1.2</a>). <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> reported that 17 of 24 (70.8%) participants assigned to aminocaproic acid had VA between 20/20 and 20/40, compared with 20 of 25 (80%) participants assigned to placebo. <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> reported similar results, with 25 of 32 (79%) participants assigned to drug versus 18 of 27 (67%) participants assigned to placebo achieving useful VA. The summary RR for these two studies was 1.03 (95% CI 0.82 to 1.29). We graded the certainty of evidence for long‐term VA outcomes as low, downgrading for imprecision and inconsistency (<a href="./full#CD005431-tbl-0001">summary of findings Table 1</a>). </p> <p>Two additional studies evaluated final VA, with the time of measurement including both short‐ and long‐term time points ranging from five days to 3.4 years, in <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>, or from zero to nine months, in <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>. Forty‐six of 48 (95.8%) children in the aminocaproic acid group and 44 of 46 (95.6%) children in the placebo group had good final VA in <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>. <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a> reported that the number of participants with final VA of 20/40 or better was 22 of 28 (78.6%) in the aminocaproic acid group and 14 of 21 (66.6%) in the placebo group. The summary RR for final VA of 20/40 or better for these two studies was 1.05 (95% CI 0.93 to 1.18; <a href="./references#CD005431-fig-0005" title="">Analysis 1.3</a>). We graded the certainty of evidence for final VA outcomes as low, downgrading for imprecision and indirectness (<a href="./full#CD005431-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD005431-sec-0076"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p>In general, the hyphemas in participants assigned to systemic aminocaproic acid took longer to clear than those in participants assigned to placebo or control groups (<a href="./references#CD005431-fig-0006" title="">Analysis 1.4</a>). <a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a> noted that drug‐treated hyphemas tended to take longer to clear compared with controls but reported that this was significant only among hyphemas filling more than half of the anterior chamber. Of the five remaining studies using oral aminocaproic acid, the mean time to resolution of the primary hemorrhage ranged from 4.1 days, <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>, to 6.7 days, <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>, in the aminocaproic acid group and 2.4 days, <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>, to 6.3 days, <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>, in the placebo group among all participants. Two studies evaluated time to clear the initial hyphema after excluding participants who rebled (<a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>; <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>). In both studies, the group receiving aminocaproic acid took longer to clear the initial hyphema than the group receiving placebo (4.0 days versus 2.8 days in <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>, and 5.3 days versus 2.6 days in <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>). In <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>, the time to resolution appeared to be associated with initial hyphema severity, with larger initial hyphemas taking longer to resolve. The longer resolution times for drug‐treated groups were statistically significant as reported in two studies (<a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>; <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>); however, there were insufficient data to perform a meta‐analysis. In contrast, in <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>, the mean time to resolution was longer in the placebo than the aminocaproic acid group. We graded the certainty of evidence for time to resolution of primary hemorrhage as low, downgrading for imprecision and indirectness (<a href="./full#CD005431-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD005431-sec-0077"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>All RCTs comparing systemic aminocaproic acid versus placebo reported results for risk of secondary hemorrhage. Participants assigned to the systemic aminocaproic acid group experienced a secondary hemorrhage less often than participants in the placebo group (RR 0.28, 95% CI 0.13 to 0.60; <a href="./references#CD005431-fig-0007" title="">Analysis 1.5</a>). Because an intention‐to‐treat analysis was not performed in two studies of systemic aminocaproic acid, each of which excluded one participant from analysis (<a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>), we performed a sensitivity analysis to assess the effect of excluding these studies. This resulted in an inconclusive effect of aminocaproic acid (RR 0.43, 95% CI 0.17 to 1.08). We graded the certainty of evidence for risk of secondary hemorrhage as low, downgrading for inconsistency and indirectness (<a href="./full#CD005431-tbl-0001">summary of findings Table 1</a>). </p> <p>Of the six studies comparing systemic aminocaproic acid versus placebo, four excluded people with sickle cell trait (<a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>; <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>; <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>). <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> reported that eight participants had sickle cell trait, although the trial investigators did not say to which group these participants had been assigned. The one participant who had a secondary hemorrhage in the aminocaproic acid group and two of the nine participants who had a secondary hemorrhage in the placebo group also had sickle cell trait. Of the eight participants with sickle cell trait, five rebled. </p> <p>Nearly all studies reported initial hyphema severity, mostly by the proportion of anterior chamber filled with blood or by the height of the hyphema in millimeters. There did not appear to be any overall pattern in the proportion of participants who had a secondary hemorrhage within groups defined by initial hyphema severity (<a href="#CD005431-tbl-0008">Table 2</a>). Two studies reported that all secondary hemorrhages occurred in initially less severe hyphemas (<a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a>; <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>), while one study found evidence of a higher proportion of secondary hemorrhages when the initial hyphema was more severe (<a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a>). </p> <div class="table" id="CD005431-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes by initial hyphema severity</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severity scale</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reported severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary hemorrhage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Systemic aminocaproic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to resolution of the primary hyphema was significantly longer (P &lt; 0.05) for participants receiving drug for whom the hyphema filled more than ½ of the anterior chamber. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reported no statistically significant differences across groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ to ¾ of anterior chamber</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ¾ to total of anterior chamber, but excluded total hyphema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In topical tranexamic acid group:</p> <p>33/45 (73%) grade 1</p> <p>8/45 (18%) grade 2</p> <p>4/45 (8%) grade 3</p> <p>0/45 (0%) grade 4</p> <p> </p> <p>In oral prednisone group:</p> <p>33/45 (73%) grade 1</p> <p>8/45 (18%) grade 2</p> <p>4/45 (9%) grade 3</p> <p>0/45 (0%) grade 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/49 (61%) participants: 13/24 (54%) in drug group; 17/25 (68%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 (33%) secondary hemorrhage (in placebo group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding secondary hemorrhages, mean time to resolution of 3.4 days in drug group (range 1 to 11 days, 13 eyes); mean time to resolution of 2.2 days in placebo group (range 1 to 4 days, 16 eyes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/49 (29%) participants: 9/24 (37.5%) in drug group; 5/25 (20%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 (33%) secondary hemorrhage (in drug group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding secondary hemorrhages, mean time to resolution of 7.1 days in drug group (range 6 to 9 days, 8 eyes); mean time to resolution of 4.0 days in placebo group (range 3 to 4 days, 5 eyes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ or more of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/49 (10%) participants: 2/24 (8.3%) in drug group; 3/25 (12%) in placebo group<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 (33%) secondary hemorrhage (in drug group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding secondary hemorrhages, time to resolution of 10 days in drug group (1 eye); mean of placebo 4.3 days (range 3 to 5 days, 3 eyes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 mm (SD 1.7, n = 21) in drug group; 1.7 mm (SD 1.0, n = 13) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"All who rebled had initial hyphemas of 15% or less"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% (28/28) hyphemas in drug group were &lt; 25% of anterior chamber; 86% (18/21) hyphemas in placebo group were &lt; 25% of anterior chamber. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 secondary hemorrhage in drug group; 6 secondary hemorrhages in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88/94 (94%) participants: 44/48 (92%) in drug group; 44/46 (96%) in placebo group<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 secondary hemorrhage in drug group and 2 secondary hemorrhages in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/94 (6%) participants: 4/48 (8%) in aminocaproic acid group; 2/46 (4%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No rebleeds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Topical aminocaproic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ¼ of anterior chamber; excluded microscopic hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/80 (81%) participants: 34/41 (83%) in drug group; 31/39 (79.5%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Reported no effect of hyphema size on secondary hyphema (RR 0.7, 95% CI 0.2 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ¼ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/80 (18%) participants: 7/41 (17%) in drug group; 7/39 (18%) in placebo group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber; excluded total or blackball hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/80 (1%) participants: 0/41 in drug group; 1/39 (2.5%) in placebo group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mm (SE 0) in drug group (range 0 to 4 mm); 2 mm (SE 0) in placebo group (range 0 to 8 mm) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Size of primary hyphema in 2 participants with secondary hemorrhages in drug group: 0.3 and 1 mm; in 8 participants with secondary hemorrhages in placebo group: 0.8, 0.9, 1, 1.4, 1.8, 2, 2, and 4.5 mm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Low‐dose vs standard‐dose aminocaproic acid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 mm (SD 2.0, range 0.1 to 9.9) in low‐dose group (n = 25); 1.5 mm (SD 2.2, range 0.1 to 9.9) in standard‐dose group (n = 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 secondary hemorrhage in low‐dose group; 5 secondary hemorrhages in standard‐dose group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Systemic vs topical aminocaproic acid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/64 (69%) participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/64 (9%) participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ to ¾ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/64 (13%) participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ¾ to total of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/64 (9%) participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Tranexamic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic, but excluding individuals with unlayered microscopic hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/238 (7%) participants: 6/80 (7%) in aminocaproic acid group; 4/78 (5%) in prednisolone group; 7/80 (9%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43 (5%) secondary hemorrhages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ¼ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173/238 (72%) participants: 56/80 (70%) in aminocaproic acid group; 61/78 (78%) in prednisolone group; 56/80 (70%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/43 (70%) secondary hemorrhages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ¼ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/238 (15%) participants: 13/80 (16%) in aminocaproic acid group; 10/78 (13%) in prednisolone group; 13/80 (16%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/43 (16%) secondary hemorrhages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber; excluded total hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/238 (5%) participants: 5/80 (6%) in aminocaproic acid group; 3/78 (4%) in prednisolone group; 4/80 (5%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/43 (9%) secondary hemorrhages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 0 to 1 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/35 (23%) participants: 4/17 (24%) in drug group; 4/18 (22%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 2 to 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/35 (34%) participants: 6/17 (35%) in drug group; 6/18 (33%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 4 to 5 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/35 (29%) participants: 5/17 (29%) in drug group; 5/18 (28%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 6 to 7 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/35 (14%) participants: 2/17 (12%) in drug group; 3/18 (17%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 1 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/112 (9%) participants: 8/59 (14%) in drug group; 2/53 (4%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 2 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/112 (29%) participants: 15/59 (25%) in drug group; 18/53 (34%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/112 (33%) participants: 18/59 (31%) in drug group; 19/53 (36%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 4 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/112 (16%) participants: 9/59 (15%) in drug group; 9/53 (17%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 5 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/112 (8%) participants: 6/59 (10%) in drug group; 3/53 (6%) in control group<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 6 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/112 (4%) participants: 3/59 (5%) in drug group; 1/53 (2%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 7 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 8 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/112 (1%) participants: 0/59 (0%) in drug group; 1/53 (2%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 mm in drug group (n = 102); 2.1 mm in control group (n = 130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 mm in 2 participants in drug group with a secondary hemorrhage; 2.2 mm in 12 participants in control group with a secondary hemorrhage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean of proportion of anterior chamber area filled with blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68% in drug group (n = 19); 63% in placebo group (n = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aminomethylbenzoic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber, and level is lower than the inferior border of pupil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/92 (51%) participants: 31/60 (52%) in drug group; 16/32 (50%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ of anterior chamber, and level is higher than the inferior border of the pupil but not exceeding the median line </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/92 (33%) participants: 19/60 (32%) in drug group; 11/32 (34%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber or filling the entire anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/92 (16%) participants: 10/60 (17%) in drug group; 5/32 (16%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Systemic corticosteroids vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0% to 33% of anterior chamber area filled with blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/43 (88%) participants: 21/23 (91%) in prednisone group; 17/20 (85%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4 (50%) secondary hemorrhages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 30 hyphemas resolved in 5 days or less; 8 hyphemas resolved in more than 5 days</p> <p>2. 34 participants with final visual acuity between 20/20 and 20/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 33% to 75% of anterior chamber filled with blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43 (12%) participants: 2/23 (9%) in prednisone group; 3/20 (15%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4 (50%) secondary hemorrhages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 1 hyphema resolved in 5 days or less; 4 hyphemas resolved in more than 5 days</p> <p>2. 5 participants with final visual acuity between 20/20 and 20/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>See above under 'Tranexamic acid vs control'</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Topical corticosteroids vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mm in topical corticosteroid group (n = 58); 3.5 mm in control group (n = 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participant with secondary hemorrhage in topical corticosteroid group; 4 participants with secondary hemorrhage in control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Antifibrinolytics vs systemic corticosteroids</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/112 (21%) participants: 11/56 (20%) in aminocaproic acid group; 13/56 (23%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/8 (38%) secondary hemorrhages: 2 in aminocaproic acid group; 1 in prednisone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height 0.1 to 3.9 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80/112 (71%) participants: 41/56 (73%) in aminocaproic acid group; 39/56 (70%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/8 (50%) secondary hemorrhages: 1 in aminocaproic acid group; 3 in prednisone group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height 4.0 to 5.9 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/112 (4%) participants: 3/56 (6%) in aminocaproic acid group; 1/56 (2%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height 6.0 to 11 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/112 (2%) participants: 0/56 (0%) in aminocaproic acid group; 2/56 (4%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total hyphema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/112 (2%) participants: 1/56 (2%) in aminocaproic acid group; 1/56 (2%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8 (12%) secondary hemorrhage: 1 in aminocaproic acid group; none in prednisone group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>See above under 'Tranexamic acid vs control'</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Conjugated estrogens vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; 20% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/85 (65%) participants: 28/39 (72%) in estrogen group; 27/46 (59%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/20 (65%) secondary hemorrhages: 8 in estrogen group; 5 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling 20% to 40% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/85 (20%) participants: 5/39 (13%) in estrogen group; 12/46 (26%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/20 (20%) secondary hemorrhages: 1 in estrogen group; 3 in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling 40% to 60% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/85 (6%) participants: 2/39 (5%) in estrogen group; 3/46 (7%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/20 (5%) secondary hemorrhage: none in estrogen group; 1 in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling 60% to 80% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/85 (2%) participants: 1/39 (3%) in estrogen group; 1/46 (2%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; 80% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/85 (7%) participants: 3/39 (8%) in estrogen group; 3/46 (7%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/20 (10%) secondary hemorrhages: 1 in estrogen group; 1 in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Cycloplegics vs miotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 1 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/58 (34%) participants: 10/28 (36%) in the cycloplegic group; 10/30 (33%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1 (100%) secondary hemorrhage (in cycloplegic group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 1.9 days (SD 1.4); mean time to resolution in miotic group of 2.5 days (SD 1) </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 2 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/58 (38%) participants: 10/28 (36%) in the cycloplegic group; 12/30 (40%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 3.3 days (SD 1.8); mean time to resolution in miotic group of 4.2 days (SD 1.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/58 (21%) participants: 6/28 (21%) in the cycloplegic group; 6/30 (20%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 3.2 days (SD 1.9); mean time to resolution in miotic group of 4.0 days (SD 1.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 4 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/58 (7%) participants: 2/28 (7%) in the cycloplegic group; 2/30 (7%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 2.5 days (1 resolved on day 2 and 1 on day 3); mean time to resolution in miotic group of 4.0 days (1 resolved on day 3 and 1 on day 5) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aspirin vs no aspirin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Reported that "the two groups were comparable with respect to age, cause, and extent of hyphema" and that 2 of 3 eyes with a secondary hemorrhage in the aspirin group (n = 23) had an initial total hyphema, while of the 2 eyes with a secondary hemorrhage in the control group (n = 28), 1 had 30% and 1 had almost total hyphema            </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Traditional Chinese medicine vs control treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants who were "cured" (defined as the resolution of the primary hemorrhage after 5 days of treatment, visual acuity of 0.7 or better after resolution of the primary hemorrhage, and no recurrence of bleeding for 1 week following resolution of the primary hemorrhage) was 29/45 (64%) in the traditional Chinese medicine group and 10/38 (26%) in the control group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Monocular vs binocular patching</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42/64 (66%) participants: 21/35 (60%) in the monocular patching group; 21/29 (72%) in the binocular patching group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/14 (50%) secondary hemorrhages: 4 in the monocular group; 3 in the binocular group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62% (13/21) of participants with final visual acuity of 20/50 or better in the monocular group; 71% (15/21) of participants with final visual acuity of 20/50 or better in the binocular group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/64 (22%) participants: 9/35 (26%) in the monocular patching group; 5/29 (17%) in the binocular patching group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7/14 (50%) secondary hemorrhages: 4 in the monocular group; 3 in the binocular group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57% (8/14) of participants with final visual acuity of 20/50 or better in the monocular group; 62% (5/8) of participants with final visual acuity of 20/50 or better in the binocular group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ or more of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/64 (12%) participants: 5/35 (14%) in the monocular patching group; 3/29 (10%) in the binocular patching group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Ambulatory vs conservative treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79/137 (58%) participants: 47/71 (66%) in the ambulatory group; 32/66 (48%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/30 (53%) secondary hemorrhages: 9 in the ambulatory group; 7 in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/137 (20%) participants: 11/71 (16%) in the ambulatory group; 17/66 (26%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/30 (17%) secondary hemorrhages: 4 in the ambulatory group; 1 in the conservative group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ but not total anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/137 (14%) participants: 8/71 (11%) in the ambulatory group; 11/66 (17%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/30 (20%) secondary hemorrhages: 3 in the ambulatory group; 3 in the conservative group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total hyphema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/137 (8%) participants: 5/71 (7%) in the ambulatory group; 6/66 (9%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/30 (10%) secondary hemorrhages: 2 in the ambulatory group; 1 in the conservative group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Elevation of head vs lying flat</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ½ of anterior chamber, and level was lower than the inferior border of pupil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/74 (49%) participants: 18/35 (51%) with elevation of the head; 18/39 (46%) lying flat </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ of anterior chamber, and level was higher than the inferior border of the pupil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/74 (26%) participants: 6/35 (17%) with elevation of the head; 13/39 (33%) lying flat </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber or filling the entire anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/74 (26%) participants: 11/35 (31%) with elevation of the head; 8/39 (21%) lying flat </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Other (topical corticosteroids vs antibiotics, cycloplegics vs miotics, monocular vs binocular patching, ambulatory vs conservative treatment, enzymes, and ocular hypotensive agents)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 4% (8/213) of participants with elevated intraocular pressure across all participants;</p> <p>2. 22% (47/213) of participants with complications;</p> <p>3. 78% (166/213) of participants with final visual acuity better than 20/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 85% (133/157) of participants with elevated intraocular pressure across all participants;</p> <p>2. 78% (123/157) of participants with complications;</p> <p>3. 28% (44/157) of participants with final visual acuity better than 20/60</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported severity for entire study population rather than by trials of topical corticosteroids vs antibiotics, cycloplegics vs miotics, monocular vs binocular patching, and ambulatory vs conservative treatment. See under "Other outcomes." </p> <p>Abbreviations: CI: confidence interval; n: number of participants; NR: not reported; RR: risk ratio; SD: standard deviation; SE: standard error. </p> </div> </div> </section> <section id="CD005431-sec-0078"> <h5 class="title">Time to rebleed</h5> <p>Five of the six studies that evaluated systemic aminocaproic acid reported data on the time between the initial injury and a secondary hemorrhage (<a href="./references#CD005431-fig-0008" title="">Analysis 1.6</a>). Of the 10 participants who had a secondary hemorrhage in <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>, the one participant in the aminocaproic acid group rebled on day 1, and the nine placebo‐treated participants rebled between days 2 and 7. Of the three participants in <a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> who experienced a secondary hemorrhage, the two treated with aminocaproic acid had a rebleed on days 3 and 4, and the placebo‐treated participant rebled on day 4. All three participants who rebled in <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> were in the placebo group and rebled on day 2. In the one aminocaproic acid‐treated participant who rebled in <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>, the secondary hemorrhage occurred on day 4, and three of the five participants in the placebo group rebled on day 3, one on day 5, and one on day 6. Of the three participants who rebled in <a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a>, one rebled on day 2 (placebo); one rebled on day 6 (aminocaproic acid); and one rebled on day 7 (placebo). </p> <p>Overall, there appeared to be little difference in the time for a secondary hemorrhage to occur, although the small numbers of events make statistical testing unreliable. We graded the certainty of evidence for time to secondary hemorrhage as low, downgrading for imprecision and indirectness. </p> </section> <section id="CD005431-sec-0079"> <h5 class="title">Risk of corneal blood stain</h5> <p>One study examining oral aminocaproic acid reported outcomes for corneal blood stain (<a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a>). Two participants in the placebo group who also had secondary hemorrhages required surgery "due to increased intraocular pressure and early corneal bloodstaining" (RR 0.17, 95% CI 0.01 to 3.39; <a href="./references#CD005431-fig-0009" title="">Analysis 1.7</a>; <a href="#CD005431-tbl-0009">Table 3</a>). We graded the certainty of evidence for corneal blood stain as low, downgrading for imprecision and indirectness. </p> <div class="table" id="CD005431-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of corneal blood staining</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/112</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Prednisone/cortisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atropine plus cortisone eye drops</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Estrogen</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estrogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/85</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Binocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/137</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: not reported.</p> </div> </div> </section> <section id="CD005431-sec-0080"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> reported that 14 participants in the study cohort experienced PAS formation. The difference between groups was reported to be non‐significant, although the number of participants for each group was not reported (<a href="#CD005431-tbl-0010">Table 4</a>). </p> <div class="table" id="CD005431-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of peripheral anterior synechiae</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Prednisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Conjugated estrogen</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjugated estrogens</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/85</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/137</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: not reported</p> </div> </div> </section> <section id="CD005431-sec-0081"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>Three studies reported the number of participants with elevated IOP in the systemic aminocaproic acid and placebo groups (Kraft 1987; Kutner 1987; Teboul 1995). No study included participants with sickle cell disease/trait (<a href="./references#CD005431-fig-0010" title="">Analysis 1.8</a>). Teboul 1995 reported that six participants (three in each group) developed transient increases in IOP that did not persist following discharge (RR 0.96, 95% CI 0.18 to 5.00). In the remaining two studies, the investigators reported that participants had IOP greater than 25 mmHg at follow‐up, with Kraft 1987 reporting that two participants (one in each group) had elevated IOP, and Kutner 1987 reporting that four participants (one in the aminocaproic acid group and three in the control group) had elevated IOP at time of discharge (summary RR 0.38, 95% CI 0.08 to 1.82; <a href="./references#CD005431-fig-0011" title="">Analysis 1.9</a>; <a href="#CD005431-tbl-0011">Table 5</a>). We graded the certainty of evidence for IOP as low, downgrading for imprecision and indirectness. </p> <div class="table" id="CD005431-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of elevated intraocular pressure</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/49</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/94</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard‐dose systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose oral aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/112</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/160</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Prednisone/cortisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/158</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atropine plus cortisone eye drops</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Binocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambulation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lying in right and left lateral position</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lying in semi‐reclining position</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/74</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD005431-sec-0082"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> reported that two participants (7.4%) in the placebo group and no participants in the aminocaproic acid group developed optic atrophy (RR 0.17, 95% CI 0.01 to 3.39; <a href="./references#CD005431-fig-0012" title="">Analysis 1.10</a>; <a href="#CD005431-tbl-0012">Table 6</a>). We graded the certainty of evidence for optic atrophy as low, downgrading for imprecision and indirectness. </p> <div class="table" id="CD005431-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Risk of optic atrophy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Cortisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atropine plus cortisone eye drops</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/137</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: not reported.</p> </div> </div> </section> <section id="CD005431-sec-0083"> <h5 class="title">Adverse effects</h5> <p>Adverse events occurred significantly more often in participants treated with oral aminocaproic acid than in those who received placebo (RR 8.60, 95% CI 2.09 to 35.50; <a href="./references#CD005431-fig-0013" title="">Analysis 1.11</a>). We graded the certainty of evidence as moderate, downgrading for imprecision (<a href="./full#CD005431-tbl-0001">summary of findings Table 1</a>). In addition to increased nausea and vomiting in the aminocaproic acid group, <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a> reported that two participants experienced diarrhea and one participant had muscle cramps (<a href="#CD005431-tbl-0013">Table 7</a>). No participants in <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> had diarrhea or muscle cramps, but 10 participants (45%) in the aminocaproic acid group had at least one complication, compared with only one participant (8%) in the placebo group. Complications other than nausea and vomiting reported in <a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> included lightheadedness and systemic hypotension. </p> <div class="table" id="CD005431-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Risk of non‐ocular adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of complication</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 8 of 24; placebo group 1 of 25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Systemic aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 6 of 21; placebo group: 0 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lightheadedness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 7 of 21; placebo group: 1 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 4 of 21; placebo group: 1 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total complications</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 10 of 21; placebo group: 1 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Systemic aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 6 of 28; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 2 of 28; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muscle cramps</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 1 of 28; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 3 of 24; placebo group: 3 of 27</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic vs topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness, nausea, vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral group: 5 of 29; topical group: 1 of 35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Low‐dose vs standard‐dose systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 5 of 25; standard‐dose group: 9 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness and hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 0 of 25; standard‐dose group: 5 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Syncope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 0 of 25; standard‐dose group: 2 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 0 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash or pruritis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 2 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hot flashes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 0 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth or nose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 0 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid vs oral prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminocaproic acid group: 0 of 56; prednisone group: 0 of 56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 1 of 19; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 0 of 80; placebo group: 0 of 80</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Aminomethylbenzoic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminomethylbenzoic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 7 of 60; placebo group: NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: not reported.</p> </div> </div> </section> <section id="CD005431-sec-0084"> <h5 class="title">Quality of life outcomes</h5> <p>No study reported any quality of life outcomes.</p> </section> <section id="CD005431-sec-0085"> <h5 class="title">Economic outcomes</h5> <p>Two studies reported duration of hospitalization, although insufficient details precluded meta‐analysis (<a href="./references#CD005431-fig-0014" title="">Analysis 1.12</a>). <a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a> reported mean duration of hospitalization of 5.7 days in the aminocaproic acid group and 7.3 days in the placebo group; the difference was not statistically significant. This trend was reversed in Teboul 1995, in which the aminocaproic acid group had a longer hospital stay (7.3 days) compared with the placebo group (5.4 days) (P &lt; 0.001). </p> </section> </section> <section id="CD005431-sec-0086"> <h4 class="title">Topical aminocaproic acid versus control</h4> <p>Two studies evaluated topical aminocaproic acid versus placebo (<a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a>; <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a>). We assessed both studies as at overall low risk of bias. </p> <section id="CD005431-sec-0087"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> reported that 10 of 24 (42%) participants in the topical aminocaproic acid group and 13 of 27 (48%) participants in the placebo group had VAs of 20/40 or better seven days after study enrollment (RR 0.87, 95% CI 0.47 to 1.60; <a href="./references#CD005431-fig-0015" title="">Analysis 2.1</a>). We graded the certainty of evidence for short‐term visual acuity outcomes as low, downgrading two levels for imprecision (<a href="./full#CD005431-tbl-0002">summary of findings Table 2</a>). </p> <p><a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> did not report on the proportion of participants with good VA, but did report that there was no significant difference in VA between topical aminocaproic acid‐treated participants and placebo‐treated participants after two weeks of follow‐up. </p> <p>Neither study reported long‐term VA or final VA outcomes.</p> </section> <section id="CD005431-sec-0088"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p>In <a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a>, the mean time to resolution of primary hemorrhage in the topical aminocaproic acid group was 11.1 days (standard deviation (SD) 4.7) versus 9.3 days (SD 4.2) in the placebo group receiving gel and 9.5 days (SD 3.9) in the placebo group not receiving gel. <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> reported no significant difference in time to clearance of the primary hyphema between topical aminocaproic acid‐treated participants and placebo‐treated participants. However, these studies included all participants, including those with a secondary hemorrhage (<a href="./references#CD005431-fig-0016" title="">Analysis 2.2</a>). We graded the certainty of evidence for resolution of primary hemorrhage as low, downgrading for inconsistency and indirectness (<a href="./full#CD005431-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005431-sec-0089"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>Participants receiving topical aminocaproic acid experienced a secondary hemorrhage less often than participants receiving placebo (RR 0.48, 95% CI 0.20 to 1.10; <a href="./references#CD005431-fig-0017" title="">Analysis 2.3</a>). <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> reported that two participants in the aminocaproic acid group and one participant in the placebo group had sickle cell trait, but did not report on the rebleed rate for participants with sickle cell trait/disease. <a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> reported no effect of initial hyphema size on secondary hemorrhages. We graded the certainty of evidence for secondary hemorrhage as low, downgrading for imprecision and indirectness (<a href="./full#CD005431-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005431-sec-0090"> <h5 class="title">Time to rebleed</h5> <p>In <a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a>, the mean time to rebleed was 3.2 days (SD 0.5) in the five participants in the topical aminocaproic acid group who rebled versus 3.0 days (SD 0.8) in the seven participants in the placebo group who rebled (P = 0.18). <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> reported that of the participants in their study who rebled, those receiving topical aminocaproic acid took longer to rebleed (one participant on day 6) compared with those receiving placebo (eight participants; range in days 2 to 6). However, this result was observed after the exclusion of one participant in the aminocaproic acid group who had taken aspirin and rebled on day 3. Overall, there appeared to be little difference in the time for a secondary hemorrhage to occur, although the small numbers of events make statistical testing unreliable (<a href="./references#CD005431-fig-0018" title="">Analysis 2.4</a>). </p> </section> <section id="CD005431-sec-0091"> <h5 class="title">Risk of corneal blood stain</h5> <p>Neither study reported outcomes for corneal blood stain.</p> </section> <section id="CD005431-sec-0092"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p>Neither study reported outcomes for PAS formation.</p> </section> <section id="CD005431-sec-0093"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>Pieramici 2003 reported the number of participants receiving aminocaproic acid who had elevated IOP during the seven‐day trial compared with participants receiving placebo (RR 2.25, 95% CI 0.22 to 23.28; <a href="./references#CD005431-fig-0019" title="">Analysis 2.5</a>). This study enrolled three participants (6%) with sickle cell disease/trait, but it was not clear if any of these participants developed elevated IOP. <a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> reported no significant differences in initial or final IOP between treatment groups (<a href="#CD005431-tbl-0011">Table 5</a>). We graded the certainty of evidence for IOP outcomes as low, downgrading two levels for imprecision. </p> </section> <section id="CD005431-sec-0094"> <h5 class="title">Risk of optic atrophy</h5> <p>Neither study reported outcomes for optic atrophy.</p> </section> <section id="CD005431-sec-0095"> <h5 class="title">Adverse effects</h5> <p>Systemic hypotension was observed in 13% of participants in the topical aminocaproic acid group versus 11% of participants in the placebo group in <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> (<a href="#CD005431-tbl-0013">Table 7</a>). <a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> did not report adverse events. </p> </section> <section id="CD005431-sec-0096"> <h5 class="title">Quality of life outcomes</h5> <p>Neither study reported any quality of life outcomes.</p> </section> <section id="CD005431-sec-0097"> <h5 class="title">Economic outcomes</h5> <p>Neither study reported any economic outcomes.</p> </section> </section> <section id="CD005431-sec-0098"> <h4 class="title">Low‐dose versus standard‐dose aminocaproic acid</h4> <p>Only one study compared low‐dose (50 mg/kg) versus standard‐dose (100 mg/kg) oral aminocaproic acid (<a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a>), thereby precluding meta‐analysis. </p> <section id="CD005431-sec-0099"> <h5 class="title">Visual acuity</h5> <p>Although "final" VA was measured, the time from injury to final VA was not reported. Final VAs of 20/40 or better were attained by 16 of 25 (64.0%) participants receiving low‐dose aminocaproic acid and 25 of 32 (78.1%) participants receiving standard‐dose aminocaproic acid (RR 0.82, 95% CI 0.58 to 1.16; <a href="./references#CD005431-fig-0020" title="">Analysis 3.1</a>). We graded the certainty of evidence for final VA as low, downgrading for imprecision and indirectness. </p> </section> <section id="CD005431-sec-0100"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p>No significant difference was reported between groups in time to resolution of the primary hemorrhage (mean difference (MD) −0.14 days, 95% CI −1.24 to 0.96). The mean time for resolution of the primary hemorrhage was 3.1 days (SD 2.3) in the low‐dose group and 3.3 days (SD 1.8) in the standard‐dose group (<a href="./references#CD005431-fig-0021" title="">Analysis 3.2</a>). We graded the certainty of evidence as moderate, downgrading for imprecision. </p> </section> <section id="CD005431-sec-0101"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>The investigators reported that one of 25 (4.0%) eyes receiving low‐dose aminocaproic acid rebled, and five of 33 (15.2%) eyes receiving standard‐dose aminocaproic acid rebled (RR 0.26, 95% CI 0.03 to 2.12; <a href="./references#CD005431-fig-0022" title="">Analysis 3.3</a>). Participants with sickle cell trait were excluded from this study, and there did not appear to be an effect of initial hyphema severity on the rate of secondary hemorrhage (<a href="#CD005431-tbl-0008">Table 2</a>). We graded the certainty of evidence for secondary hemorrhage as low, downgrading two levels for imprecision. </p> </section> <section id="CD005431-sec-0102"> <h5 class="title">Time to rebleed</h5> <p>The one participant who rebled in the low‐dose group rebled on day 4. Of the five participants who rebled in the standard‐dose group, one did so on day 2, two on day 3, and two on day 6 (<a href="./references#CD005431-fig-0023" title="">Analysis 3.4</a>). </p> </section> <section id="CD005431-sec-0103"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0104"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0105"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>No participant in the low‐dose group and two participants in the standard‐dose group experienced elevated IOP requiring surgical intervention (RR 0.25, 95% CI 0.01 to 5.06; <a href="./references#CD005431-fig-0024" title="">Analysis 3.5</a>; <a href="#CD005431-tbl-0011">Table 5</a>). We graded the certainty of evidence for IOP outcomes as low, downgrading two levels for imprecision. </p> </section> <section id="CD005431-sec-0106"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0107"> <h5 class="title">Adverse effects</h5> <p>Adverse events reported between groups are summarized in <a href="./references#CD005431-fig-0025" title="">Analysis 3.6</a> and <a href="#CD005431-tbl-0013">Table 7</a>. Nausea or vomiting was reported in five participants in the low‐dose group and nine participants in the standard‐dose group. Dizziness and hypotension were reported in five participants and syncope in two participants in the standard‐dose group. Other adverse events in the low‐dose group included diarrhea and dry mouth or nose, each in one participant. Rash or pruritis was reported in one participant in the low‐dose group and two participants in the standard‐dose group. We graded the certainty of evidence for adverse events as low, downgrading two levels for imprecision. </p> </section> <section id="CD005431-sec-0108"> <h5 class="title">Quality of life outcomes</h5> <p>No study reported any quality of life outcomes.</p> </section> <section id="CD005431-sec-0109"> <h5 class="title">Economic outcomes</h5> <p>The mean hospital stay was 5.4 days (SD 1.1) in the low‐dose group and 5.5 days (SD 1.4) in the standard‐dose group (MD −0.10, 95% CI −0.75 to 0.55; <a href="./references#CD005431-fig-0026" title="">Analysis 3.7</a>). We graded the certainty of evidence as moderate, downgrading for imprecision. </p> </section> </section> <section id="CD005431-sec-0110"> <h4 class="title">Systemic versus topical aminocaproic acid</h4> <p>One study compared systemic versus topical aminocaproic acid (<a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a>). </p> <section id="CD005431-sec-0111"> <h5 class="title">Visual acuity</h5> <p>Final VAs of 20/40 or better were attained by 20 of 29 (85.7%) participants receiving systemic aminocaproic acid and 30 of 35 (69.0%) participants receiving topical aminocaproic acid (RR 0.80, 95% CI 0.61 to 1.06; <a href="./references#CD005431-fig-0027" title="">Analysis 4.1</a>). We graded the certainty of evidence for final VA as low, downgrading for imprecision and indirectness. </p> </section> <section id="CD005431-sec-0112"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0113"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>One of 29 (3%) eyes in the oral group versus one of 35 (3%) eyes in the topical group had a secondary hemorrhage (RR 1.21, 95% CI 0.08 to 18.46; <a href="./references#CD005431-fig-0028" title="">Analysis 4.2</a>). Two participants in each group had sickle cell trait, but there was no report on the rate of secondary hemorrhage by this condition or by initial hyphema severity. We graded the certainty of evidence for secondary hemorrhage as low, downgrading two levels for imprecision. </p> </section> <section id="CD005431-sec-0114"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> reported that the secondary hemorrhage in the participant in the systemic aminocaproic acid group occurred on day 3, and the secondary hemorrhage in the participant in the topical aminocaproic acid group occurred on day 5. </p> </section> <section id="CD005431-sec-0115"> <h5 class="title">Risk of corneal blood stain</h5> <p>No incident of corneal blood staining was reported in either group (<a href="#CD005431-tbl-0009">Table 3</a>). </p> </section> <section id="CD005431-sec-0116"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> reported that four participants experienced PAS formation, but the number of participants in each group was not reported. </p> </section> <section id="CD005431-sec-0117"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0118"> <h5 class="title">Risk of optic atrophy</h5> <p>No incident of optic atrophy was reported in either group (<a href="#CD005431-tbl-0012">Table 6</a>). </p> </section> <section id="CD005431-sec-0119"> <h5 class="title">Adverse effects</h5> <p>There were no significant differences between groups in adverse events reported (<a href="./references#CD005431-fig-0029" title="">Analysis 4.3</a>; <a href="#CD005431-tbl-0013">Table 7</a>; <a href="#CD005431-tbl-0014">Table 8</a>). Of the 35 participants in the topical aminocaproic acid group, four reported feeling a conjunctival or corneal foreign body sensation; three experienced transient punctate corneal staining; and one had dizziness, nausea, and vomiting on two occasions. Five of the 29 participants in the systemic aminocaproic acid group had dizziness, nausea, and vomiting. We graded the certainty of evidence for adverse events as low, downgrading two levels for imprecision. </p> <div class="table" id="CD005431-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Risk of other ocular events</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival/corneal foreign body sensation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient punctate corneal staining</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitreous and retinal hemorrhage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Traumatic cataract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Non‐drug medical intervention</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Traumatic cataract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitreous hemorrhage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Commotio retinae</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occluded pupil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optic atrophy with nasalization of optic cup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optic atrophy without nasalization of optic cup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/137</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: not reported.</p> </div> </div> </section> <section id="CD005431-sec-0120"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> did not report any quality of life outcomes. </p> </section> <section id="CD005431-sec-0121"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> did not report any economic outcomes. </p> </section> </section> <section id="CD005431-sec-0122"> <h4 class="title">Systemic tranexamic acid versus control</h4> <p>We analyzed data from seven studies reporting results comparing tranexamic acid versus control (<a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a>; <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>; <a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a>; <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>; <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a>; <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a>). Five studies were RCTs, and two studies were quasi‐randomized controlled clinical trials. </p> <section id="CD005431-sec-0123"> <h5 class="title">Visual acuity</h5> <p>Five studies reported short‐term VA. In the study by <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>, 39 of 60 (65%) participants in the tranexamic acid group had VA of 20/40 or better compared with 35 of 62 (56%) participants in the placebo group. Visual acuity was measured at discharge or resolution of the hyphema. <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> also measured VA at the time of discharge (range five to 15 days): 41 of 77 (57%) participants in the tranexamic acid group had VA of 20/40 or better compared with 35 of 79 (44%) participants in the placebo group. <a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a> reported that all participants had a final VA of 20/30 or better with the exception of one participant in the control group. The time of measurement for final VA was not reported, but participants were followed up for only one week. <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> reported that all 59 participants in the tranexamic acid group had VA between 20/20 and 20/40 two weeks after the initial trauma, and all 53 participants in the control group had VA between 20/20 and 20/50 two weeks after the initial trauma. A meta‐analysis of these four studies showed little to no effect of tranexamic acid (RR 1.12, 95% CI 1.00 to 1.25; <a href="./references#CD005431-fig-0030" title="">Analysis 5.1</a>). In addition, <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> reported mean VAs of 0.9 in both the tranexamic acid and control groups at day 5 after the trauma. <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> did not report VA. We graded the certainty of evidence for short‐term VA as moderate, downgrading for risk of bias (<a href="./full#CD005431-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD005431-sec-0124"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p>Five studies reported time to resolution of primary hemorrhage (<a href="./references#CD005431-fig-0031" title="">Analysis 5.2</a>). <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> found no significant difference in time to primary resolution between participants receiving tranexamic acid (mean 4.0 days, SD 2.2) and those receiving placebo (mean 3.7 days, SD 1.6), after excluding participants who had secondary hemorrhages. <a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a> also found no difference in time to resolution between groups, but included participants with and without secondary hemorrhages in the analysis (tranexamic group: mean 4.6, SD 2.4; control group: mean 3.9, SD 2.4). <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> reported a delay in resolution in the tranexamic acid group. Although <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> did not report time to resolution of the primary hyphema directly, the investigators estimated the daily rate of improvement in the hyphema by calculating the geometric mean of the per cent area of the hyphema remaining at each day following injury; these calculations indicated that tranexamic acid‐treated hyphemas cleared faster than those treated with placebo. We graded the certainty of evidence for time to resolution as very low, downgrading for risk of bias, inconsistency, and indirectness (<a href="./full#CD005431-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD005431-sec-0125"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>All seven studies reported the risk of a secondary hemorrhage (<a href="./references#CD005431-fig-0032" title="">Analysis 5.3</a>). The summary RR comparing oral tranexamic acid to placebo or control was 0.33 (95% CI 0.21 to 0.53) using a fixed‐effect model. We graded the certainty of evidence for secondary hemorrhage as low, downgrading for risk of bias and indirectness (<a href="./full#CD005431-tbl-0003">summary of findings Table 3</a>). </p> <p>No study evaluating tranexamic acid reported on the presence of sickle cell trait. Two studies had all‐white populations, thus it is unlikely that any participant would have had this condition (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a>). Although all investigators reported initial hyphema severity, only <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> reported the proportion of secondary hemorrhages in groups defined by the severity of the initial hyphema, finding no effect of severity on rebleed rate (<a href="#CD005431-tbl-0008">Table 2</a>). <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> reported that the initial size of the hyphemas that underwent secondary hemorrhage was 1.0 mm (one secondary hemorrhage) in the study group and 2.2 mm (12 secondary hemorrhages) in the control group. </p> </section> <section id="CD005431-sec-0126"> <h5 class="title">Time to rebleed</h5> <p>Three studies reported the time interval between the initial injury and the time of the secondary hemorrhage (<a href="./references#CD005431-fig-0033" title="">Analysis 5.4</a>). In <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>, the mean time to rebleed in eight participants who experienced a secondary hemorrhage in the tranexamic acid group was 3.4 days (SD 0.7) compared with 3.8 days (SD 1.0) in the 21 participants who rebled in the placebo group. This difference was reported as not significant. In <a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a>, rebleeding occurred between days 2 and 3 in participants who rebled in both groups, and <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> reported that the secondary hemorrhage took place at day 3 in the two participants in the tranexamic group who experienced this event, and that time to rebleed ranged from day 2 to day 7 in the 12 participants who rebled in the control group. We graded the certainty of evidence as low, downgrading for risk of bias and imprecision. </p> </section> <section id="CD005431-sec-0127"> <h5 class="title">Risk of corneal blood stain</h5> <p>Two studies reported corneal blood staining as an outcome (<a href="./references#CD005431-fig-0034" title="">Analysis 5.5</a>; <a href="#CD005431-tbl-0009">Table 3</a>). <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> observed corneal blood staining in one of 53 participants in the control group, and <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> reported observing no corneal bleeding in either the tranexamic acid group or the placebo group. </p> </section> <section id="CD005431-sec-0128"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p>No study reported this outcome.</p> </section> <section id="CD005431-sec-0129"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>Four of the five studies for this comparison reported the number of participants with transient increases in IOP in each group following the treatment period (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>; <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a>; <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a>). No study reported including participants with sickle cell disease/trait. <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> defined elevated IOP as greater than 21 mmHg during the hospital stay and requiring medical or surgical treatment, or both. <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> and <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> defined transient elevated IOP as 25 mmHg or greater. <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> did not define IOP by a pressure level but stated that three participants required surgery for elevated IOP. The summary RR was 1.20 (95% CI 0.73 to 1.98) when comparing tranexamic acid versus control (<a href="./references#CD005431-fig-0035" title="">Analysis 5.6</a>; <a href="#CD005431-tbl-0011">Table 5</a>). In addition, <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> reported no instances of secondary glaucoma. We graded the certainty of evidence for elevated IOP as low, downgrading for risk of bias and imprecision. </p> </section> <section id="CD005431-sec-0130"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> reported one incident of optic atrophy in the tranexamic acid group and no incidents in the placebo group (<a href="#CD005431-tbl-0012">Table 6</a>). </p> </section> <section id="CD005431-sec-0131"> <h5 class="title">Adverse effects</h5> <p>Two studies reported adverse effects (<a href="./references#CD005431-fig-0036" title="">Analysis 5.7</a>; <a href="#CD005431-tbl-0013">Table 7</a>). <a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> reported that one of 19 participants receiving tranexamic acid complained of nausea. <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> reported that medical staff observed no adverse events in either the drug‐treated or the control group. </p> </section> <section id="CD005431-sec-0132"> <h5 class="title">Quality of life outcomes</h5> <p>No study reported any quality of life outcomes.</p> </section> <section id="CD005431-sec-0133"> <h5 class="title">Economic outcomes</h5> <p>Three studies reported on length of hospitalization (<a href="./references#CD005431-fig-0037" title="">Analysis 5.8</a>). <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> reported that the mean hospital stay was six days (SD 1.6) for participants in the tranexamic acid group and 6.3 days (SD 1.8) for participants in the control group. This difference was not significant. In <a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>, the mean length of hospitalization for the tranexamic acid group was six days, compared with seven days for the control group. <a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> reported that the length of hospitalization for the tranexamic acid group was 6.8 days compared with 6.5 days for the control group. </p> <p>One study reported the mean number of days off work (<a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a>). The mean period off work for the tranexamic acid group was 17 days compared with 20 days for the control group. We graded the certainty of evidence for duration of hospitalization as low, downgrading for risk of bias and inconsistency. </p> </section> </section> <section id="CD005431-sec-0134"> <h4 class="title">Aminomethylbenzoic acid versus placebo</h4> <p>We did not perform meta‐analysis because only one study compared aminomethylbenzoic acid with placebo (<a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a>). </p> <section id="CD005431-sec-0135"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0136"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0137"> <h5 class="title">Risk of secondary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> reported that participants treated with oral aminomethylbenzoic acid were less likely to rebleed compared with participants treated with placebo (RR 0.10, 95% CI 0.02 to 0.41; <a href="./references#CD005431-fig-0038" title="">Analysis 6.1</a>). We graded the certainty of evidence for secondary hemorrhage as low, downgrading for risk of bias and indirectness. </p> </section> <section id="CD005431-sec-0138"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0139"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0140"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0141"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0142"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0143"> <h5 class="title">Adverse events</h5> <p>Of the 60 participants who received oral aminomethylbenzoic acid, seven reported nausea and vomiting; adverse events for the placebo group were not reported (<a href="#CD005431-tbl-0013">Table 7</a>). </p> </section> <section id="CD005431-sec-0144"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report any quality of life outcomes. </p> </section> <section id="CD005431-sec-0145"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> did not report any economic outcomes. </p> </section> </section> <section id="CD005431-sec-0146"> <h4 class="title">Corticosteroids versus control</h4> <section id="CD005431-sec-0147"> <h5 class="title">Visual acuity</h5> <p>Three studies compared systemic corticosteroids versus placebo (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>; <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>). Two studies compared short‐term visual acuity, both at the time of resolution or discharge (range five to 12 days). A meta‐analysis of these two studies showed no to little effect of oral prednisone, with a summary RR of 1.20 (95% CI 0.97 to 1.49; <a href="./references#CD005431-fig-0039" title="">Analysis 7.1</a>). <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> followed participants for up to 6 months, with final visual acuity between 20/20 and 20/50 in 21 of 23 (91%) participants in the prednisone group and 18 of 20 (90%) participants in the placebo group (RR 1.01, 95% CI 0.84 to 1.23; <a href="./references#CD005431-fig-0040" title="">Analysis 7.2</a>). We graded the certainty of evidence for variable‐length VA as low, downgrading for indirectness and imprecision. We graded the certainty of evidence for short‐term VA as low, downgrading for indirectness and imprecision (<a href="./full#CD005431-tbl-0004">summary of findings Table 4</a>). </p> <p>Two studies administering topical corticosteroids reported short‐term VA. Again, the VA outcomes could not be combined because different cut points were used across studies (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>; <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a>). <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that six of 13 (46%) participants assigned to corticosteroid eye drops and 13 of 21 (62%) participants assigned to control eye drops achieved short‐term VA better than 20/60 (RR 0.75, 95% CI 0.38 to 1.47; <a href="./references#CD005431-fig-0041" title="">Analysis 7.3</a>). We graded the certainty of the evidence for short‐term visual acuity as very low, downgraded for imprecision, indirectness, and risk of bias. <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> reported that 56 of 58 (97%) participants in the corticosteroid group had final VA of 0.9 (between 20/20 and 20/25), and 53 of 59 (90%) in the control group achieved VA better than 0.7 (about 20/30). At discharge, mean VA in the group assigned to corticosteroids was 0.96, compared with 0.91 in the control group (RR 1.02, 95% CI 0.94 to 1.11; <a href="./references#CD005431-fig-0042" title="">Analysis 7.4</a>). We graded the certainty of the evidence for VA at discharge as low, downgrading for imprecision and risk of bias (<a href="./full#CD005431-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD005431-sec-0148"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p>Two studies evaluated the effect of systemic corticosteroids on time to resolution of the hyphema (<a href="./references#CD005431-fig-0043" title="">Analysis 7.5</a>). In <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>, the authors reported means of 4.4 days and 4.5 days for the resolution of primary hemorrhage in groups receiving prednisone and placebo, respectively. This result remained non‐significant when participants who rebled were excluded from the analysis. <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> reported that time to resolution was shorter in hyphemas that were initially less severe (<a href="#CD005431-tbl-0008">Table 2</a>). <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> also found no significant difference in time to resolution of primary hemorrhage in participants without a secondary hemorrhage between the prednisolone group (mean 3.5 days, SD 1.8) and the placebo group (mean 3.7 days, SD 1.6). We graded the certainty of evidence for time to resolution of primary hemorrhage as low, downgrading for indirectness and imprecision (<a href="./full#CD005431-tbl-0004">summary of findings Table 4</a>). <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>, the one study that evaluated topical corticosteroids and measured time to resolution of primary hemorrhage, reported that the primary hyphema was resolved within one week in 10 of 13 (77%) participants assigned to corticosteroid eye drops and 16 of 21 (76%) participants assigned to the control group (<a href="./references#CD005431-fig-0044" title="">Analysis 7.6</a>). We graded the certainty of evidence as very low, downgrading for indirectness, imprecision, and risk of bias (<a href="./full#CD005431-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD005431-sec-0149"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>We analyzed data from three studies evaluating systemic corticosteroids and reporting results for the risk of secondary hemorrhage (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a>; <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>). The summary RR comparing oral corticosteroids to placebo was 0.63 (95% CI 0.40 to 0.97; <a href="./references#CD005431-fig-0045" title="">Analysis 7.7</a>) using a fixed‐effect model; however, this was not an intention‐to‐treat analysis due to missing data from the exclusion of four participants by <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>. We graded the certainty of evidence for risk of secondary hemorrhage as low, downgrading for indirectness and imprecision (<a href="./full#CD005431-tbl-0004">summary of findings Table 4</a>). A meta‐analysis of secondary hemorrhage including data from <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> (topical corticosteroids versus placebo eye drops) and <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> (topical corticosteroids versus complete bed rest with no simultaneous local therapy) did not show a statistically significant difference (RR 0.29, 95% CI 0.05 to 1.53; <a href="./references#CD005431-fig-0046" title="">Analysis 7.8</a>). We graded the certainty of evidence as very low, downgrading for indirectness, imprecision, and risk of bias (<a href="./full#CD005431-tbl-0004">summary of findings Table 4</a>). </p> <p>None of the five studies reported on the presence of sickle cell trait.</p> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> observed no effect of initial hyphema severity on the proportion of participants with a secondary hemorrhage, but <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> found that there was a lower proportion of secondary hemorrhages in participants with hyphemas that were initially less severe (2/38 (13%) versus 2/5 (40%), where severity was defined as blood filling one‐third versus more than one‐third of the anterior chamber) (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0150"> <h5 class="title">Time to rebleed</h5> <p>In <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>, rebleeding occurred a mean of 3.2 days (SD 0.8) from the time of trauma in the 14 participants who rebled in the prednisolone group and 3.8 days (SD 1.0) in the 21 participants who rebled in the placebo group. This difference was reported as not significant. In <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>, the mean time to rebleed in three participants who experienced a secondary hemorrhage in the prednisone group was 2.3 days compared with 2.6 days in the four participants who rebled in the placebo group. As in <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>, this difference was not significant (<a href="./references#CD005431-fig-0047" title="">Analysis 7.9</a>). </p> </section> <section id="CD005431-sec-0151"> <h5 class="title">Risk of corneal blood stain</h5> <p>In <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>, one of 43 participants experienced corneal blood staining; the study group in which the blood stain occurred was not reported (<a href="./references#CD005431-fig-0048" title="">Analysis 7.10</a>). In <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a>, one participant in the control group experienced corneal blood staining compared with no participants in the group receiving corticosteroid eye drops (RR 0.34, 95% CI 0.01 to 8.15; <a href="./references#CD005431-fig-0049" title="">Analysis 7.11</a>). </p> <p>Complications of hyphema, including corneal blood staining; pigment on endothelium, anterior lens capsule, or vitreous; posterior synechiae; PAS; anterior chamber blood clots; and fibrous membrane formation, were documented among participants in <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>. Fifty‐four per cent of participants in the corticosteroid group had complications, compared with 70% of participants in the control group, although this difference was not significant, and the risk of corneal blood staining was not reported separately (<a href="#CD005431-tbl-0009">Table 3</a>). </p> </section> <section id="CD005431-sec-0152"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> reported no instance of PAS formation in either group (<a href="./references#CD005431-fig-0050" title="">Analysis 7.12</a>; <a href="#CD005431-tbl-0010">Table 4</a>). </p> </section> <section id="CD005431-sec-0153"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> reported that nine of 78 (11.5%) participants in the prednisolone group and 12 of 80 (15%) participants in the placebo group had an IOP greater than 21 mmHg during hospitalization that required medical treatment, surgical treatment, or both. Two participants in <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> had elevated IOP that was controlled by acetazolamide therapy alone, one each in the prednisolone and the control group. No participant in this cohort had IOP greater than 35 mmHg (RR 0.78, 95% CI 0.36 to 1.68; <a href="./references#CD005431-fig-0051" title="">Analysis 7.13</a>). Five participants in <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> developed "elevated" IOP (undefined), three of 58 in the topical corticosteroids group and two of 59 in the control group (RR 1.53, 95% CI 0.26 to 8.80; <a href="./references#CD005431-fig-0052" title="">Analysis 7.14</a>). This information is included in <a href="#CD005431-tbl-0011">Table 5</a>. </p> </section> <section id="CD005431-sec-0154"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> reported one incident of optic atrophy in the 58 participants assigned to topical corticosteroid eye drops (RR 3.05, 95% CI 0.13 to 73.39; <a href="./references#CD005431-fig-0053" title="">Analysis 7.15</a>). </p> </section> <section id="CD005431-sec-0155"> <h5 class="title">Adverse effects</h5> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> reported that medical staff observed no adverse events in either the drug‐treated or the control group. </p> </section> <section id="CD005431-sec-0156"> <h5 class="title">Quality of life outcomes</h5> <p>No study reported any quality of life outcomes.</p> </section> <section id="CD005431-sec-0157"> <h5 class="title">Economic outcomes</h5> <p>In <a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>, participants treated with prednisolone were hospitalized a mean of 5.9 days (SD 1.4), while those treated with placebo were hospitalized a mean of 6.3 days (SD 1.8). The mean difference between groups was −0.40 days (95% CI −0.90 to 0.10) (<a href="./references#CD005431-fig-0054" title="">Analysis 7.16</a>). </p> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> reported duration of hospitalization: the mean length of stay for participants assigned to corticosteroid drops was 5.9 days, compared with 8.9 days for participants assigned to the control group (<a href="./references#CD005431-fig-0055" title="">Analysis 7.17</a>). </p> </section> </section> <section id="CD005431-sec-0158"> <h4 class="title">Systemic aminocaproic acid versus systemic prednisone</h4> <section id="CD005431-sec-0159"> <h5 class="title">Visual acuity</h5> <p>Only one study compared systemic aminocaproic acid versus systemic prednisone (<a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a>), precluding meta‐analysis. After five days of hospitalization, 10 of 56 (18%) participants in the aminocaproic acid group had short‐term VA of 20/200 or worse compared with seven of 56 (12.5%) participants in the prednisone group. These results were not statistically different (RR 0.84, 95% CI 0.58 to 1.2; <a href="./references#CD005431-fig-0056" title="">Analysis 8.1</a>). Likewise, there was no difference in final VA of 20/40 or better between groups (26 of 56 (46%) participants in the aminocaproic acid group and 31 of 56 (55%) participants in the prednisone group). </p> </section> <section id="CD005431-sec-0160"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> did not follow participants past discharge and so did not report on time to resolution of the primary hyphema. However, they did report that "at discharge" (mean time to discharge = five days), 43% of participants in the aminocaproic acid group compared with 75% of participants in the prednisone group had complete resolution of their hyphema. This difference was statistically significant (P = 0.001). </p> </section> <section id="CD005431-sec-0161"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>The risk of secondary hemorrhage was equal for both groups, four eyes out of 56 eyes per group (RR 1.00, 95% CI 0.26 to 3.80; <a href="./references#CD005431-fig-0057" title="">Analysis 8.2</a>). Participants with sickle cell trait/disease were excluded from this study. Initial hyphema severity did not appear to affect rate of secondary hemorrhage (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0162"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0163"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0164"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0165"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>No significant differences were reported for mean IOPs at time of discharge between groups. </p> </section> <section id="CD005431-sec-0166"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0167"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> reported that no participant experienced any adverse event (<a href="./references#CD005431-fig-0058" title="">Analysis 8.3</a>). </p> </section> <section id="CD005431-sec-0168"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> did not report any quality of life outcomes. </p> </section> <section id="CD005431-sec-0169"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> reported an overall mean duration of hospitalization of five days across both treatment groups. </p> </section> </section> <section id="CD005431-sec-0170"> <h4 class="title">Topical tranexamic acid versus systemic prednisone</h4> <section id="CD005431-sec-0171"> <h5 class="title">Visual acuity</h5> <p>One study examined topical tranexamic acid versus systemic prednisone, assigning 45 participants to tranexamic acid eye drops and 45 to oral prednisone (<a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a>). Forty‐four participants in each group had visual acuity better than 20/40 within five days (RR 1.00, 95% CI 0.94 to 1.06; <a href="./references#CD005431-fig-0059" title="">Analysis 9.1</a>). We did not perform a meta‐analysis because only one study compared these two treatments. </p> </section> <section id="CD005431-sec-0172"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p>The time to resolution of the primary hyphema in participants assigned to topical tranexamic acid was a mean (SD) of 3.17 (1.46) days compared with 4.66 (2.13) days in the oral prednisone group (<a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a>). </p> </section> <section id="CD005431-sec-0173"> <h5 class="title">Risk of secondary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> reported that the number of participants experiencing a rebleed in the tranexamic acid group was two of 45 compared with seven of 45 in the oral prednisone group (RR 0.29, 95% CI 0.06 to 1.30; <a href="./references#CD005431-fig-0061" title="">Analysis 9.3</a>). </p> </section> <section id="CD005431-sec-0174"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0175"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0176"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0177"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0178"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0179"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0180"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0181"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> did not report this outcome. </p> </section> </section> <section id="CD005431-sec-0182"> <h4 class="title">Conjugated estrogen versus placebo</h4> <section id="CD005431-sec-0183"> <h5 class="title">Visual acuity</h5> <p>Visual acuity at time of discharge was partially reported by the one study that compared conjugated estrogen versus placebo (<a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a>). Among all participants, 61% had VA better than 6/12; 30% had VA better than 6/60; and 9% had VA of 6/60 or worse at time of discharge. These results were not reported by treatment group. We graded the certainty of evidence for visual acuity as moderate, downgrading for imprecision. </p> </section> <section id="CD005431-sec-0184"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0185"> <h5 class="title">Risk of secondary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> reported that 10 of 39 estrogen‐treated participants rebled (25.6%), and 10 of 46 placebo‐treated participants rebled (21.7%). These results were not statistically different (RR 1.18, 95% CI 0.55 to 2.54; <a href="./references#CD005431-fig-0062" title="">Analysis 10.1</a>). </p> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> did not report on the presence of sickle cell trait/disease. The risk of secondary hemorrhage by initial hyphema severity did not appear to differ across severity ratings (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0186"> <h5 class="title">Time to rebleed</h5> <p>The time to rebleed among all participants was a mean of 3.5 days after injury, with a range of one to eight days. These results were not reported by treatment group. </p> </section> <section id="CD005431-sec-0187"> <h5 class="title">Risk of corneal blood stain</h5> <p>In the estrogen group, two of 39 (5%) participants had corneal blood staining compared with two of 46 (4%) participants in the placebo group (RR 1.18, 95% CI 0.55 to 7.99; <a href="./references#CD005431-fig-0063" title="">Analysis 10.2</a>). </p> </section> <section id="CD005431-sec-0188"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p>Fifteen cases of PAS were reported among all participants. These results were not reported by treatment group (<a href="#CD005431-tbl-0010">Table 4</a>). </p> </section> <section id="CD005431-sec-0189"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>Thirteen cases of secondary glaucoma were reported among all participants, four of which occurred prior to secondary hemorrhage (<a href="#CD005431-tbl-0011">Table 5</a>). These results were not reported by treatment group. </p> </section> <section id="CD005431-sec-0190"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0191"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0192"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> did not report any quality of life outcomes. </p> </section> <section id="CD005431-sec-0193"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> did not report any economic outcomes. </p> </section> </section> <section id="CD005431-sec-0194"> <h4 class="title">Cycloplegics versus miotics</h4> <p>Two studies evaluated the effect of cycloplegics compared with miotics (<a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a>; <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>). </p> <section id="CD005431-sec-0195"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that nine of 17 (53%) participants in the homatropine group and 11 of 17 (65%) participants in the pilocarpine group had short‐term VA better than 20/60 (RR 0.82, 95% CI 0.46 to 1.45; <a href="./references#CD005431-fig-0064" title="">Analysis 11.1</a>). We graded the certainty of evidence for short‐term VA as low, downgrading for imprecision and risk of bias (<a href="./full#CD005431-tbl-0005">summary of findings Table 5</a>). <a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> did not report on VA. </p> </section> <section id="CD005431-sec-0196"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> reported a longer time to resolution with the pilocarpine group (mean 3.6 days, SD 1.3) compared with the atropine group (mean 2.7 days, SD 1.7), an MD of −0.82 days (95% CI −1.68 to ‐0.12; <a href="./references#CD005431-fig-0065" title="">Analysis 11.2</a>). There was a slight increase in time to resolution with larger size of initial hyphema (<a href="#CD005431-tbl-0008">Table 2</a>). In <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>, there was no significant difference in the proportion of participants with absorption within one week between cycloplegic (12/17) and miotic (13/17) groups. </p> </section> <section id="CD005431-sec-0197"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>In <a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a>, only one participant experienced a secondary hemorrhage, who was in the cycloplegic group and had an initial hyphema height of 1 mm. The one participant with a secondary hemorrhage in <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> was in the homatropine group. The meta‐analysis combining results from these two studies was not significant (RR 1.03, 95% CI 0.15 to 6.99; <a href="./references#CD005431-fig-0066" title="">Analysis 11.3</a>; <a href="#CD005431-tbl-0008">Table 2</a>). We graded the certainty of the evidence as very low, downgrading for imprecision, risk of bias, and inconsistency (<a href="./full#CD005431-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD005431-sec-0198"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> reported that the time to rebleed in the one participant with a secondary hyphema was two days (<a href="./references#CD005431-fig-0067" title="">Analysis 11.4</a>). </p> </section> <section id="CD005431-sec-0199"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that the number of complications of hyphema, including corneal blood staining; pigment on endothelium, anterior lens capsule, or vitreous; posterior synechiae; PAS; anterior chamber blood clots; and fibrous membrane formation, were similar in all groups. </p> </section> <section id="CD005431-sec-0200"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that the number of complications of hyphema, including corneal blood staining; pigment on endothelium, anterior lens capsule, or vitreous; posterior synechiae; PAS; anterior chamber blood clots; and fibrous membrane formation, were similar in all groups. </p> </section> <section id="CD005431-sec-0201"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>Neither study reported this outcome.</p> </section> <section id="CD005431-sec-0202"> <h5 class="title">Risk of optic atrophy</h5> <p>Neither study reported this outcome.</p> </section> <section id="CD005431-sec-0203"> <h5 class="title">Adverse events</h5> <p>Neither study reported this outcome.</p> </section> <section id="CD005431-sec-0204"> <h5 class="title">Quality of life outcomes</h5> <p>Neither study reported any quality of life outcomes.</p> </section> <section id="CD005431-sec-0205"> <h5 class="title">Economic outcomes</h5> <p>Neither study reported any economic outcomes.</p> </section> </section> <section id="CD005431-sec-0206"> <h4 class="title">Aspirin versus observation</h4> <p>Only one study compared aspirin versus observation (<a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>), therefore we did not perform a meta‐analysis. </p> <section id="CD005431-sec-0207"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0208"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0209"> <h5 class="title">Risk of secondary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> reported that three of 23 (13%) eyes in the aspirin group rebled, and two of 28 (7%) eyes in the observation group rebled. These results were not statistically different (RR 1.83, 95% CI 0.33 to 10.02; <a href="./references#CD005431-fig-0068" title="">Analysis 12.1</a>). The study investigators reported that two of the three eyes that rebled in the aspirin group initially had a total hyphema; of the two eyes that rebled in the control group, one had an initial hyphema of 30% and one had an "almost total" hyphema (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0210"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0211"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0212"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0213"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0214"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0215"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0216"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report any quality of life outcomes. </p> </section> <section id="CD005431-sec-0217"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> did not report any economic outcomes. </p> </section> </section> <section id="CD005431-sec-0218"> <h4 class="title">Traditional Chinese medicine versus control</h4> <p>We did not perform a meta‐analysis for traditional Chinese medicine versus control treatment because only one study evaluated these interventions (<a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>). The authors of <a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> reported only one outcome: the proportion of participants who were "cured." The outcome of being cured was a composite outcome defined as the resolution of the primary hemorrhage after five days of treatment; VA of 0.7 or better after resolution of the primary hemorrhage; and no recurrence of bleeding for one week following resolution of the primary hemorrhage. One week after completing treatment, 29 of 45 (64%) participants in the traditional Chinese medicine group and 10 of 38 (26%) participants in the control group met these criteria for being "cured." </p> <section id="CD005431-sec-0219"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0220"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0221"> <h5 class="title">Risk of secondary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0222"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0223"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0224"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0225"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0226"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0227"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0228"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report any quality of life outcomes. </p> </section> <section id="CD005431-sec-0229"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> did not report any economic outcomes. </p> </section> </section> <section id="CD005431-sec-0230"> <h4 class="title">Monocular versus binocular patching</h4> <p>We identified two studies that compared the use of monocular versus binocular patches (<a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>; <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>). </p> <section id="CD005431-sec-0231"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that 22 of 26 (85%) participants in the monocular group compared with 24 of 27 (89%) participants in the binocular group had short‐term VA better than 20/60 (RR 0.82, 95% CI 0.67 to 1.00; <a href="./references#CD005431-fig-0069" title="">Analysis 13.1</a>). <a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> reported that 21 of 26 (81%) participants in the monocular group compared with 20 of 20 (100%) participants in the binocular group had VA better than 20/50, although the time at which VA was measured was not specified (RR 0.95, 95% CI 0.77 to 1.18; <a href="./references#CD005431-fig-0070" title="">Analysis 13.2</a>). We graded the certainty of the evidence for both of these analyses of VA as low, downgrading for imprecision and risk of bias (<a href="./full#CD005431-tbl-0006">summary of findings Table 6</a>). <a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> also reported that of participants with an initial hyphema filling less than one‐third of the anterior chamber, 67% (28/42) had VA of 20/50 or better compared with 59% (13/22) of those with more severe hyphemas (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0232"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported resolution of the primary hyphema within one week in 22 of 26 (85%) participants with monocular patching and 24 of 27 (89%) participants with binocular patching. </p> </section> <section id="CD005431-sec-0233"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>In <a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>, there were eight participants each with a secondary hemorrhage from the group with a patch on both eyes (n = 35; 23%) and the group with a patch only on the injured eye (n = 29; 28%). <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> also found no difference between groups for risk of secondary hemorrhage (one of 26 (3.8%) participants in the group with a monocular patch and two of 27 (7.4%) participants in the group with binocular patches). Meta‐analyzing these two studies produced an RR of 0.77 (95% CI 0.35 to 1.72; <a href="./references#CD005431-fig-0071" title="">Analysis 13.3</a>). The proportion of secondary hyphemas in <a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> was greater in participants with initially more severe hyphemas (32% (7 of 22)) than in those with an initial hyphema filling less than one‐third of the anterior chamber (17% (7 of 42)) (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0234"> <h5 class="title">Time to rebleed</h5> <p>A mean of three days between injury and secondary hemorrhage was reported for eight participants in the group with a monocular patch as well as for eight participants in the group with binocular patches (<a href="./references#CD005431-fig-0072" title="">Analysis 13.4</a>) (<a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>). </p> </section> <section id="CD005431-sec-0235"> <h5 class="title">Risk of corneal blood stain</h5> <p>In <a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>, one participant in each of the two treatment groups experienced corneal blood staining (RR 0.83, 95% CI 0.95 to 12.68; <a href="./references#CD005431-fig-0073" title="">Analysis 13.5</a>). </p> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that the risk of complications of hyphema, including corneal blood staining; pigment on endothelium, anterior lens capsule, or vitreous; posterior synechiae; PAS; anterior chamber blood clots; and fibrous membrane formation, were similar in both groups. </p> </section> <section id="CD005431-sec-0236"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that the risk of complications of hyphema, including corneal blood staining; pigment on endothelium, anterior lens capsule, or vitreous; posterior synechiae; PAS; anterior chamber blood clots; and fibrous membrane formation, were similar in both groups. </p> </section> <section id="CD005431-sec-0237"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>In <a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>, three participants in the monocular patching group developed secondary glaucoma, while no participants in the binocular patching group developed secondary glaucoma (RR 5.83, 95% CI 0.31 to 108.52; <a href="./references#CD005431-fig-0074" title="">Analysis 13.6</a>; <a href="#CD005431-tbl-0011">Table 5</a>). </p> </section> <section id="CD005431-sec-0238"> <h5 class="title">Risk of optic atrophy</h5> <p>Neither study reported this outcome.</p> </section> <section id="CD005431-sec-0239"> <h5 class="title">Adverse events</h5> <p>Neither study reported this outcome.</p> </section> <section id="CD005431-sec-0240"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> noted no difference between groups on the "cooperation index," which included a number of outcomes including those associated with quality of life (pain, restlessness, activity, and emotional state while in the hospital). </p> </section> <section id="CD005431-sec-0241"> <h5 class="title">Economic outcomes</h5> <p>Neither study reported any economic outcomes.</p> </section> </section> <section id="CD005431-sec-0242"> <h4 class="title">Ambulatory versus conservative treatment</h4> <section id="CD005431-sec-0243"> <h5 class="title">Visual acuity</h5> <p>Two studies compared ambulatory (i.e. moderate activity allowed) versus conservative treatment, which comprised bed rest alone (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>), or bed rest with elevation of the head, bilateral ocular patches, and a shield over the injured eye (<a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>). In <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>, VA was not reported by treatment group, but the authors distinguished between poor VA due to the initial trauma and that due to secondary effects of the hyphema. They stated that poor VA due to hyphema occurred in nine of 71 (13%) participants in the ambulatory group compared with four of 66 (6%) participants in the conservative group. Overall, the proportion of participants with good VA was 104 of 137 (76%), with more participants in the ambulatory group having good VA. In <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>, 22 of 26 (85%) participants in the ambulatory group had short‐term VA better than 20/60 compared with 20 of 26 (77%) participants in the conservative group (RR 1.10, 95% CI 0.84 to 1.44; <a href="./references#CD005431-fig-0075" title="">Analysis 14.1</a>). We graded the certainty of the evidence as low, downgrading for imprecision and risk of bias (<a href="./full#CD005431-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD005431-sec-0244"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> reported a mean of 5.8 days between the initial injury and resolution of the hyphema in the ambulatory group, compared with 5.6 days in the bed rest group. However, <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> observed a significant difference in the speed of reabsorption. The primary hyphema was resolved within one week in 13 of 26 (50%) participants in the ambulatory group compared with 22 of 26 (85%) participants in the conservative group (<a href="./references#CD005431-fig-0076" title="">Analysis 14.2</a>). We graded the certainty of the evidence as low, downgrading for imprecision and risk of bias (<a href="./full#CD005431-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD005431-sec-0245"> <h5 class="title">Risk of secondary hemorrhage</h5> <p>in <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>, 18 of 71 (25%) participants in the ambulatory group and 12 of 66 (18%) participants in the bed rest group developed a secondary hemorrhage. <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported only one secondary hemorrhage, which occurred in the conservatively treated group. Combining the results of the two trials showed no evidence of a treatment effect (RR 1.28, 95% CI 0.68 to 2.40; <a href="./references#CD005431-fig-0077" title="">Analysis 14.3</a>). We graded the certainty of the evidence as low, downgrading for imprecision and inconsistency (<a href="./full#CD005431-tbl-0006">summary of findings Table 6</a>). In <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>, the proportion of participants with a secondary hemorrhage appeared to be smaller with more severe initial hyphemas (16 of 30 (53%) versus 14 of 90 (16%) for those with an initial hyphema filling less than one‐third compared with one‐third or more of the anterior chamber) (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0246"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> reported that the majority of secondary hemorrhages occurred between days 2 and 5 following injury, although two secondary hemorrhages took place on day 7 following the initial injury. </p> </section> <section id="CD005431-sec-0247"> <h5 class="title">Risk of corneal blood stain</h5> <p>Nine participants in <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> developed corneal blood staining: five of 71 (7%) participants in the ambulatory group and four of 66 (6%) participants in the group receiving bed rest (RR 0.83, 95% CI 0.47 to 1.46; <a href="./references#CD005431-fig-0078" title="">Analysis 14.4</a>; <a href="#CD005431-tbl-0009">Table 3</a>). </p> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that the risk of complications of hyphema, including corneal blood staining; pigment on endothelium, anterior lens capsule, or vitreous; posterior synechiae; PAS; anterior chamber blood clots; and fibrous membrane formation, were similar in both groups. </p> </section> <section id="CD005431-sec-0248"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> did not report on this outcome. <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported that the risk of complications of hyphema, including corneal blood staining; pigment on endothelium, anterior lens capsule, or vitreous; posterior synechiae; PAS; anterior chamber blood clots; and fibrous membrane formation, were similar in both groups. </p> </section> <section id="CD005431-sec-0249"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>In <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>, 17 of the 71 (23.9%) participants in the group that was allowed moderate activity developed IOP of 25 mmHg or greater, while 19 of the 66 (28.8%) participants in the group assigned to bed rest developed an elevated IOP (RR 0.83, 95% CI 0.47 to 1.46; <a href="./references#CD005431-fig-0079" title="">Analysis 14.5</a>; <a href="#CD005431-tbl-0011">Table 5</a>). </p> </section> <section id="CD005431-sec-0250"> <h5 class="title">Risk of optic atrophy</h5> <p>Neither study reported this outcome.</p> </section> <section id="CD005431-sec-0251"> <h5 class="title">Adverse events</h5> <p>Neither study reported this outcome.</p> </section> <section id="CD005431-sec-0252"> <h5 class="title">Quality of life outcomes</h5> <p>Neither study reported any quality of life outcomes.</p> </section> <section id="CD005431-sec-0253"> <h5 class="title">Economic outcomes</h5> <p>Neither study reported any economic outcomes.</p> </section> </section> <section id="CD005431-sec-0254"> <h4 class="title">Elevation of the head versus control</h4> <p>One study compared elevation of the head by assigning participants to a semi‐reclined body position or to lying on their right or left side (<a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a>). </p> <section id="CD005431-sec-0255"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0256"> <h5 class="title">Time to resolution of primary hemorrhage</h5> <p>Time to resolution was compared by level of hyphema. The time to resolution was somewhat shorter for participants with their head elevated compared with those lying flat if the initial hyphema filled up to half of the anterior chamber, but longer if the blood filled more than half of the anterior chamber (level of blood &lt; one‐half of the anterior chamber: 1.7 days (n = 18) versus 2.8 days (n = 18); level of blood = one‐half of the anterior chamber: 2.2 days (n = 6) versus 3.1 days (n = 13); level of blood &gt; one‐half of anterior chamber: 9.0 days (n = 11) versus 8.0 days (n = 8)) (<a href="#CD005431-tbl-0008">Table 2</a>). </p> </section> <section id="CD005431-sec-0257"> <h5 class="title">Risk of secondary hemorrhage</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0258"> <h5 class="title">Time to rebleed</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0259"> <h5 class="title">Risk of corneal blood stain</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0260"> <h5 class="title">Risk of peripheral anterior synechiae formation</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0261"> <h5 class="title">Risk of glaucoma or elevated intraocular pressure</h5> <p>Fifteen participants developed secondary glaucoma, eight of 35 (23%) in the group in the semi‐reclined position and seven of 39 (18%) in the group lying flat (<a href="#CD005431-tbl-0011">Table 5</a>) (<a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a>). </p> </section> <section id="CD005431-sec-0262"> <h5 class="title">Risk of optic atrophy</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0263"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report this outcome. </p> </section> <section id="CD005431-sec-0264"> <h5 class="title">Quality of life outcomes</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report any quality of life outcomes. </p> </section> <section id="CD005431-sec-0265"> <h5 class="title">Economic outcomes</h5> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> did not report any economic outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005431-sec-0266" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005431-sec-0266"></div> <section id="CD005431-sec-0267"> <h3 class="title" id="CD005431-sec-0267">Summary of main results</h3> <p>We included 30 studies in this review, of which 23 were RCTs and seven used a quasi‐randomized method to assign participants to treatment groups. The primary outcome for all but three studies was the risk of a secondary hemorrhage. The primary outcomes for this review were VA and time to resolution of primary hemorrhage. Secondary outcomes for this review were sequelae of the traumatic hyphema, including risk of and time to rebleed, risk of corneal blood staining, risk of PAS formation, risk of pathologic increase in IOP or glaucoma development, and risk of optic atrophy development. </p> <section id="CD005431-sec-0268"> <h4 class="title">Antifibrinolytic agents</h4> <p>The use of antifibrinolytic agents such as aminocaproic acid and tranexamic acid in traumatic hyphema is controversial, because while they are reported to reduce the rate of recurrent ocular hemorrhage, this is at the cost of gastric and other systemic adverse events. We found no effect of any antifibrinolytic agent on VA measured at any time point. Neither systemic nor topical aminocaproic acid had an effect on final VA, nor did tranexamic acid. Hyphemas in participants administered systemic aminocaproic acid appeared to take longer to clear than in participants not receiving systemic aminocaproic acid, although the numbers were small and the conclusions unreliable. As expected, it took less time for hyphemas to clear in participants who did not have a secondary hemorrhage than in those who experienced a secondary hemorrhage. Antifibrinolytics appeared to prolong the time to resolution in both groups that had a rebleed and that did not, but the available evidence was insufficient to draw any firm conclusions about the time for a hyphema to clear in those treated with an antifibrinolytic. </p> <p>Oral aminocaproic acid appeared to reduce the risk of a secondary hemorrhage, but in a sensitivity analysis excluding studies that did not adhere to an intention‐to‐treat analysis, we found a non‐significant effect of this drug on the rate of rebleeds. Likewise, evidence showing an effect of topical aminocaproic acid on the rate of rebleeds was equivocal: although appearing to reduce the rate of secondary hemorrhage, the number of events was small. Consequently, although there was some evidence supporting an effect of aminocaproic acid in reducing the risk of secondary hemorrhage, it appears to be less convincing than previously reported (<a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a>). There appeared to be little difference in the time for a secondary hemorrhage to occur between participants receiving aminocaproic acid (systemic or topical) and controls, but again the evidence is weak due to a small number of incidents. In addition, there appears to be no effect of either systemic or topically applied aminocaproic acid on the timing of the rebleed or on the number of events related to the traumatic hyphema itself (i.e. corneal blood staining, PAS formation, elevated IOP, or development of optic atrophy). However, the small number of events renders significance testing unreliable. Unfortunately, there was insufficient evidence to conclude whether aminocaproic acid would be beneficial specifically for individuals with sickle cell trait/disease. Whether aminocaproic acid is useful for people with sickle cell trait/disease is of extreme importance, because such individuals are at higher risk for elevated IOP if blood cells remain in the anterior chamber (<a href="./references#CD005431-bbs2-0104" title="LaiJC , FekratS , BarrronY , GoldbergMF . Traumatic hyphema in children: risk factors for complications. Archives of Ophthalmology2001;119(1):64-70.">Lai 2001</a>). </p> <p>Aminocaproic acid is reported to have several side effects, including nausea, vomiting, muscle cramps, conjunctival hyperemia, headache, rash, pruritis, dyspnea, toxic confusional states, arrhythmias, and systemic hypotension. Its use is contraindicated in pregnant women and in people with coagulopathies or with renal diseases, and it should be used cautiously in people with hepatic, cardiovascular, or cerebrovascular diseases. There were no statistically significant differences in adverse events reported between systemic and topical aminocaproic acid or between standard versus low doses of aminocaproic acid. </p> <p>Tranexamic acid was not statistically different from controls in terms of final VA, time to resolution of primary hemorrhage, time to rebleed, or duration of hospitalization. Tranexamic acid is reported to have fewer gastric side effects than aminocaproic acid. The results of one study comparing aminomethylbenzoic acid versus placebo suggested that people treated with oral aminomethylbenzoic acid were less likely to rebleed compared with those given placebo. </p> </section> <section id="CD005431-sec-0269"> <h4 class="title">Corticosteroids</h4> <p>Topical corticosteroids are commonly used to treat hyphema; the mechanism of action of corticosteroids is believed to be due to reduced inflammation, stabilization of the blood‐ocular barrier, or direct inhibition of fibrinolysis, thus preventing secondary rebleeds. Two studies evaluated the effect of systemic corticosteroids (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>), and two studies evaluated the effect of topical corticosteroids (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>; <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a>). No significant differences were found in terms of time to resolution of primary hemorrhage, time to rebleed, or increased IOP. </p> <p>One study compared systemic aminocaproic acid versus topical prednisolone (<a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a>). This study concluded that more hyphemas had resolved at discharge in participants in the prednisolone group than in participants in the systemic aminocaproic acid group. No other differences between agents were noted in this study, although the investigators did not follow participants after discharge.  </p> </section> <section id="CD005431-sec-0270"> <h4 class="title">Other pharmaceutical interventions</h4> <p>Two studies compared homatropine as a cycloplegic, paralyzing the ciliary muscle and dilating the pupil, to pilocarpine, which constricts the pupil (<a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a>; <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>). A secondary hemorrhage occurred in only one participant in each study. Such small numbers of events makes significance testing unreliable. The traumatic hyphemas took longer to resolve in participants receiving pilocarpine. No other outcomes or other miotics or cycloplegics were studied. </p> <p>No effect was seen with the use of conjugated estrogens in one study (<a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a>). </p> <p>No statistically significant difference was reported for risk of rebleed in participants who were given aspirin in comparison with those who were not (<a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>). </p> <p>One study compared traditional Chinese medicine versus antihemorrhagics (<a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>), but this study only measured a composite outcome of "cure," which was defined as complete resolution within five days, VA of 0.7 or better, and no rebleed within one week of resolution of the primary hemorrhage. No single outcome was reported separately and so could not be compared. Although the authors reported a positive effect of the intervention, the findings should be interpreted with caution due to the biases present in the study and the use of a composite outcome measure. </p> </section> <section id="CD005431-sec-0271"> <h4 class="title">Non‐pharmaceutical interventions</h4> <p>No differences in VA, risk of secondary hemorrhage, or time to rebleed were reported in participants receiving a single versus binocular patch (<a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>; <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>). </p> <p>One study evaluated the effect of raising the head (semi‐reclined position) compared with alternatively right and left lateral positions on time to resolution of primary hemorrhage (<a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a>). The results were inconsistent: small hyphemas resolved sooner, but larger hyphemas took longer when the head was raised. The time of follow‐up was not mentioned, and participants were not masked to treatment assignment. </p> <p>Studies comparing moderate activity versus complete bed rest did not show any statistically significant difference between groups in risk of secondary hemorrhage, final VA, time to rebleed, or time to resolution of the primary hemorrhage (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>; <a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a>). Occurrences of complications (elevated IOP or corneal blood staining) were also comparable. </p> </section> </section> <section id="CD005431-sec-0272"> <h3 class="title" id="CD005431-sec-0272">Overall completeness and applicability of evidence</h3> <p>Our search strategy was comprehensive. We believe that we identified all or a high proportion of published trials of interventions for hyphema, and that our review is reasonably complete. </p> <p>Only a few studies or a single study evaluated a particular intervention. For example, only one study compared a low dose (50 mg/kg) versus the standard dose (100 mg/kg) of oral aminocaproic acid, and one study compared aminomethylbenzoic acid versus placebo (<a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a>). Only two studies compared topical corticosteroids versus control (<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>; <a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a>), and only two studies compared systemic corticosteroids versus control (<a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a>; <a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a>). One study compared aminocaproic acid versus prednisolone (<a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a>), and one study compared conjugated estrogen versus placebo (<a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a>). Only two studies compared cycloplegic versus miotic usage, both of which evaluated homatropine versus pilocarpine (<a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a>; <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>). One study compared aspirin versus control (<a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a>). One study compared traditional Chinese medicine versus antihemorrhagic agents as the control (<a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a>). Only two studies evaluated monocular versus binocular patching (<a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a>; <a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>), and no studies compared binocular or monocular patching versus no patching. Only one study compared the effect of elevation of the head versus control (<a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a>). The limited number of studies evaluating any given intervention made the application of meta‐analytic methods unreliable or impossible for many outcomes. </p> <p>Another limitation of the validity of some of the results was the lack of information on people with sickle cell disease/trait. Two included studies reported on the occurrence of secondary hemorrhage in participants with sickle cell trait/disease. <a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> mentioned that the one participant who had a secondary hemorrhage in the aminocaproic acid group and two of the nine participants who had a secondary hemorrhage in the placebo group also had sickle cell trait, but they did not report to which groups the eight sickle cell trait participants had originally been assigned. <a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> reported that two participants in the aminocaproic acid group and one participant in the placebo group had sickle cell trait, but the authors did not comment on the rebleed rate of these participants. The subgroup of participants with sickle cell trait/disease is especially important because this group has been shown to be at higher risk for elevated IOP when erythrocytes are present in the anterior chamber (<a href="./references#CD005431-bbs2-0104" title="LaiJC , FekratS , BarrronY , GoldbergMF . Traumatic hyphema in children: risk factors for complications. Archives of Ophthalmology2001;119(1):64-70.">Lai 2001</a>). It has been shown that even modest elevations in IOP are potentially deleterious in sickle cell disease/trait (<a href="./references#CD005431-bbs2-0100" title="GoldbergMF . Sickled erythrocytes, hyphema, and secondary glaucoma: I. The diagnosis and treatment of sickled erythrocytes in human hyphemas. Ophthalmic Surgery1979;10(4):17-31.">Goldberg 1979a</a>; <a href="./references#CD005431-bbs2-0101" title="GoldbergMF , DizonR , MosesVK . Sickled erythrocytes, hyphema, and secondary glaucoma: VI. The relationship between intracameral blood cells and aqueous humor pH, PO2, and PCO2 . Ophthalmic Surgery1979;10(4):78-88.">Goldberg 1979b</a>; <a href="./references#CD005431-bbs2-0102" title="GoldbergMF , TsoMO . Sickled erythrocytes, hyphema, and secondary glaucoma: VII. The passage of sickled erythrocytes out of the anterior chamber of the human and monkey eye: light and electron microscopic studies. Ophthalmic Surgery1979;10(4):89-123.">Goldberg 1979c</a>), and specifically that permanent infarction of the optic nerve with substantial loss of vision can occur in such individuals. Careful monitoring of IOP is indicated, and early surgery to decompress the eye is often required in patients with sickle cell disease/trait. In such patients, an empirical suggestion was to decompress the anterior chamber if IOP persisted at 24 mmHg for 24 or more hours (<a href="./references#CD005431-bbs2-0100" title="GoldbergMF . Sickled erythrocytes, hyphema, and secondary glaucoma: I. The diagnosis and treatment of sickled erythrocytes in human hyphemas. Ophthalmic Surgery1979;10(4):17-31.">Goldberg 1979a</a>). </p> </section> <section id="CD005431-sec-0273"> <h3 class="title" id="CD005431-sec-0273">Certainty of the evidence</h3> <p>We included 27 studies in this review, of which 20 were RCTs and seven were quasi‐randomized studies. Overall, the risk of bias was higher in the non‐randomized studies because sequence generation and allocation concealment were inadequate. In many cases, the studies were not reported clearly, and participants were inappropriately excluded from the analyses in some studies.  </p> </section> <section id="CD005431-sec-0274"> <h3 class="title" id="CD005431-sec-0274">Potential biases in the review process</h3> <p>Many of the included studies were published more than 20 years ago, and it was therefore not possible to contact the investigators to obtain missing information. One review author abstracted data from some of the foreign language articles. </p> </section> <section id="CD005431-sec-0275"> <h3 class="title" id="CD005431-sec-0275">Agreements and disagreements with other studies or reviews</h3> <p>We found some evidence for a favorable effect of aminocaproic acid and tranexamic acid on the risk of secondary hemorrhage. The evidence for a preventive effect of antifibrinolytics on rebleeds was not nearly as strong as that reported in the reviews by <a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a> and <a href="./references#CD005431-bbs2-0109" title="SheppardJD , CrouchER , WilliamsPB , Crouch ER Jr, RastogiS , Garcia-ValenzuelaE . Hyphema. Updated: 22 December 2009. emedicine.medscape.com/1190165.overview (accessed 8 January 2010).">Sheppard 2009</a>. However, <a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a> included observational studies as well as RCTs and controlled clinical trials, but did not take into account any biases in the individual studies. <a href="./references#CD005431-bbs2-0109" title="SheppardJD , CrouchER , WilliamsPB , Crouch ER Jr, RastogiS , Garcia-ValenzuelaE . Hyphema. Updated: 22 December 2009. emedicine.medscape.com/1190165.overview (accessed 8 January 2010).">Sheppard 2009</a> cited only some of the trials and also included observational studies. In these two reviews, no effect of either aminocaproic acid or tranexamic acid was found on VA. <a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a> presented a stronger case for the use of corticosteroids to prevent secondary hemorrhage than we have reported here or than is reported by <a href="./references#CD005431-bbs2-0109" title="SheppardJD , CrouchER , WilliamsPB , Crouch ER Jr, RastogiS , Garcia-ValenzuelaE . Hyphema. Updated: 22 December 2009. emedicine.medscape.com/1190165.overview (accessed 8 January 2010).">Sheppard 2009</a>. Our review agrees with most of the existing literature in that there is little evidence for the use of bilateral patching, sedation, or bed rest in the management of traumatic hyphema (<a href="./references#CD005431-bbs2-0109" title="SheppardJD , CrouchER , WilliamsPB , Crouch ER Jr, RastogiS , Garcia-ValenzuelaE . Hyphema. Updated: 22 December 2009. emedicine.medscape.com/1190165.overview (accessed 8 January 2010).">Sheppard 2009</a>; <a href="./references#CD005431-bbs2-0110" title="WaltonW , Von HagenS , GrigorianR , ZarbinM . Management of traumatic hyphema. Survey of Ophthalmology2002;47(4):297-334.">Walton 2002</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005431-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005431-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodologic quality summary: review authors' judgements about each methodologic quality item for each included study. Green: low risk of bias; red: high risk of bias; yellow: unclear risk of bias." data-id="CD005431-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodologic quality summary: review authors' judgements about each methodologic quality item for each included study. Green: low risk of bias; red: high risk of bias; yellow: unclear risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 1: Short‐term visual acuity from 20/20 to 20/40" data-id="CD005431-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 1: Short‐term visual acuity from 20/20 to 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 2: Long‐term visual acuity between 20/20 and 20/40" data-id="CD005431-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 2: Long‐term visual acuity between 20/20 and 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 3: Final visual acuity between 20/20 and 20/40" data-id="CD005431-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 3: Final visual acuity between 20/20 and 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0006"> <p> <div class="table" id="CD005431-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to resolution of primary hemorrhage (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Christianson 1979</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Crouch 1976</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1 days (4.0 days in study participants without secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (31 without a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 days (2.8 days in study participants without secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (18 without a secondary hemorrhage)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kraft 1987</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 days (5.3 days in study participants without secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (22 without a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days (2.6 days in study participants without a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (24 without a secondary hemorrhage)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kutner 1987</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (no participant had a secondary hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 study participants without a secondary hemorrhage</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>McGetrick 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5 days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (1 study participant had a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (7 study participants had a secondary hemorrhage)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teboul 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7 days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (1 study participant had a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (2 study participants had a secondary hemorrhage)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 4: Time to resolution of primary hemorrhage (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0006">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 5: Risk of secondary hemorrhage" data-id="CD005431-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 5: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0008"> <p> <div class="table" id="CD005431-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to rebleed (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Christianson 1979</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Crouch 1976</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 of 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 7: 2 on day 2; 2 on day 3; 4 on day 4; and 1 on day 7</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kraft 1987</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 3 and 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 4</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kutner 1987</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 of 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 of 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All rebled on Day 2</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>McGetrick 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 of 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 3 to 6: 5 on day 3; 1 on day 5; and 1 on day 6</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teboul 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 and 7</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 6: Time to rebleed (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0008">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 7: Risk of corneal blood stain" data-id="CD005431-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 7: Risk of corneal blood stain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0010"> <p> <div class="table" id="CD005431-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Risk of glaucoma or increases in IOP</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Odds Ratio [95% CI]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total patients (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Patients with sickle cell/trait</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Transient increase in IOP</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teboul 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 [0.18, 5.00]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient IOP greater than 25 mmHg, all patients had normal IOP at discharge (5 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (excluded)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Persistent increase in IOP</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kraft 1987</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 [0.06, 17.69]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP greater than 25 mmHg at follow‐up (6 weeks to 18 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (excluded)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kutner 1987</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 [0.02, 1.81]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated IOP at time of discharge (6 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None (excluded)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 8: Risk of glaucoma or increases in IOP </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0010">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 9: Risk of glaucoma or elevated IOP" data-id="CD005431-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 9: Risk of glaucoma or elevated IOP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 10: Risk of optic atrophy" data-id="CD005431-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 10: Risk of optic atrophy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 11: Adverse effects: nausea or vomiting" data-id="CD005431-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 11: Adverse effects: nausea or vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0014"> <p> <div class="table" id="CD005431-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Duration of hospitalization (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) duration of hospitalization for drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) duration of hospitalization in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>McGetrick 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teboul 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Systemic aminocaproic acid versus placebo, Outcome 12: Duration of hospitalization (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical aminocaproic acid versus placebo, Outcome 1: Short‐term visual acuity from 20/20 to 20/40" data-id="CD005431-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Topical aminocaproic acid versus placebo, Outcome 1: Short‐term visual acuity from 20/20 to 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0016"> <p> <div class="table" id="CD005431-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to resolution of primary hemorrhage (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Karkhaneh 2003</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1 (4.7) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ Placebo gel: 9.3 (4.2) days</p> <p>No placebo gel: 9.5 (3.9) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ Placebo gel: 39</p> <p>No placebo gel: 52</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pieramici 2003</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "no difference between treatment groups"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "no difference between treatment groups"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Topical aminocaproic acid versus placebo, Outcome 2: Time to resolution of primary hemorrhage (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0016">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical aminocaproic acid versus placebo, Outcome 3: Risk of secondary hemorrhage" data-id="CD005431-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Topical aminocaproic acid versus placebo, Outcome 3: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0018"> <p> <div class="table" id="CD005431-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to rebleed (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Karkhaneh 2003</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 of 41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 4: Mean = 3.2 days; SD = 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ Placebo gel: 7 of 39</p> <p>No placebo gel: 8 of 52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ Placebo gel: Mean = 3 days; SD = 0.8</p> <p>No placebo gel: Mean = 3 days; SD = 0.8</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pieramici 2003</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 3 and 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 of 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 6: 3 on day 2; 1 on day 3; 2 on day 4; and 2 on day 6</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Topical aminocaproic acid versus placebo, Outcome 4: Time to rebleed (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0018">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical aminocaproic acid versus placebo, Outcome 5: Risk of glaucoma or elevated IOP" data-id="CD005431-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Topical aminocaproic acid versus placebo, Outcome 5: Risk of glaucoma or elevated IOP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 1: Unspecified time for visual acuity between 20/20 and 20/40" data-id="CD005431-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 1: Unspecified time for visual acuity between 20/20 and 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 2: Time to resolution of primary hemorrhage (days)" data-id="CD005431-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 2: Time to resolution of primary hemorrhage (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 3: Risk of secondary hemorrhage" data-id="CD005431-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 3: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0023"> <p> <div class="table" id="CD005431-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to rebleed (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in the low dose group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in the low dose group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in the standard dose group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in the standard dose group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Palmer 1986</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 of 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 6: 1 on day 2; 2 on day 3; and 2 on day 6</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 4: Time to rebleed (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 5: Risk of glaucoma or elevated IOP" data-id="CD005431-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 5: Risk of glaucoma or elevated IOP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 6: Adverse effects" data-id="CD005431-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 6: Adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 7: Duration of hospitalization (days)" data-id="CD005431-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Low‐dose versus standard‐dose aminocaproic acid, Outcome 7: Duration of hospitalization (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Systemic versus topical aminocaproic acid, Outcome 1: Short‐term visual acuity from 20/20 to 20/40" data-id="CD005431-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Systemic versus topical aminocaproic acid, Outcome 1: Short‐term visual acuity from 20/20 to 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Systemic versus topical aminocaproic acid, Outcome 2: Risk of secondary hemorrhage" data-id="CD005431-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Systemic versus topical aminocaproic acid, Outcome 2: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Systemic versus topical aminocaproic acid, Outcome 3: Adverse effects" data-id="CD005431-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Systemic versus topical aminocaproic acid, Outcome 3: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Systemic tranexamic acid versus control, Outcome 1: Short‐term visual acuity from 20/20 to 20/40" data-id="CD005431-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 1: Short‐term visual acuity from 20/20 to 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0031"> <p> <div class="table" id="CD005431-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to resolution of primary hemorrhage (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rahmani 1999</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.0 (2.2) days in study participants without secondary hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7 (1.6) days in study participants without secondary hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sukumaran 1988</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6 (2.4) days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (2 study participants had a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (2.4) days in all study participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (6 study participants had a secondary hemorrhage)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vangsted 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Varnek 1980</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Welsh 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 2: Time to resolution of primary hemorrhage (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0031">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Systemic tranexamic acid versus control, Outcome 3: Risk of secondary hemorrhage" data-id="CD005431-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 3: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0033"> <p> <div class="table" id="CD005431-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to rebleed (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rahmani 1999</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 4: Mean = 3.4 days; SD = 0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 6: Mean = 3.8 days; SD = 1.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sukumaran 1988</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 of 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 3</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vangsted 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 of 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 of 53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Varnek 1980</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 of 130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days 2 to 7: 5 occurred on Day 4</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Welsh 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 4: Time to rebleed (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0033">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Systemic tranexamic acid versus control, Outcome 5: Risk of corneal blood stain" data-id="CD005431-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 5: Risk of corneal blood stain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Systemic tranexamic acid versus control, Outcome 6: Risk of glaucoma or elevated IOP" data-id="CD005431-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 6: Risk of glaucoma or elevated IOP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Systemic tranexamic acid versus control, Outcome 7: Adverse effects: nausea or vomiting" data-id="CD005431-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 7: Adverse effects: nausea or vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0037"> <p> <div class="table" id="CD005431-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Duration of hospitalization (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) duration of hospitalization for drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) duration of hospitalization in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rahmani 1999</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.0 (1.6) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 (1.8) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vangsted 1983</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Varnek 1980</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Systemic tranexamic acid versus control, Outcome 8: Duration of hospitalization (days) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0037">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Aminomethylbenzoic acid versus placebo, Outcome 1: Risk of secondary hemorrhage" data-id="CD005431-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Aminomethylbenzoic acid versus placebo, Outcome 1: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 1: Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40, systemic corticosteroids" data-id="CD005431-fig-0039" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 1: Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40, systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 2: Visual acuity between 20/20 and 20/50 at resolution of hyphema, systemic corticosteroids" data-id="CD005431-fig-0040" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 2: Visual acuity between 20/20 and 20/50 at resolution of hyphema, systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 3: Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40, topical corticosteroids" data-id="CD005431-fig-0041" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 3: Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40, topical corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 4: Final visual acuity between 20/20 and 20/25, topical corticosteroids" data-id="CD005431-fig-0042" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 4: Final visual acuity between 20/20 and 20/25, topical corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0043"> <p> <div class="table" id="CD005431-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to resolution of primary hemorrhage (days), systemic corticosteroids</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to resolution in drug group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to resolution in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rahmani 1999</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5 days (SD = 1.8) in study participants without a secondary hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7 days (SD = 1.6) in study participants without a secondary hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Spoor 1980</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.45 days (4.01 days in study participants without a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (20 without a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.48 days (3.60 days in study participants without a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (16 without a secondary hemorrhage)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 5: Time to resolution of primary hemorrhage (days), systemic corticosteroids </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0043">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0044"> <p> <div class="table" id="CD005431-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to resolution of primary hemorrhage (days), topical corticosteroids</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to resolution in drug group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to resolution in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rakusin 1972</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 resolved within 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1 study participant had a secondary hemorrhage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 resolved within 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (2 study participants had a secondary hemorrhage)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 6: Time to resolution of primary hemorrhage (days), topical corticosteroids </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0044">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 7: Risk of secondary hemorrhage, systemic corticosteroids" data-id="CD005431-fig-0045" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 7: Risk of secondary hemorrhage, systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 8: Risk of secondary hemorrhage, topical corticosteroids" data-id="CD005431-fig-0046" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 8: Risk of secondary hemorrhage, topical corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0047"> <p> <div class="table" id="CD005431-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to rebleed (days), systemic corticosteroids</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in the drug group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean time to rebleed in the drug group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in the control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean time to rebleed in the control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rahmani 1999</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 of 78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2 days (SD = 0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 days (SD = 1.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Spoor 1980</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 of 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 days</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 9: Time to rebleed (days), systemic corticosteroids </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0047">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 10: Risk of corneal blood stain, systemic corticosteroids" data-id="CD005431-fig-0048" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 10: Risk of corneal blood stain, systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 11: Risk of corneal blood stain, topical corticosteroids" data-id="CD005431-fig-0049" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 11: Risk of corneal blood stain, topical corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 12: Risk of peripheral anterior synechiae, systemic corticosteroids" data-id="CD005431-fig-0050" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 12: Risk of peripheral anterior synechiae, systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 13: Risk of glaucoma or elevated IOP, systemic corticosteroids" data-id="CD005431-fig-0051" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 13: Risk of glaucoma or elevated IOP, systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 14: Risk of glaucoma or elevated IOP, topical corticosteroids" data-id="CD005431-fig-0052" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 14: Risk of glaucoma or elevated IOP, topical corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 15: Risk of optic atrophy, topical corticosteroids" data-id="CD005431-fig-0053" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.15</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 15: Risk of optic atrophy, topical corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-007.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus control, Outcome 16: Duration of hospitalization (days), systemic corticosteroids" data-id="CD005431-fig-0054" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-007.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.16</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 16: Duration of hospitalization (days), systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-007.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0055"> <p> <div class="table" id="CD005431-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Duration of hospitalization (days), topical corticosteroids</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) duration of hospitalization for drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in drug treated group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) duration of hospitalization in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Zetterstrom 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9 days (SD not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9 days (SD not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.17</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus control, Outcome 17: Duration of hospitalization (days), topical corticosteroids </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0055">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Aminocaproic acid versus prednisone, Outcome 1: Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40" data-id="CD005431-fig-0056" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Aminocaproic acid versus prednisone, Outcome 1: Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Aminocaproic acid versus prednisone, Outcome 2: Risk of secondary hemorrhage" data-id="CD005431-fig-0057" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Aminocaproic acid versus prednisone, Outcome 2: Risk of secondary hemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Aminocaproic acid versus prednisone, Outcome 3: Adverse effect: any adverse event" data-id="CD005431-fig-0058" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Aminocaproic acid versus prednisone, Outcome 3: Adverse effect: any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Topical tranexamic acid versus prednisone, Outcome 1: Short‐term visual acuity from 20/20 to 20/40" data-id="CD005431-fig-0059" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Topical tranexamic acid versus prednisone, Outcome 1: Short‐term visual acuity from 20/20 to 20/40 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0060"> <p> <div class="table" id="CD005431-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to resolution of primary hemorrhage</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in topical tranexamic acid group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in topical tranexamic acid group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean (SD) time to resolution in oral prednisone group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>HNumber of particiants in oral prenisone groupeading 4</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Derakhshan 2022</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.14 (1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.66 (2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Topical tranexamic acid versus prednisone, Outcome 2: Time to resolution of primary hemorrhage </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0060">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Topical tranexamic acid versus prednisone, Outcome 3: Risk of secondary hemorrhage" data-id="CD005431-fig-0061" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Topical tranexamic acid versus prednisone, Outcome 3: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Conjugated estrogen versus placebo, Outcome 1: Risk of secondary hemorrhage" data-id="CD005431-fig-0062" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Conjugated estrogen versus placebo, Outcome 1: Risk of secondary hemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Conjugated estrogen versus placebo, Outcome 2: Risk of corneal blood stain" data-id="CD005431-fig-0063" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Conjugated estrogen versus placebo, Outcome 2: Risk of corneal blood stain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Cycloplegics versus miotics, Outcome 1: Short‐term visual acuity" data-id="CD005431-fig-0064" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Cycloplegics versus miotics, Outcome 1: Short‐term visual acuity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Cycloplegics versus miotics, Outcome 2: Time to resolution of primary hemorrhage (days)" data-id="CD005431-fig-0065" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Cycloplegics versus miotics, Outcome 2: Time to resolution of primary hemorrhage (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Cycloplegics versus miotics, Outcome 3: Risk of secondary hemorrhage" data-id="CD005431-fig-0066" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Cycloplegics versus miotics, Outcome 3: Risk of secondary hemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0067"> <p> <div class="table" id="CD005431-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to rebleed (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in the cycloplegic group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean time to rebleed in the cycloplegic group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in the miotic group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean time to rebleed in the miotic group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bedrossian 1974</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 of 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Cycloplegics versus miotics, Outcome 4: Time to rebleed (days)</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0067">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Aspirin versus observation, Outcome 1: Risk of secondary hemorrhage" data-id="CD005431-fig-0068" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Aspirin versus observation, Outcome 1: Risk of secondary hemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Monocular versus binocular patching, Outcome 1: Short‐term visual acuity" data-id="CD005431-fig-0069" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Monocular versus binocular patching, Outcome 1: Short‐term visual acuity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Monocular versus binocular patching, Outcome 2: Variable time length 'final' visual acuity" data-id="CD005431-fig-0070" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Monocular versus binocular patching, Outcome 2: Variable time length 'final' visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Monocular versus binocular patching, Outcome 3: Risk of secondary hemorrhage" data-id="CD005431-fig-0071" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Monocular versus binocular patching, Outcome 3: Risk of secondary hemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0072"> <p> <div class="table" id="CD005431-tblf-0017"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to rebleed (days)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in monocular patching group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in monocular patching group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of rebleeds in binocular patching group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to rebleed in binocular patching group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Edwards 1973</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 of 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 of 29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 3 days</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Monocular versus binocular patching, Outcome 4: Time to rebleed (days)</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0072">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Monocular versus binocular patching, Outcome 5: Risk of corneal blood stain" data-id="CD005431-fig-0073" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Monocular versus binocular patching, Outcome 5: Risk of corneal blood stain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-013.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Monocular versus binocular patching, Outcome 6: Risk of glaucoma or elevated IOP" data-id="CD005431-fig-0074" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-013.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13: Monocular versus binocular patching, Outcome 6: Risk of glaucoma or elevated IOP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-013.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Ambulatory versus conservative treatment, Outcome 1: Short‐term visual acuity" data-id="CD005431-fig-0075" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Ambulatory versus conservative treatment, Outcome 1: Short‐term visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0076"> <p> <div class="table" id="CD005431-tblf-0018"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Time to resolution of primary hemorrhage</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to resolution in ambulatory group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in ambulatory group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time to resolution in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Read 1974</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Ambulatory versus conservative treatment, Outcome 2: Time to resolution of primary hemorrhage </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0076">Navigate to figure in review</a></div> </div> <div class="figure" id="CD005431-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Ambulatory versus conservative treatment, Outcome 3: Risk of secondary hemorrhage" data-id="CD005431-fig-0077" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Ambulatory versus conservative treatment, Outcome 3: Risk of secondary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Ambulatory versus conservative treatment, Outcome 4: Risk of corneal blood stain" data-id="CD005431-fig-0078" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: Ambulatory versus conservative treatment, Outcome 4: Risk of corneal blood stain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005431-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/urn:x-wiley:14651858:media:CD005431:CD005431-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Ambulatory versus conservative treatment, Outcome 5: Risk of glaucoma or elevated IOP" data-id="CD005431-fig-0079" src="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_t/tCD005431-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: Ambulatory versus conservative treatment, Outcome 5: Risk of glaucoma or elevated IOP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/media/CDSR/CD005431/image_n/nCD005431-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005431-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Systemic aminocaproic acid compared with placebo for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic aminocaproic acid compared with placebo for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> 100 mg aminocaproic acid every 4 hours </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic aminocaproic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> 20/40 or better ≤ 2 weeks after treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>769 per</b> </p> <p><b>1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>699 per 1000</b> </p> <p>(438 to 1015)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.57 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 5 other studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medium‐term visual acuity</b> 20/40 or better &gt; 2 weeks and ≤ 2 months after treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term visual acuity</b> 20/40 or better &gt; 2 months after treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>731 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>752 per 1000</b><br/>(599 to 942) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> (0.82 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 4 other studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> 20/40 or better at resolution of hyphema </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>866 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>908 per 1000</b><br/>(805 to 1021) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> (0.93 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 4 other studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average time to resolution of the hemorrhage ranged from 4.1 to 6.7 days in participants receiving oral aminocaproic acid and from 2.4 to 6.3 days in participants receiving placebo (data not meta‐analyzable). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary hemorrhage</b> at any time point </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/>(19 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> (0.13 to 0.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> nausea or vomiting </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/>(36 to 612) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.60</b> (2.09 to 35.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 3 other studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1).<br/><sup>3</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Systemic aminocaproic acid compared with placebo for traumatic hyphema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005431-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical aminocaproic acid compared with placebo for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical aminocaproic acid compared with placebo for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> 25% to 30% aminocaproic acid in gel every 6 hours </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Topical aminocaproic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> 20/40 or better ≤ 2 weeks after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>481 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b><br/>(226 to 770) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.47 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 1 other study.</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medium‐term visual acuity</b> 20/40 or better &gt; 2 weeks and ≤ 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported no difference between groups after 2 weeks of follow‐up.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term visual acuity</b> 20/40 or better &gt; 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> 20/40 or better at resolution of hyphema </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 study, average time to resolution of the hemorrhage was 11.1 days in participants receiving topical aminocaproic acid compared with 9.3 days in those receiving placebo with gel, and 9.5 days in those receiving placebo without gel; in the second study, the authors reported "no difference" in time to resolution between study groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary hemorrhage</b> at any time point </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b><br/>(45 to 250) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> (0.20 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> systemic hypotension </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported that 13% of participants in the topical aminocaproic acid group versus 11% of participants in the placebo group had systemic hypotension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−2).<br/><sup>2</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1).<br/><sup>3</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1).<br/><sup>4</sup>Downgraded for imprecision (−1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical aminocaproic acid compared with placebo for traumatic hyphema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005431-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Systemic tranexamic acid compared with control for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic tranexamic acid compared with control for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> 25 to 75 mg/kg tranexamic acid per day </p> <p><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Tranexamic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> 20/40 or better ≤ 2 weeks after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>646 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>724 per 1000</b> (646 to 807) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> (1.00 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported by 2 other studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medium‐term visual acuity</b> 20/40 or better &gt; 2 weeks and ≤ 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term visual acuity</b> 20/40 or better &gt; 2 months after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> 20/40 or better at resolution of hyphema </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 study, average time to resolution of the hemorrhage was 4.0 days in 72 participants receiving tranexamic acid and 3.7 days in 59 participants receiving placebo. In another study, average time to resolution was 4.6 days in 17 participants receiving tranexamic acid and 3.9 days in 18 participants not receiving the drug. A third study reported that resolution was delayed in the tranexamic acid group, and a fourth study reported faster resolution in the tranexamic acid group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary hemorrhage</b> at any time point </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(36 to 91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.21 to 0.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>754 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> nausea </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported that 1 of 19 participants receiving tranexamic acid complained of nausea; another study reported that no adverse events were observed in either the drug‐treated or the control group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (−1).<br/><br/><sup>2</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1).<br/><sup>3</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Systemic tranexamic acid compared with control for traumatic hyphema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005431-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Systemic or topical corticosteroids compared with placebo or control treatment for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic or topical corticosteroids compared with placebo or control treatment for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> oral or topical corticosteroids </p> <p><b>Comparison:</b> placebo or a control treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Placebo or control treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corticosteroids</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>493 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b><br/>(478 to 735) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.97 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> between 20/20 and 20/40 at end of treatment; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>900 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>909 per 1000</b> </p> <p>(756 to 1107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> (0.84 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/40 ≤ 2 weeks after treatment; topical corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b><br/>(235 to 910) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b> (0.38 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> between 20/20 and 20/25 at end of treatment; topical corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>943 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>962 per 1000</b> </p> <p>(887 to 1047)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.94 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b>; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The first study reported that average resolution of primary hemorrhage was 3.5 days in the oral corticosteroid group and 3.7 days in the control group. The second study reported that average resolution of primary hemorrhage was 4.45 days in the oral corticosteroid group and 4.48 days in the control group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b>; </p> <p>topical corticosteroids</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A single study reported that hyphema cleared in 10/13 participants in the corticosteroid group and 16/21 participants in the control group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; oral corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>259 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b><br/>(103 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b> (0.40 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; topical corticosteroids </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(4 to 115) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.29</b> (0.05 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for indirectness (outcome unrelated to visual acuity or possible complications) (−1).<br/><sup>3</sup>Downgraded for risk of bias (−1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Systemic or topical corticosteroids compared with placebo or control treatment for traumatic hyphema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005431-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Other pharmaceutical agents compared with placebo or other control interventions for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Other pharmaceutical agents compared with placebo or other control interventions for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> other pharmaceutical agent </p> <p><b>Comparison:</b> placebo or other control interventions </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Placebo or <b>other control interventions</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pharmaceutical agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/60 at end of treatment; cycloplegics vs miotics </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>434 per 1000</b><br/>(211 to 768) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.46 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% homatropine versus 4% pilocarpine</p> <p> </p> <p>Visual acuity measured at end of treatment, typically within 2 weeks of occurrence of hyphema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; conjugated estrogen </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b><br/>(120 to 552) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> (0.55 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjugated estrogen, 5 to 10 mg intramuscularly for children under 10 years of age and 20 mg intravenously for children 10 years of age or older and adults, vs placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; cycloplegics </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(3 to 149) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> (0.15 to 6.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% homatropine versus 4% pilocarpine in first study; 1% atropine versus 2% pilocarpine in second study </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; aspirin </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(24 to 716) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.83</b> (0.33 to 10.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg aspirin 3 times/day for 5 days vs observation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for risk of bias (−1).<br/><sup>3</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Other pharmaceutical agents compared with placebo or other control interventions for traumatic hyphema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005431-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Non‐pharmaceutical interventions compared with control for traumatic hyphema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐pharmaceutical interventions compared with control for traumatic hyphema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with traumatic hyphema </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> non‐pharmaceutical interventions </p> <p><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Non‐pharmacuetical agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/60 at end of treatment; monocular vs binocular eye patching </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>808 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>662 per 1000</b><br/>(541 to 808) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.67 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity measured at end of treatment, typically within 2 weeks of occurrence of hyphema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Final visual acuity</b> between 20/20 and 20/50; monocular vs binocular eye patching </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>846 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>803 per 1000</b><br/>(652 to 998) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.77 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time frame when visual acuity measured not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term visual acuity</b> between 20/20 and 20/50 at end of treatment; </p> <p>ambulatory vs bed rest</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>846 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>931 per 1000</b><br/>(710 to 1218) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> (0.84 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (1)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity measured at end of treatment, typically within 2 weeks of occurrence of hyphema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to resolution of primary hemorrhage</b>; ambulatory vs bed rest </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A single study reported that mean resolution of primary hemorrhage was 5.8 days in the ambulatory group and 5.6 days in the bed rest group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; monocular vs binocular eye patching </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b><br/>(51 to 254) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> (0.35 to 1.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (2)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of secondary hemorrhage</b>; ambulatory treatment vs bed rest </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b><br/>(108 to 445) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.28</b> (0.68 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (−1).<br/><sup>2</sup>Downgraded for risk of bias (−1).<br/><sup>3</sup>Downgraded for inconsistency (large variation in effect estimate across trials) (−1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Non‐pharmaceutical interventions compared with control for traumatic hyphema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of outcomes* reported by intervention</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcomes</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Adverse effects</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Duration of hospitalization or quality of life outcomes</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Visual acuity</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Time to resolution of primary hemorrhage</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary hemorrhage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of corneal blood staining</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of PAS formation</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of pathologic increase in IOP or glaucoma</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of optic atrophy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of rebleed</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to rebleed</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Aminocaproic acid vs placebo</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Oral aminocaproic acid</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Topical aminocaproic acid</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Low‐dose</b> <b>vs standard‐dose aminocaproic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Oral vs topical aminocaproic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Oral tranexamic acid vs control</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0013" title="IRCT201106016675N. Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201106016675N1 (first received 19 July 2011). MasoumiR , MasoumiN , FooladiN , GoddessS . The effect of tranexamic acid in reducing the recurrence of anterior chamber bleeding in blunt trauma hyphae. Journal of Ardabil University of Medical Sciences2011;11(3):259-68. ">Masoumi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No rebleeds occurred</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization and days off work reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Aminomethylbenzoic acid vs placebo</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Corticosteroids vs control</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Oral corticosteroids</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of PAS formation reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>Topical corticosteroids</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of optic atrophy reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Oral aminocaproic acid vs oral prednisone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Oral tranexamic acid vs oral prednisone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0020" title="SamavatiM , AkbarzadehS , Mani KashaniK . Effects of oral tranexamic acid vs oral prednisolone on rebleeding in traumatic hyphema. Bina Journal of Ophthalmology2006;12(1):64-9. ">Samavati 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Topical tranexamic acid vs oral prednisone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Conjugated estrogen vs placebo</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Cycloplegics vs miotics</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Aspirin vs observation</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Traditional Chinese medicine vs control treatment</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Monocular vs binocular patching</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of secondary glaucoma reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life outcomes reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Ambulatory vs conservative treatment</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term VA reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of rebleed reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partially reported**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of corneal blood staining reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient increases in IOP reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="11" rowspan="1" scope="col" valign="top"> <p><b>Elevation of the head vs control</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to resolution reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of secondary glaucoma reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>*See <a href="#CD005431-sec-0023">Types of outcome measures</a> for detailed descriptions of outcomes.<br/>**Noted as 'partially reported' if some information was reported but it was insufficient for quantitative data analyses. </p> <p>Abbreviations: IOP: intraocular pressure; NS: not significant; PAS: peripheral anterior synechiae; VA: visual acuity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of outcomes* reported by intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes by initial hyphema severity</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severity scale</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reported severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary hemorrhage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Systemic aminocaproic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0002" title="ChristiansonMD , CrawfordJS . Epsilon aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1979;88(4):782. ">Christianson 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to resolution of the primary hyphema was significantly longer (P &lt; 0.05) for participants receiving drug for whom the hyphema filled more than ½ of the anterior chamber. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reported no statistically significant differences across groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ to ¾ of anterior chamber</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ¾ to total of anterior chamber, but excluded total hyphema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0005" title="DerakhshanA , FirooziJ , EsmaeiliS , BakhtiariE , AbbaspourM , AbrishamiM , et al. Systemic prednisolone versus topical tranexamic acid for prevention of rebleeding in patients with traumatic hyphema: A randomized clinical trial. Journal Francais d'Ophtalmologie2022;45(1):9‐12. IRCT20201110049345N1. Effect of Systemic Prednisolone and Topical Tranexamic Acid on Prevention of Rebleeding in Traumatic Hyphema. https://www.irct.ir/trial/52222 (first received 1 December 2020). ">Derakhshan 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In topical tranexamic acid group:</p> <p>33/45 (73%) grade 1</p> <p>8/45 (18%) grade 2</p> <p>4/45 (8%) grade 3</p> <p>0/45 (0%) grade 4</p> <p> </p> <p>In oral prednisone group:</p> <p>33/45 (73%) grade 1</p> <p>8/45 (18%) grade 2</p> <p>4/45 (9%) grade 3</p> <p>0/45 (0%) grade 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/49 (61%) participants: 13/24 (54%) in drug group; 17/25 (68%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 (33%) secondary hemorrhage (in placebo group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding secondary hemorrhages, mean time to resolution of 3.4 days in drug group (range 1 to 11 days, 13 eyes); mean time to resolution of 2.2 days in placebo group (range 1 to 4 days, 16 eyes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/49 (29%) participants: 9/24 (37.5%) in drug group; 5/25 (20%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 (33%) secondary hemorrhage (in drug group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding secondary hemorrhages, mean time to resolution of 7.1 days in drug group (range 6 to 9 days, 8 eyes); mean time to resolution of 4.0 days in placebo group (range 3 to 4 days, 5 eyes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ or more of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/49 (10%) participants: 2/24 (8.3%) in drug group; 3/25 (12%) in placebo group<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 (33%) secondary hemorrhage (in drug group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluding secondary hemorrhages, time to resolution of 10 days in drug group (1 eye); mean of placebo 4.3 days (range 3 to 5 days, 3 eyes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 mm (SD 1.7, n = 21) in drug group; 1.7 mm (SD 1.0, n = 13) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"All who rebled had initial hyphemas of 15% or less"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% (28/28) hyphemas in drug group were &lt; 25% of anterior chamber; 86% (18/21) hyphemas in placebo group were &lt; 25% of anterior chamber. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 secondary hemorrhage in drug group; 6 secondary hemorrhages in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88/94 (94%) participants: 44/48 (92%) in drug group; 44/46 (96%) in placebo group<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 secondary hemorrhage in drug group and 2 secondary hemorrhages in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/94 (6%) participants: 4/48 (8%) in aminocaproic acid group; 2/46 (4%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No rebleeds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Topical aminocaproic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0008" title="KarkhanehR , NaeeniM , ChamsH , AbdollahiM , MansouriMR . Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. European Journal of Ophthalmology2003;13(1):57-61. ">Karkhaneh 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ¼ of anterior chamber; excluded microscopic hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/80 (81%) participants: 34/41 (83%) in drug group; 31/39 (79.5%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Reported no effect of hyphema size on secondary hyphema (RR 0.7, 95% CI 0.2 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ¼ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/80 (18%) participants: 7/41 (17%) in drug group; 7/39 (18%) in placebo group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber; excluded total or blackball hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/80 (1%) participants: 0/41 in drug group; 1/39 (2.5%) in placebo group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mm (SE 0) in drug group (range 0 to 4 mm); 2 mm (SE 0) in placebo group (range 0 to 8 mm) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Size of primary hyphema in 2 participants with secondary hemorrhages in drug group: 0.3 and 1 mm; in 8 participants with secondary hemorrhages in placebo group: 0.8, 0.9, 1, 1.4, 1.8, 2, 2, and 4.5 mm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Low‐dose vs standard‐dose aminocaproic acid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 mm (SD 2.0, range 0.1 to 9.9) in low‐dose group (n = 25); 1.5 mm (SD 2.2, range 0.1 to 9.9) in standard‐dose group (n = 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 secondary hemorrhage in low‐dose group; 5 secondary hemorrhages in standard‐dose group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Systemic vs topical aminocaproic acid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/64 (69%) participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/64 (9%) participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ to ¾ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/64 (13%) participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ¾ to total of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/64 (9%) participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Tranexamic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic, but excluding individuals with unlayered microscopic hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/238 (7%) participants: 6/80 (7%) in aminocaproic acid group; 4/78 (5%) in prednisolone group; 7/80 (9%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43 (5%) secondary hemorrhages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ¼ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173/238 (72%) participants: 56/80 (70%) in aminocaproic acid group; 61/78 (78%) in prednisolone group; 56/80 (70%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/43 (70%) secondary hemorrhages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ¼ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/238 (15%) participants: 13/80 (16%) in aminocaproic acid group; 10/78 (13%) in prednisolone group; 13/80 (16%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/43 (16%) secondary hemorrhages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber; excluded total hyphemas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/238 (5%) participants: 5/80 (6%) in aminocaproic acid group; 3/78 (4%) in prednisolone group; 4/80 (5%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/43 (9%) secondary hemorrhages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0023" title="SukumaranK . The role of tranexamic acid (Cyklokapron) in the treatment of traumatic hyphaema. Medical Journal of Malaysia1988;43(2):155-8. ">Sukumaran 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 0 to 1 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/35 (23%) participants: 4/17 (24%) in drug group; 4/18 (22%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 2 to 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/35 (34%) participants: 6/17 (35%) in drug group; 6/18 (33%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 4 to 5 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/35 (29%) participants: 5/17 (29%) in drug group; 5/18 (28%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 6 to 7 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/35 (14%) participants: 2/17 (12%) in drug group; 3/18 (17%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 1 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/112 (9%) participants: 8/59 (14%) in drug group; 2/53 (4%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 2 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/112 (29%) participants: 15/59 (25%) in drug group; 18/53 (34%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/112 (33%) participants: 18/59 (31%) in drug group; 19/53 (36%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 4 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/112 (16%) participants: 9/59 (15%) in drug group; 9/53 (17%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 5 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/112 (8%) participants: 6/59 (10%) in drug group; 3/53 (6%) in control group<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 6 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/112 (4%) participants: 3/59 (5%) in drug group; 1/53 (2%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 7 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 8 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/112 (1%) participants: 0/59 (0%) in drug group; 1/53 (2%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 mm in drug group (n = 102); 2.1 mm in control group (n = 130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 mm in 2 participants in drug group with a secondary hemorrhage; 2.2 mm in 12 participants in control group with a secondary hemorrhage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean of proportion of anterior chamber area filled with blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68% in drug group (n = 19); 63% in placebo group (n = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aminomethylbenzoic acid vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber, and level is lower than the inferior border of pupil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/92 (51%) participants: 31/60 (52%) in drug group; 16/32 (50%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ of anterior chamber, and level is higher than the inferior border of the pupil but not exceeding the median line </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/92 (33%) participants: 19/60 (32%) in drug group; 11/32 (34%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber or filling the entire anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/92 (16%) participants: 10/60 (17%) in drug group; 5/32 (16%) in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Systemic corticosteroids vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0% to 33% of anterior chamber area filled with blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/43 (88%) participants: 21/23 (91%) in prednisone group; 17/20 (85%) in placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4 (50%) secondary hemorrhages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 30 hyphemas resolved in 5 days or less; 8 hyphemas resolved in more than 5 days</p> <p>2. 34 participants with final visual acuity between 20/20 and 20/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 33% to 75% of anterior chamber filled with blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43 (12%) participants: 2/23 (9%) in prednisone group; 3/20 (15%) in placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4 (50%) secondary hemorrhages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 1 hyphema resolved in 5 days or less; 4 hyphemas resolved in more than 5 days</p> <p>2. 5 participants with final visual acuity between 20/20 and 20/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>See above under 'Tranexamic acid vs control'</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Topical corticosteroids vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hyphema height in millimeters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mm in topical corticosteroid group (n = 58); 3.5 mm in control group (n = 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participant with secondary hemorrhage in topical corticosteroid group; 4 participants with secondary hemorrhage in control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Antifibrinolytics vs systemic corticosteroids</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/112 (21%) participants: 11/56 (20%) in aminocaproic acid group; 13/56 (23%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/8 (38%) secondary hemorrhages: 2 in aminocaproic acid group; 1 in prednisone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height 0.1 to 3.9 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80/112 (71%) participants: 41/56 (73%) in aminocaproic acid group; 39/56 (70%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/8 (50%) secondary hemorrhages: 1 in aminocaproic acid group; 3 in prednisone group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height 4.0 to 5.9 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/112 (4%) participants: 3/56 (6%) in aminocaproic acid group; 1/56 (2%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height 6.0 to 11 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/112 (2%) participants: 0/56 (0%) in aminocaproic acid group; 2/56 (4%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total hyphema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/112 (2%) participants: 1/56 (2%) in aminocaproic acid group; 1/56 (2%) in prednisone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8 (12%) secondary hemorrhage: 1 in aminocaproic acid group; none in prednisone group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>See above under 'Tranexamic acid vs control'</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Conjugated estrogens vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; 20% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/85 (65%) participants: 28/39 (72%) in estrogen group; 27/46 (59%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/20 (65%) secondary hemorrhages: 8 in estrogen group; 5 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling 20% to 40% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/85 (20%) participants: 5/39 (13%) in estrogen group; 12/46 (26%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/20 (20%) secondary hemorrhages: 1 in estrogen group; 3 in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling 40% to 60% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/85 (6%) participants: 2/39 (5%) in estrogen group; 3/46 (7%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/20 (5%) secondary hemorrhage: none in estrogen group; 1 in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling 60% to 80% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/85 (2%) participants: 1/39 (3%) in estrogen group; 1/46 (2%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; 80% of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/85 (7%) participants: 3/39 (8%) in estrogen group; 3/46 (7%) in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/20 (10%) secondary hemorrhages: 1 in estrogen group; 1 in control group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Cycloplegics vs miotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0001" title="BedrossianRH . The management of traumatic hyphema. Annals of Ophthalmology1974;6(10):1016-8. ">Bedrossian 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 1 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/58 (34%) participants: 10/28 (36%) in the cycloplegic group; 10/30 (33%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1 (100%) secondary hemorrhage (in cycloplegic group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 1.9 days (SD 1.4); mean time to resolution in miotic group of 2.5 days (SD 1) </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 2 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/58 (38%) participants: 10/28 (36%) in the cycloplegic group; 12/30 (40%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 3.3 days (SD 1.8); mean time to resolution in miotic group of 4.2 days (SD 1.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/58 (21%) participants: 6/28 (21%) in the cycloplegic group; 6/30 (20%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 3.2 days (SD 1.9); mean time to resolution in miotic group of 4.0 days (SD 1.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyphema height of 4 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/58 (7%) participants: 2/28 (7%) in the cycloplegic group; 2/30 (7%) in the miotic group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No secondary hemorrhages in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to resolution in cycloplegic group of 2.5 days (1 resolved on day 2 and 1 on day 3); mean time to resolution in miotic group of 4.0 days (1 resolved on day 3 and 1 on day 5) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aspirin vs no aspirin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0012" title="MarcusM , BiednerB , LifshitzT , YassurY . Aspirin and secondary bleeding after traumatic hyphema. Annals of Ophthalmology1988;20(4):157-8. ">Marcus 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Reported that "the two groups were comparable with respect to age, cause, and extent of hyphema" and that 2 of 3 eyes with a secondary hemorrhage in the aspirin group (n = 23) had an initial total hyphema, while of the 2 eyes with a secondary hemorrhage in the control group (n = 28), 1 had 30% and 1 had almost total hyphema            </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Traditional Chinese medicine vs control treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0027" title="WangXL . Yunnan Baiyao for contusion hyphema in 45 cases. Jiangsu Journal of Traditional Chinese Medicine1994;15(7):21. ">Wang 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants who were "cured" (defined as the resolution of the primary hemorrhage after 5 days of treatment, visual acuity of 0.7 or better after resolution of the primary hemorrhage, and no recurrence of bleeding for 1 week following resolution of the primary hemorrhage) was 29/45 (64%) in the traditional Chinese medicine group and 10/38 (26%) in the control group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Monocular vs binocular patching</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42/64 (66%) participants: 21/35 (60%) in the monocular patching group; 21/29 (72%) in the binocular patching group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/14 (50%) secondary hemorrhages: 4 in the monocular group; 3 in the binocular group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62% (13/21) of participants with final visual acuity of 20/50 or better in the monocular group; 71% (15/21) of participants with final visual acuity of 20/50 or better in the binocular group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/64 (22%) participants: 9/35 (26%) in the monocular patching group; 5/29 (17%) in the binocular patching group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7/14 (50%) secondary hemorrhages: 4 in the monocular group; 3 in the binocular group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57% (8/14) of participants with final visual acuity of 20/50 or better in the monocular group; 62% (5/8) of participants with final visual acuity of 20/50 or better in the binocular group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ or more of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/64 (12%) participants: 5/35 (14%) in the monocular patching group; 3/29 (10%) in the binocular patching group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Ambulatory vs conservative treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ⅓ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79/137 (58%) participants: 47/71 (66%) in the ambulatory group; 32/66 (48%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/30 (53%) secondary hemorrhages: 9 in the ambulatory group; 7 in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ⅓ to ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/137 (20%) participants: 11/71 (16%) in the ambulatory group; 17/66 (26%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/30 (17%) secondary hemorrhages: 4 in the ambulatory group; 1 in the conservative group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ but not total anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/137 (14%) participants: 8/71 (11%) in the ambulatory group; 11/66 (17%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/30 (20%) secondary hemorrhages: 3 in the ambulatory group; 3 in the conservative group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total hyphema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/137 (8%) participants: 5/71 (7%) in the ambulatory group; 6/66 (9%) in the conservative group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/30 (10%) secondary hemorrhages: 2 in the ambulatory group; 1 in the conservative group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Elevation of head vs lying flat</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ½ of anterior chamber, and level was lower than the inferior border of pupil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/74 (49%) participants: 18/35 (51%) with elevation of the head; 18/39 (46%) lying flat </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling ½ of anterior chamber, and level was higher than the inferior border of the pupil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/74 (26%) participants: 6/35 (17%) with elevation of the head; 13/39 (33%) lying flat </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber or filling the entire anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/74 (26%) participants: 11/35 (31%) with elevation of the head; 8/39 (21%) lying flat </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Other (topical corticosteroids vs antibiotics, cycloplegics vs miotics, monocular vs binocular patching, ambulatory vs conservative treatment, enzymes, and ocular hypotensive agents)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &lt; ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 4% (8/213) of participants with elevated intraocular pressure across all participants;</p> <p>2. 22% (47/213) of participants with complications;</p> <p>3. 78% (166/213) of participants with final visual acuity better than 20/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood filling &gt; ½ of anterior chamber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. 85% (133/157) of participants with elevated intraocular pressure across all participants;</p> <p>2. 78% (123/157) of participants with complications;</p> <p>3. 28% (44/157) of participants with final visual acuity better than 20/60</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*<a href="./references#CD005431-bbs2-0018" title="RakusinW . Emergencies in ophthalmology. South African Medical Journal1973;47(30):1338. RakusinW . Traumatic hyphema. American Journal of Ophthalmology1972;74(2):284-92. ">Rakusin 1972</a> reported severity for entire study population rather than by trials of topical corticosteroids vs antibiotics, cycloplegics vs miotics, monocular vs binocular patching, and ambulatory vs conservative treatment. See under "Other outcomes." </p> <p>Abbreviations: CI: confidence interval; n: number of participants; NR: not reported; RR: risk ratio; SD: standard deviation; SE: standard error. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes by initial hyphema severity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of corneal blood staining</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/112</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Prednisone/cortisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atropine plus cortisone eye drops</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Estrogen</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estrogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/85</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Binocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/137</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NR: not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of corneal blood staining</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of peripheral anterior synechiae</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Prednisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Conjugated estrogen</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0021" title="SpaethGL , LevyPM . Traumatic hyphema: its clinical characteristics and failure of estrogens to alter its course. A double-blind study. American Journal of Ophthalmology1966;62(6):1098-106. ">Spaeth 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjugated estrogens</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/85</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/137</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NR: not reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of peripheral anterior synechiae</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of elevated intraocular pressure</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/49</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0024" title="TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Ophthalmology1995;102(11):1646-53. TeboulBK , JacobJL , Barsoum-HomsyM , BrunetteI , ChevretteL , MilotJ , et al. Clinical evaluation of aminocaproic acid for the management of traumatic hyphema in children. In: American Academy of Ophthalmology; 1995 10-12; Atlanta, Georgia. 1995:175. ">Teboul 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/94</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard‐dose systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose oral aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0025" title="VangstedP , NielsenPJ . Tranexamic acid and traumatic hyphaema. A prospective study. Acta Ophthalmologica1983;61(3):447-53. ">Vangsted 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/112</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/160</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Prednisone/cortisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0022" title="SpoorTC , HammerM , BellosoH . Traumatic hyphema. Failure of steroids to alter its course: a double-blind prospective study. Archives of Ophthalmology1980;98(1):116-9. ">Spoor 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/158</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atropine plus cortisone eye drops</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0006" title="EdwardsWC , LaydenWE . Monocular versus binocular patching in traumatic hyphema. American Journal of Ophthalmology1973;76(3):359-62. ">Edwards 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Binocular patching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambulation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0030" title="ZiQL . The clinical observation of alternatively right and left lateral position in the cases of hyphema. Journal of Nursing Science1999;14(5):263-4. ">Zi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lying in right and left lateral position</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lying in semi‐reclining position</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/74</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of elevated intraocular pressure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Risk of optic atrophy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0003" title="Crouch ER Jr, FrenkelM . Aminocaproic acid in the treatment of traumatic hyphema. American Journal of Ophthalmology1976;81(3):355-60. ">Crouch 1976</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Cortisone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0029" title="ZetterstromB . The treatment of contusion of the eye. Acta Ophthalmologica1969;47(2):784-91. ">Zetterstrom 1969</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atropine plus cortisone eye drops</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Non‐drug medical interventions</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/137</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NR: not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Risk of optic atrophy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0013"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Risk of non‐ocular adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of complication</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0009" title="KraftSP , ChristiansonMD , CrawfordJS , WagmanRD , AntoszykJH . Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. Ophthalmology1987;94(10):1232-7. ">Kraft 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 8 of 24; placebo group 1 of 25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005431-bbs2-0010" title="Anonymous. Traumatic hyphema therapy. Ophthalmology1988;95(5):707-9. KutnerB , FourmanS , BreinK , HobsonS , MrvosD , SheppardJ , et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Archives of Ophthalmology1987;105(2):206-8. ">Kutner 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Systemic aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 6 of 21; placebo group: 0 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lightheadedness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 7 of 21; placebo group: 1 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 4 of 21; placebo group: 1 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total complications</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 10 of 21; placebo group: 1 of 13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005431-bbs2-0014" title="Anonymous. Aminocaproic acid. Archives of Ophthalmology1984;102(6):818, 820-1. McGetrickJJ , JampolLM , GoldbergMF , FrenkelM , FiscellaRG . Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema. Archives of Ophthalmology1983;101(7):1031-3. ">McGetrick 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Systemic aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 6 of 28; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 2 of 28; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muscle cramps</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 1 of 28; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0016" title="PieramiciDJ , GoldbergMF , MeliaBM . Topical aminocaproic acid (Caprogel) in the treatment of traumatic hyphema: results of a phase III multicenter placebo controlled trial. Investigative Ophthalmology &amp; Visual Science2000;41:ARVO Abstract 1616. PieramiciDJ , GoldbergMF , MeliaM , FekratS , BradfordCA , FaulknerA , et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology2003;110(11):2106-12. ">Pieramici 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 3 of 24; placebo group: 3 of 27</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic vs topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness, nausea, vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral group: 5 of 29; topical group: 1 of 35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD005431-bbs2-0015" title="PalmerDJ , GoldbergMF , FrenkelM , FiscellaR , AndersonRJ . A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology1986;93(1):102-8. ">Palmer 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Low‐dose vs standard‐dose systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 5 of 25; standard‐dose group: 9 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness and hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 0 of 25; standard‐dose group: 5 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Syncope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 0 of 25; standard‐dose group: 2 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 0 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash or pruritis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 2 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hot flashes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 0 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth or nose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose group: 1 of 25; standard‐dose group: 0 of 33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0007" title="FarberMD , FiscellaR , GoldbergMF . Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1991;98(3):279-86. FarberMD , FiscellaR , GoldbergMF . A randomized clinical trial of Amicar vs. prednisone for the treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1990 10-11; Atlanta, Georgia. 1990:119. ">Farber 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid vs oral prednisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminocaproic acid group: 0 of 56; prednisone group: 0 of 56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0028" title="WelshN , SchoemanH , BlignautP . The effect of Cyklokapron in traumatic hyphema. A double masked study. South African Archives of Ophthalmology1983;10(3-4):67-74. ">Welsh 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 1 of 19; placebo group: 0 of 20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0017" title="RahmaniB , JahadiHR , RajaeefardA . An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology1999;106(2):380-5. RahmaniB , JahadiHR , SalourH . Comparison of tranexamic acid and prednisolone in treatment of traumatic hyphema. In: American Academy of Ophthalmology; 1997 10-11; San Francisco, California. 1997:210. RahmaniB , JahadiHR . Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology1999;106(2):375-9. ">Rahmani 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 0 of 80; placebo group: 0 of 80</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b><i>Aminomethylbenzoic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005431-bbs2-0011" title="LiuSC , DenJS . The effect of aminomethylbenzoic acid on preventing secondary hyphema. Journal of Eye Injuries and Ophthalmic Occupational Diseases2002;24(2):127-8. ">Liu 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminomethylbenzoic acid vs placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug group: 7 of 60; placebo group: NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>NR: not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Risk of non‐ocular adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005431-tbl-0014"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Risk of other ocular events</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. with outcome/no. in group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total no. with outcome/total no.</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Aminocaproic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0004" title="CrouchER , WilliamsPB . Topical aminocaproic acid in the treatment of patients with traumatic hyphema—reply. Archives of Ophthalmology1998;116(3):395-6. Crouch ER Jr, WilliamsPB , GrayMK , CrouchER , ChamesM . Topical aminocaproic acid in the treatment of traumatic hyphema. Archives of Ophthalmology1997;115(9):1106-12. ">Crouch 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival/corneal foreign body sensation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient punctate corneal staining</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic aminocaproic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Tranexamic acid</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005431-bbs2-0026" title="VarnekL , DalsgaardC , HansenA , KlieF . The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica1980;58(5):787-93. ">Varnek 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitreous and retinal hemorrhage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Traumatic cataract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tranexamic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/232</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b><i>Non‐drug medical intervention</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD005431-bbs2-0019" title="ReadJ , GoldbergMF . Comparison of medical treatment for traumatic hyphema. Transactions of the American Academy of Ophthalmology and Otolaryngology1974;78(5):OP799-OP815. ReadJ . Traumatic hyphema: surgical vs medical management. Annals of Ophthalmology1975;7(5):659-62, 664-6, 668-70. ">Read 1974</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Traumatic cataract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitreous hemorrhage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Commotio retinae</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occluded pupil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optic atrophy with nasalization of optic cup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/137</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optic atrophy without nasalization of optic cup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate ambulatory activity, patching and shielding of injured eye</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bed rest with elevation of the head, bilateral patches and eye shield</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/137</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>NR: not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Risk of other ocular events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/full#CD005431-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic aminocaproic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Short‐term visual acuity from 20/20 to 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Long‐term visual acuity between 20/20 and 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Final visual acuity between 20/20 and 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Time to resolution of primary hemorrhage (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.13, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Time to rebleed (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Risk of corneal blood stain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Risk of glaucoma or increases in IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Transient increase in IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Persistent increase in IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Risk of glaucoma or elevated IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.08, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Risk of optic atrophy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse effects: nausea or vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.60 [2.09, 35.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Duration of hospitalization (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic aminocaproic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical aminocaproic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Short‐term visual acuity from 20/20 to 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Time to resolution of primary hemorrhage (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.20, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Time to rebleed (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Risk of glaucoma or elevated IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical aminocaproic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Low‐dose versus standard‐dose aminocaproic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Unspecified time for visual acuity between 20/20 and 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Time to resolution of primary hemorrhage (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Time to rebleed (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Risk of glaucoma or elevated IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Nausea or vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Dizziness or hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.4 Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.5 Rash or pruritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.6 Hot flashes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.7 Dry mouth or nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Duration of hospitalization (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Low‐dose versus standard‐dose aminocaproic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Systemic versus topical aminocaproic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Short‐term visual acuity from 20/20 to 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Conjunctival corneal foreign body sensation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Transient punctate corneal staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Dizziness, nausea, vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Systemic versus topical aminocaproic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Systemic tranexamic acid versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Short‐term visual acuity from 20/20 to 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.00, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Time to resolution of primary hemorrhage (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.21, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Time to rebleed (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Risk of corneal blood stain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Risk of glaucoma or elevated IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.73, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Adverse effects: nausea or vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Duration of hospitalization (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Systemic tranexamic acid versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Aminomethylbenzoic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Aminomethylbenzoic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Corticosteroids versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40, systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.97, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Visual acuity between 20/20 and 20/50 at resolution of hyphema, systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40, topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Final visual acuity between 20/20 and 20/25, topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Time to resolution of primary hemorrhage (days), systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Time to resolution of primary hemorrhage (days), topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Risk of secondary hemorrhage, systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Risk of secondary hemorrhage, topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.05, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Time to rebleed (days), systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.10 Risk of corneal blood stain, systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.11 Risk of corneal blood stain, topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.12 Risk of peripheral anterior synechiae, systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.13 Risk of glaucoma or elevated IOP, systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.14 Risk of glaucoma or elevated IOP, topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.15 Risk of optic atrophy, topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.16 Duration of hospitalization (days), systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.17 Duration of hospitalization (days), topical corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Corticosteroids versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Aminocaproic acid versus prednisone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Short‐term (5 to 14 days) visual acuity from 20/20 to 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Adverse effect: any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Aminocaproic acid versus prednisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Topical tranexamic acid versus prednisone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Short‐term visual acuity from 20/20 to 20/40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Time to resolution of primary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Topical tranexamic acid versus prednisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Conjugated estrogen versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Risk of corneal blood stain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Conjugated estrogen versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Cycloplegics versus miotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Short‐term visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Time to resolution of primary hemorrhage (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.15, 6.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Time to rebleed (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Cycloplegics versus miotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Aspirin versus observation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Aspirin versus observation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Monocular versus binocular patching</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Short‐term visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Variable time length 'final' visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.35, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Time to rebleed (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Risk of corneal blood stain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.6 Risk of glaucoma or elevated IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Monocular versus binocular patching</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005431-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Ambulatory versus conservative treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Short‐term visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Time to resolution of primary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Risk of secondary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.68, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Risk of corneal blood stain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 Risk of glaucoma or elevated IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Ambulatory versus conservative treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005431.pub5/references#CD005431-tbl-0028">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005431.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005431-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005431-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005431-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD005431-note-0017">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD005431-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD005431-note-0021">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD005431-note-0018">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005431-note-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005431-note-0016">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005431\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005431\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005431\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005431\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005431\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005431.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005431.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005431.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005431.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005431.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724821702"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005431.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724821706"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005431.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6c2adeb9f4ca',t:'MTc0MDcyNDgyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 